0001368148-22-000053.txt : 20220506 0001368148-22-000053.hdr.sgml : 20220506 20220506082100 ACCESSION NUMBER: 0001368148-22-000053 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220506 DATE AS OF CHANGE: 20220506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ATHERSYS, INC / NEW CENTRAL INDEX KEY: 0001368148 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 204864095 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33876 FILM NUMBER: 22898921 BUSINESS ADDRESS: STREET 1: 3201 CARNEGIE AVENUE CITY: CLEVELAND STATE: OH ZIP: 44115-2634 BUSINESS PHONE: 216-431-9900 MAIL ADDRESS: STREET 1: 3201 CARNEGIE AVENUE CITY: CLEVELAND STATE: OH ZIP: 44115-2634 FORMER COMPANY: FORMER CONFORMED NAME: BTHC VI Inc DATE OF NAME CHANGE: 20060629 10-Q 1 athx-20220331.htm 10-Q athx-20220331
false2022Q1ATHERSYS, INC / NEW000136814812/31.3333.6667P30D00013681482022-01-012022-03-3100013681482022-04-29xbrli:shares00013681482022-03-31iso4217:USD00013681482021-12-310001368148srt:AffiliatedEntityMember2022-03-310001368148srt:AffiliatedEntityMember2021-12-310001368148athx:ConsolidatedEntityExcludingRelatedPartyMember2022-03-310001368148athx:ConsolidatedEntityExcludingRelatedPartyMember2021-12-31iso4217:USDxbrli:shares0001368148srt:AffiliatedEntityMember2022-01-012022-03-310001368148srt:AffiliatedEntityMember2021-01-012021-03-3100013681482021-01-012021-03-310001368148us-gaap:PreferredStockMember2021-12-310001368148us-gaap:CommonStockMember2021-12-310001368148us-gaap:AdditionalPaidInCapitalMember2021-12-310001368148us-gaap:RetainedEarningsMember2021-12-310001368148us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001368148athx:ConsolidatedEntityExcludingRelatedPartyMemberus-gaap:CommonStockMember2022-01-012022-03-310001368148athx:ConsolidatedEntityExcludingRelatedPartyMemberus-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001368148athx:ConsolidatedEntityExcludingRelatedPartyMember2022-01-012022-03-310001368148us-gaap:CommonStockMember2022-01-012022-03-310001368148us-gaap:RetainedEarningsMember2022-01-012022-03-310001368148us-gaap:PreferredStockMember2022-03-310001368148us-gaap:CommonStockMember2022-03-310001368148us-gaap:AdditionalPaidInCapitalMember2022-03-310001368148us-gaap:RetainedEarningsMember2022-03-310001368148us-gaap:PreferredStockMember2020-12-310001368148us-gaap:CommonStockMember2020-12-310001368148us-gaap:AdditionalPaidInCapitalMember2020-12-310001368148us-gaap:RetainedEarningsMember2020-12-3100013681482020-12-310001368148us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001368148athx:ConsolidatedEntityExcludingRelatedPartyMemberus-gaap:CommonStockMember2021-01-012021-03-310001368148athx:ConsolidatedEntityExcludingRelatedPartyMemberus-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001368148athx:ConsolidatedEntityExcludingRelatedPartyMember2021-01-012021-03-310001368148us-gaap:CommonStockMember2021-01-012021-03-310001368148us-gaap:RetainedEarningsMember2021-01-012021-03-310001368148us-gaap:PreferredStockMember2021-03-310001368148us-gaap:CommonStockMember2021-03-310001368148us-gaap:AdditionalPaidInCapitalMember2021-03-310001368148us-gaap:RetainedEarningsMember2021-03-3100013681482021-03-31athx:segment0001368148athx:Section220LitigationMemberus-gaap:PendingLitigationMembersrt:MaximumMember2021-02-162021-02-160001368148athx:Section220LitigationMemberus-gaap:PendingLitigationMemberus-gaap:SubsequentEventMember2022-04-012022-04-300001368148us-gaap:DeferredBonusMember2021-03-310001368148us-gaap:DeferredBonusMemberathx:AdditionalEmployeesMember2021-04-300001368148athx:FormerChiefExecutiveOfficerMember2021-02-150001368148athx:FormerChiefExecutiveOfficerMember2021-02-152021-02-150001368148athx:FormerChiefExecutiveOfficerMember2022-03-310001368148athx:FormerChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMember2021-01-012021-03-310001368148athx:FormerChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001368148us-gaap:DeferredBonusMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-01-012021-03-31xbrli:pure0001368148us-gaap:DeferredBonusMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-01-012021-03-310001368148athx:HealiosFrameworkAgreementMember2021-08-012021-08-310001368148us-gaap:StockCompensationPlanMember2022-01-012022-03-310001368148us-gaap:StockCompensationPlanMember2021-01-012021-03-310001368148athx:HealiosFrameworkAgreementMember2021-08-310001368148us-gaap:EquipmentMember2022-03-310001368148us-gaap:EquipmentMember2021-12-310001368148athx:OfficeEquipmentAndLeaseholdImprovementsMember2022-03-310001368148athx:OfficeEquipmentAndLeaseholdImprovementsMember2021-12-310001368148athx:EquipmentAndLeaseholdImprovementNotYetInServiceMember2022-03-310001368148athx:EquipmentAndLeaseholdImprovementNotYetInServiceMember2021-12-310001368148athx:HealiosFrameworkAgreementMember2022-03-31athx:performanceObligation0001368148athx:HealiosFrameworkAgreementMember2021-12-310001368148athx:HealiosFrameworkAgreementMember2022-01-012022-03-310001368148athx:HealiosFrameworkAgreementMember2021-01-012021-03-310001368148srt:MinimumMember2022-03-310001368148srt:MaximumMember2022-03-310001368148athx:HealiosLicenseAgreementMember2022-01-012022-03-310001368148athx:HealiosLicenseAgreementMember2021-01-012021-03-310001368148athx:RegulatoryAndSalesMilestonesMemberathx:HealiosLicenseAgreementMember2020-01-012020-09-30athx:milestone0001368148us-gaap:TransferredAtPointInTimeMemberus-gaap:ServiceMemberathx:HealiosLicenseAgreementMember2022-01-012022-03-310001368148us-gaap:ServiceMemberus-gaap:TransferredOverTimeMemberathx:HealiosLicenseAgreementMember2022-01-012022-03-310001368148us-gaap:TransferredAtPointInTimeMemberus-gaap:ServiceMemberathx:HealiosLicenseAgreementMember2021-01-012021-03-310001368148us-gaap:ServiceMemberus-gaap:TransferredOverTimeMemberathx:HealiosLicenseAgreementMember2021-01-012021-03-310001368148us-gaap:TransferredAtPointInTimeMemberathx:HealiosLicenseAgreementMember2022-01-012022-03-310001368148us-gaap:TransferredOverTimeMemberathx:HealiosLicenseAgreementMember2022-01-012022-03-310001368148us-gaap:TransferredAtPointInTimeMemberathx:HealiosLicenseAgreementMember2021-01-012021-03-310001368148us-gaap:TransferredOverTimeMemberathx:HealiosLicenseAgreementMember2021-01-012021-03-310001368148athx:A2019EquityAndIncentiveCompensationPlanMember2019-12-310001368148srt:ChiefExecutiveOfficerMemberathx:TheInducementAwardMember2022-02-142022-02-140001368148srt:ChiefExecutiveOfficerMemberathx:TheInducementAwardMember2022-02-140001368148srt:ChiefExecutiveOfficerMemberathx:TheInducementAwardFourYearVestingMember2022-02-142022-02-140001368148srt:ChiefExecutiveOfficerMemberathx:TheInducementAwardFourYearVestingMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-02-142022-02-140001368148us-gaap:ShareBasedCompensationAwardTrancheTwoMembersrt:ChiefExecutiveOfficerMemberathx:TheInducementAwardFourYearVestingMember2022-02-142022-02-140001368148srt:ChiefExecutiveOfficerMemberathx:TheInducementAwardPerformanceBasedVestingMember2022-02-142022-02-140001368148athx:A2019EquityAndIncentiveCompensationPlanMember2022-03-310001368148athx:InducementAwardsPlanMember2022-03-310001368148athx:AspireMember2021-06-012021-06-300001368148athx:AspireMember2021-06-300001368148athx:AspireMemberus-gaap:CommonStockMember2022-01-012022-03-310001368148athx:AspireMember2022-01-012022-03-310001368148athx:AspireMemberus-gaap:CommonStockMember2021-01-012021-03-310001368148athx:AspireMember2021-01-012021-03-3100013681482021-08-310001368148athx:WarrantOneMember2021-08-310001368148athx:WarrantOneMember2021-08-012021-08-310001368148athx:WarrantTwoMember2021-08-310001368148athx:WarrantTwoMember2021-08-012021-08-310001368148srt:AffiliatedEntityMember2021-08-012021-08-3100013681482021-05-3100013681482021-06-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 10-Q

 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2022
OR 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     .
Commission file number: 001-33876
 
 
Athersys, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware 20-4864095
(State or other jurisdiction
of incorporation or organization)
 (I.R.S. Employer
Identification No.)
 
3201 Carnegie Avenue,Cleveland,Ohio 44115-2634
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (216) 431-9900
Former name, former address and former fiscal year, if changed since last report: Not Applicable
 
 
  
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $0.001 per shareATHXThe NASDAQ Stock Market LLC
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 


Large accelerated filer   Accelerated filer 
Non-accelerated filer   Smaller reporting company 
Emerging growth company    
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  ☒
The number of outstanding shares of the registrant’s common stock, $0.001 par value, as of April 29, 2022 was 251,967,791.


ATHERSYS, INC.
TABLE OF CONTENTS
 



PART I. FINANCIAL INFORMATION
Item 1.    Financial Statements.
Athersys, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
March 31,
2022
December 31,
2021
 (Unaudited) 
Assets
Current assets:
Cash and cash equivalents$21,797 $37,407 
Accounts receivable from Healios1,643 1,414 
Unbilled accounts receivable from Healios3,000 3,000 
Prepaid expenses and other4,661 4,206 
Total current assets31,101 46,027 
Operating right-of-use assets, net8,707 8,960 
Property and equipment, net3,631 3,692 
Deposits and other1,520 1,505 
Total assets$44,959 $60,184 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$16,771 $15,781 
Accounts payable to Healios1,119 1,119 
Operating lease liabilities, current1,031 1,011 
Accrued compensation and related benefits3,345 4,133 
Accrued clinical trial related costs5,770 3,773 
Accrued expenses and other727 704 
Deferred revenue - Healios2,202 3,340 
Total current liabilities30,965 29,861 
Operating lease liabilities, non-current8,488 8,755 
Advance from Healios5,199 5,199 
Stockholders’ equity:
Preferred stock, at stated value; 10,000,000 shares authorized, and no shares issued and outstanding at March 31, 2022 and December 31, 2021
  
Common stock, $0.001 par value; 600,000,000 shares authorized with 249,792,791 and 242,844,180 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively
250 243 
Additional paid-in capital605,617 599,470 
Accumulated deficit(605,560)(583,344)
Total stockholders’ equity307 16,369 
Total liabilities and stockholders’ equity$44,959 $60,184 
See accompanying notes to unaudited condensed consolidated financial statements.
4

Athersys, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share data)
(Unaudited)
 
 Three months ended
March 31,
 20222021
Revenues
Contract revenue from Healios$2,912 $ 
        Total revenues2,912  
Costs and expenses
Research and development20,944 17,508 
General and administrative4,099 8,837 
Depreciation247 244 
Total costs and expenses25,290 26,589 
Loss from operations(22,378)(26,589)
Other income, net162 121 
Net loss and comprehensive loss$(22,216)$(26,468)
Net loss per share, basic and diluted$(0.09)$(0.13)
Weighted average shares outstanding, basic and diluted244,197 208,192 
See accompanying notes to unaudited condensed consolidate
5

Athersys, Inc.
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
(Unaudited)
 Preferred StockCommon StockAdditional
Paid-in
Capital
Accumulated
Deficit
Total
Stockholders’
Equity
 Number
of Shares
Stated
Value
Number
of Shares
Par
Value
Balance at December 31, 2021 $ 242,844,180 $243 $599,470 $(583,344)$16,369 
Stock-based compensation    1,410  1,410 
Issuance of common stock  6,800,000 7 4,795  4,802 
Issuance of common stock under equity compensation plan  148,611  (58) (58)
Net and comprehensive loss     (22,216)(22,216)
Balance at March 31, 2022 $ 249,792,791 $250 $605,617 $(605,560)$307 

 Preferred StockCommon StockAdditional
Paid-in
Capital
Accumulated
Deficit
Total Stockholders’ Equity
 Number
of Shares
Stated
Value
Number
of Shares
Par
Value
Balance at December 31, 2020 $ 201,973,582 $202 $527,549 $(496,389)$31,362 
Stock-based compensation— — — — 3,903 — 3,903 
Issuance of common stock— — 15,200,000 15 30,480 — 30,495 
Issuance of common stock under equity compensation plan— — 437,925 1 (612)— (611)
Net and comprehensive loss— — — — — (26,468)(26,468)
Balance at March 31, 2021 $ 217,611,507 $218 $561,320 $(522,857)$38,681 

See accompanying notes to unaudited condensed consolidated financial statements.









6

Athersys, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
 Three months ended
March 31,
 20222021
Operating activities
Net loss$(22,216)$(26,468)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation247 244 
Stock-based compensation1,410 3,903 
Changes in operating assets and liabilities:
Accounts receivable from Healios - billed and unbilled(229) 
Prepaid expenses, deposits and other(217)(45)
Accounts payable, accrued expenses and other1,975 5,273 
Deferred revenue - Healios(1,138) 
Net cash used in operating activities(20,168)(17,093)
Investing activities
Purchases of equipment(186)(114)
Net cash used in investing activities(186)(114)
Financing activities
Proceeds from issuance of common stock, net 4,802 30,506 
Shares retained for withholding tax payments on stock-based awards(58)(622)
Net cash provided by financing activities4,744 29,884 
(Decrease) Increase in cash and cash equivalents(15,610)12,677 
Cash and cash equivalents at beginning of the period37,407 51,546 
Cash and cash equivalents at end of the period$21,797 $64,223 
See accompanying notes to unaudited condensed consolidated financial statements.

7

Athersys, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements
Three-Month Periods Ended March 31, 2022 and 2021

1. Background and Basis of Presentation
Background
Athersys, Inc., including its consolidated subsidiaries (collectively, “we,” “us,” “our,” “Athersys,” and the “Company”), is a biotechnology company focused in the field of regenerative medicine and operates in one business segment. Our operations consist of research, clinical development activities, manufacturing and manufacturing process development activities, and our most advanced program is in a pivotal Phase 3 clinical trial.
We expect that the results of the TREASURE study, the clinical trial of our partner in Japan, HEALIOS K.K. (“Healios”), followed by the results of our MASTERS-2 clinical trial, will have a significant impact, favorable or unfavorable, on our ability to access capital from potential third-party commercial partners or the equity capital markets. Depending on the nature of these results, we may accelerate or may delay certain programs. In the long term, we will have to continue to generate additional capital to meet our needs until we become cash flow positive as a result of the sales of our clinical products, if they are approved for marketing. Such capital would come from new and existing collaborations and the related license fees, milestones and potential royalties and the sale of equity securities from time to time including through our equity facility and grant-funding opportunities.
Healios Framework Agreement
On August 5, 2021, we expanded our partnership with Healios by entering into the Comprehensive Framework Agreement for Commercial Manufacturing and Ongoing Support (the “Framework Agreement”). The Framework Agreement provides for planned investment by Healios in certain manufacturing preparation activities. We have agreed to defer certain milestone payments and potentially adjust royalty payments during the initial commercial launch period. Refer to Note 6 for additional information on the Framework Agreement.
On February 16, 2021, the Company, Healios and Dr. Hardy TS Kagimoto, the Chairman and Chief Executive Officer of Healios and a member of the Company’s board of directors (the “Board”), entered into a cooperation agreement (the “Cooperation Agreement”). The Cooperation Agreement provided for the parties’ cooperation on certain commercial matters, including a commitment to work in good faith to finalize negotiations on all aspects of their supply, manufacturing, information provision and regulatory support relationship.
The Cooperation Agreement also provided for, among related matters, the dismissal with prejudice of the complaint filed by Dr. Kagimoto against the Company seeking the inspection of the Company’s books and records in the Court of Chancery of the State of Delaware on November 21, 2020 (the “Section 220 Litigation”). Pursuant to the Cooperation Agreement, in April 2021, the Company reimbursed Healios and Dr. Kagimoto for reasonable out-of-pocket fees and expenses, including legal expenses, incurred in connection with the Section 220 Litigation, which were not to exceed $0.5 million in the aggregate. In April 2022, the Company received an insurance reimbursement of $0.4 million for legal costs incurred in connection with the Section 220 Litigation.
In connection with the execution of the Framework Agreement, certain issues as contemplated by the Cooperation Agreement were resolved and the Cooperation Agreement was amended to extend certain customary standstill provisions until the conclusion of our 2023 annual meeting of stockholders.
Retention Program
In the first quarter of 2021, we entered into retention letter agreements (“Retention Agreements”) with our executive officers and certain other employees in leadership positions. Each Retention Agreement provides for, among other things, a cash retention bonus and a stock option award, each with vesting tied to continued employment. The cash retention bonuses generally represent a percentage of the employee’s annual compensation and generally vest in full if employed on May 1, 2022. The stock option awards generally vest one-third on May 1, 2022 with the remainder vesting on May 1, 2023 and include a provision for accelerated vesting upon termination without cause. The total stock compensation expense related to the stock option awards is approximately $2.7 million and is being expensed ratably over the vesting period. In April 2021, we expanded the retention program to all then-current employees of the Company, providing for a cash retention bonus with vesting also tied to continued employment through May 1, 2022. The total cash retention bonus is approximately $2.5 million, which is being expensed ratably over the respective vesting periods.
8

Chief Executive Officer Separation Letter Agreement
Effective February 15, 2021, Dr. Gil Van Bokkelen was terminated from his position as the Company’s Chief Executive Officer and Chairman of the Board. In connection with his cessation of service, the Company and Dr. Van Bokkelen entered into a separation letter agreement (the “Separation Letter”) entitling him to severance payments and benefits with an aggregate value of approximately $1.0 million payable in installments over an 18-month period, and providing for a total lump sum payment of approximately $0.2 million. At March 31, 2022, we recorded a liability in the amount of $0.2 million, which represents the remaining installments payable to Dr. Van Bokkelen. The lump sum payment was made to Dr. Van Bokkelen in March 2021. The related expense is recorded in general and administrative expense on the unaudited condensed consolidated statements of operations and comprehensive loss.
The terms of the Separation Letter also provide for the accelerated vesting of Dr. Van Bokkelen’s outstanding restricted stock units (“RSUs”) and the modification of his stock option awards by providing for accelerated vesting of his unvested stock options and the extension of time during which certain vested stock options can be exercised. In the first quarter of 2021, following the evaluation of the modification, we recorded stock compensation expense of approximately $1.4 million related to the accelerated vesting of Dr. Van Bokkelen’s stock options and $0.9 million related to the accelerated vesting of his RSUs.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and Regulation S-X. Accordingly, since they are interim statements, the accompanying financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments and disclosures that are, in the opinion of management, necessary for a fair presentation of financial position and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Our critical accounting policies, estimates and assumptions are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which is included in this Quarterly Report on Form 10-Q.

2. Going Concern
We have prepared our unaudited condensed consolidated financial statements on a going concern basis, which assumes that we will realize our assets and satisfy our liabilities in the normal course of business. However, we have incurred net losses since our inception in 1995 and have negative operating cash flows. These factors, among others, raise substantial doubt about our ability to continue as a going concern within one year after the date that these financial statements are issued.
The accompanying unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of the uncertainty concerning our ability to continue as a going concern.
At March 31, 2022, we had cash and cash equivalents of $21.8 million. We will require significant additional capital to continue our research and development programs, including progressing our clinical product candidates to potential commercialization and preparing for commercial-scale manufacturing and sales. We expect that the results of the TREASURE study, followed by the results of our MASTERS-2 clinical trial, will have a significant impact, favorable or unfavorable, on our ability to access capital from potential third-party commercial partners or the equity capital markets.
In the long term, we will have to continue to generate additional capital to meet our needs until we become cash flow positive as a result of the sales of our clinical products, if they are approved for marketing. Such capital would come from new and existing collaborations and the related license fees, milestones and potential royalties. Management plans to raise additional capital through the use of our equity purchase agreement with Aspire Capital Fund, LLC (“Aspire Capital”) and, depending on market conditions, through equity offerings. We are entitled to a new milestone payment from Healios in the amount of $3.0 million in June 2022. While management believes this plan to generate additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. For the foreseeable future, our ability to continue our operations is dependent upon the ability to obtain additional capital.
9

3. Accounting Standards Not Yet Adopted
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326). This ASU replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Subsequent to issuing ASU 2016-13, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326): Effective Dates, delaying the effective date for smaller reporting companies until January 2023. We are currently evaluating the potential impact of adoption of this standard on our consolidated financial statements and disclosures, and we do not intend to adopt this standard earlier than required.
4. Net Loss per Share
Basic and diluted net loss per share have been computed using the weighted-average number of shares of our common stock outstanding during the period. Stock-based awards of approximately 28,355,351 and 21,788,078 for the three months ended March 31, 2022 and 2021, respectively, were excluded from the calculation of diluted net loss per share because their effects would be antidilutive.
We have two warrants outstanding to purchase an aggregate of 10,000,000 shares of our common stock that were issued to Healios in August 2021 and are excluded from the calculation of diluted net loss per share, as the underlying performance condition associated with each warrant has not been satisfied and is not yet considered probable by the end of the reporting period. Refer to Note 8 for additional information.

5. Property and Equipment, net

For the periods ended
Property and equipment consists of (in thousands):March 31,
2022
December 31,
2021
Laboratory equipment$9,535 $9,352 
Office equipment and leasehold improvements4,000 4,000 
Equipment and leasehold improvements not yet in service433 458 
13,968 13,810 
Accumulated depreciation and amortization(10,337)(10,118)
$3,631 $3,692 
6. Collaborative Arrangements and Revenue Recognition
Healios Collaboration
We have a licensing collaboration with Healios to primarily develop and commercialize our cell therapy technologies for certain disease indications in Japan, pursuant to which we received nonrefundable license fee payments and are entitled to royalties on net sales. We also have the right to receive development and commercial milestone payments from Healios, subject to certain potential credits that have been negotiated from time-to-time and are associated with modifications to the arrangement. Healios is responsible for the development and commercialization of the licensed products in the licensed territories, and we provide certain services to Healios for which we are paid.
In August 2021, the Company and Healios entered into the Framework Agreement, which provides for clarification under and modifies the existing agreements between the parties and reframes our collaboration to set the stage for productive efforts as Healios and our collaboration move towards commercialization of MultiStem in Japan. It also provides Healios with deferral of certain milestone payments during the expensive initial commercial launch period. We will be entitled to new milestone payments in the amount of $3.0 million in June 2022 and $5.0 million upon the successful completion of certain commercial manufacturing activities. Additionally, accounts payable to Healios have been reduced to $1.1 million and are due on or before December 31, 2022. In August 2021, we also issued two warrants (together, the “2021 Warrants”) to Healios in connection with the Framework Agreement to purchase up to a total of 10,000,000 shares of our common stock. The 2021 Warrants are being accounted for as consideration paid or payable to a customer according to Topic 606, Revenue from Contracts with Customers, and Topic 718, Compensation Stock Compensation, under which the recognition of such equity instruments is required at the time that the underlying performance conditions become probable or are satisfied. As of March 31, 2022, the 2021 Warrants have not been recorded as the underlying performance conditions have not been satisfied and are not yet considered probable. Refer to Note 8 for further information.
10

Healios Revenue Recognition
At the inception of the Healios arrangement and again each time that the arrangement is modified, all material performance obligations are identified, which currently include one performance obligation for services necessary for regulatory approvals, manufacturing readiness, and commercial launch in Japan. We determined the transaction price includes estimated payments for reimbursable services to be performed by us for Healios and the $3.0 million milestone payment due in June 2022. We allocated the total transaction price to this one performance obligation. We began recognizing this revenue beginning in the third quarter of 2021 as the services were being performed. We expect the services to be completed by the end of 2022. During our evaluation of variable consideration in the first quarter of 2022, we decreased our estimated transaction price due to changes in the estimated cost of the reimbursable services. The remaining transaction price for the performance obligation that was not yet satisfied is approximately $1.4 million at March 31, 2022. During the three months ended March 31, 2022, we recognized approximately $2.8 million of revenue associated with this performance obligation. We recognized no revenue for the three months ended March 31, 2022, and March 31, 2021 from performance obligations satisfied in previous periods.
Accounts receivable from Healios
Accounts receivable from Healios are related to our contracts and are recorded when the right to consideration is unconditional at the amount that management expects to collect. Accounts receivable from Healios do not bear interest if paid when contractually due, and payments are generally due within thirty to forty-five days of invoicing.
Unbilled Accounts Receivable
Unbilled accounts receivable from Healios represent amounts due to us under contractual arrangements and for which we have an unconditional right to consideration, but which we have not yet invoiced Healios. At March 31, 2022, the unbilled accounts receivable from Healios was $3.0 million, which represents a milestone payment owed to us under the Framework Agreement for which we are entitled to receive payment in June 2022.
Deferred Revenue - Healios
Amounts included in deferred revenue - Healios on the condensed consolidated balance sheets are considered a contract liability. During the three months ended March 31, 2022, revenue recognized from contract liabilities as of the beginning of the respective period was $1.1 million. No revenue was recognized from contract liabilities during the three months ended March 31, 2021. At March 31, 2022, the contract liability included in deferred revenue - Healios is classified as a current liability because the rights to consideration are expected to be satisfied, in all material respects, within one year.
Advance from Healios
In 2017, we amended the clinical trial supply agreement for the manufacturing of clinical product for TREASURE to clarify a cost-sharing arrangement. The proceeds from Healios that relate specifically to the cost-sharing arrangement may either (i) result in a reduction in the proceeds we receive from Healios upon the achievement of two potential milestones and an increase to a commercial milestone under the license agreement for stroke or (ii) be repaid to Healios at our election, as defined. The cost-sharing proceeds received are recognized in advance from Healios on the unaudited condensed consolidated balance sheets until the earlier of the milestones being achieved or such amounts being repaid to Healios at our election, at which time the culmination of the earnings process or the repayment will be complete.
Disaggregation of Revenues
We recognize service revenue when earned over time. The following table presents our contract revenues disaggregated by timing of revenue recognition (in thousands):
 Three months ended
March 31, 2022
Three months ended
March 31, 2021
 Point in
Time
Over TimePoint in
Time
Over Time
Contract Revenue from Healios
Service revenue 2,912   
Total disaggregated revenues$ $2,912 $ $ 


11

7. Stock-Based Compensation
Our 2019 Equity and Incentive Compensation Plan (the “EICP”) authorized at inception an aggregate of approximately 18,500,000 shares of our common stock for awards to employees, directors and consultants. The EICP authorizes the issuance of stock-based compensation in the form of stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares and units, and other stock-based awards. Under the EICP, in the three months ended March 31, 2022, we granted 33,400 stock options and no RSUs to our employees.
On February 14, 2022, Daniel Camardo was named the Company’s Chief Executive Officer. As an inducement to Mr. Camardo’s acceptance of employment with us, Mr. Camardo was granted an initial equity award (the “Inducement Award”) to purchase 10,000,000 shares of our common stock at a per share exercise price of $0.86. With regard to 4,000,000 shares, vesting of the Inducement Award will occur over a four-year period, with 25% of such portion of the award generally vesting on the first anniversary of the grant date and the remainder generally vesting monthly in substantially equal installments over the remaining 36 months. With regard to 6,000,000 shares, vesting of the Inducement Award will generally occur upon achievement of certain Company milestones. The Inducement Award has up to a 10-year term.
As of March 31, 2022, a total of 3,628,308 shares were available for issuance under the EICP, and stock-based awards representing 23,355,351 shares of our common stock were outstanding under our current and former equity incentive plans, and inducement awards granted outside of our equity incentive plans to purchase 11,000,000 shares of our common stock were outstanding. For the three months ended March 31, 2022 and 2021, stock-based compensation expense was approximately $1.4 million and $3.9 million, respectively. At March 31, 2022, total unrecognized estimated compensation cost related to unvested stock-based awards was approximately $12.7 million, which is expected to be recognized by the end of 2026 using the straight-line method.
8. Stockholders’ Equity and Warrants
Equity Purchase Agreement
We have had equity purchase agreements in place since 2011 with Aspire Capital that provide us the ability to sell shares to Aspire Capital from time to time. Currently, we have an agreement with Aspire Capital that was entered into in June 2021 (the “2021 Equity Facility”) and includes Aspire Capital’s commitment to purchase up to an aggregate of $100.0 million of shares of our common stock over a defined timeframe. The terms of the 2021 Equity Facility are similar to the previous equity facilities with Aspire Capital, and we filed a registration statement for the resale of 40,000,000 shares of our common stock in connection with the 2021 Equity Facility. Our prior equity facility that was entered into in November 2019 was fully utilized and terminated during the third quarter of 2021.
We sold 6,800,000 shares to Aspire Capital at an average price of $0.71 per share in the first quarter of 2022, generating proceeds of $4.8 million. We sold 15,200,000 shares to Aspire Capital at an average price of $2.01 per share in the first quarter of 2021, generating proceeds of $30.5 million.
Healios 2021 Warrants
In August 2021, we issued the 2021 Warrants to Healios to purchase up to an aggregate of 10,000,000 shares of our common stock. One of the 2021 Warrants is for the purchase of up to 3,000,000 shares at an exercise price of $1.80 per share, subject to specified increases, and generally is only exercisable within 60 days of receipt of either conditional or full marketing approval from the Pharmaceuticals and Medical Devices Agency in Japan (the “PMDA”) for the intravenous administration of MultiStem to treat patients who are suffering from acute respiratory distress syndrome. The other 2021 Warrant is for the purchase of up to 7,000,000 shares at an exercise price of $2.40 per share, subject to specified increases, and generally is only exercisable within 60 days of receipt of either conditional or full marketing approval from the PMDA for the intravenous administration of MultiStem to treat patients who are suffering from ischemic stroke. The 2021 Warrants may be terminated by us under certain conditions and have an exercise cap triggered at Healios’ ownership of 19.9% of our common stock.
Increase Shares of Authorized Common Stock
In June 2021, the Company’s stockholders approved an Amendment to the Certificate of Incorporation to increase the number of shares of the Company’s authorized common stock from 300,000,000 shares to 600,000,000 shares.
12

9. Income Taxes
We have United States (“U.S.”) federal net operating loss and research and development tax credit carryforwards, as well as state and city net operating loss carryforwards, which may be used to reduce future taxable income and tax liabilities. We also have foreign net operating loss and tax credit carryforwards, and the foreign net operating loss carryforwards do not expire. Substantially all of our deferred tax assets have been fully offset by a valuation allowance due to our cumulative losses. The carrying value of our deferred tax assets and liabilities is determined by the enacted U.S. corporate income tax rate. Consequently, any changes in the U.S. corporate income tax rate impacts the carrying value of our deferred tax assets and liabilities. Also, there are significant limitations on our ability to utilize our net operating loss and tax credit carryforwards under Section 382 of the Internal Revenue Code of 1986, as amended.
Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.
This discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021. Operating results are not necessarily indicative of results that may occur in future periods.
Overview and Recent Developments
We are a biotechnology company that is focused primarily in the field of regenerative medicine. Our MultiStem® (invimestrocel) cell therapy, a patented and proprietary allogeneic stem cell product candidate, is our lead platform product and is currently in clinical development in several therapeutic and geographic areas. Our most advanced program is an ongoing Phase 3 clinical trial for the treatment of ischemic stroke. Our current clinical development programs are focused on treating neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment.
Current Programs
Our MultiStem cell therapy product development programs in the clinical development stage include the following:
Ischemic Stroke: We are conducting a pivotal Phase 3 clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MASTERS-2. Our MASTERS-2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial designed to enroll 300 patients in the United States and certain other international locations, who have suffered moderate to moderate-severe ischemic stroke. We initiated the study with a limited number of high-enrolling sites and have been bringing on additional sites over time in line with clinical product supply and clinical operations objectives. In prior periods, we have faced challenges to clinical site initiations, as well as patient screening and enrollment, due to the COVID-19 pandemic, and supply interruptions, among other things. As COVID-19 case numbers decline and supply has stabilized, we have undertaken initiatives intended to accelerate new site openings in the U.S. and abroad and increase patient enrollment at sites currently open, including by addressing site-specific operations and inventory management issues. While these plans were initially intended to enable us to complete enrollment of the MASTERS-2 study by the end of 2022, it seems more likely now to occur in early 2023. Completion continues to depend on the impact of the results of the TREASURE study being conducted by HEALIOS K.K., or Healios, discussed below, and the possible resurgence of COVID-19. We would expect, for instance, that favorable TREASURE study results would have a positive effect on site initiations and patient accruals as success drives further interest in and focus on the study among investigators and clinical research groups.
The MASTERS-2 study has received several regulatory distinctions including Special Protocol Assessment, or SPA, designation, Fast Track designation and Regenerative Medicine Advanced Therapy, or RMAT, designation from the United States Food and Drug Administration, or FDA, as well as a Final Scientific Advice positive opinion from the European Medicines Agency, or EMA.
In addition, Healios, our collaborator in Japan, has an ongoing clinical trial, TREASURE, evaluating the safety and efficacy of administration of MultiStem cell therapy for the treatment of ischemic stroke. TREASURE will be evaluated under the progressive regulatory framework for regenerative medicine therapies in Japan. Under the new framework, Healios’ ischemic stroke program has been awarded the Sakigake designation by the Pharmaceuticals and Medical Devices Agency in Japan, or PMDA, which is designed to expedite regulatory review and approval and is analogous to Fast Track designation from the FDA. In August 2021 Healios announced completion of patient enrollment in its TREASURE study and, on April 4, 2022, Healios reported that the last patient in the study completed the 365-day follow-up visit. The last patient follow-up visit represents an important milestone in the TREASURE study, as it completes the collection of all patient data and enables the final validation of the data, analyses and
13

preparation of results by Healios’ contract research organization for unblinding and topline disclosures. Healios reported that it anticipates that it will receive the final topline results and make disclosures in May 2022. We look forward to the completion of both the MASTERS-2 and TREASURE trials and using the accelerated pathways to review and approval afforded to us by the regulators in the United States, Europe and Japan.
ARDS: In January 2019 and January 2020, we announced summary results and one-year follow up results, respectively, from our exploratory clinical study of the intravenous administration of MultiStem cell therapy to treat patients who are suffering from acute respiratory distress syndrome, or ARDS, which is referred to as the MUST-ARDS study. The study results continue to demonstrate a predictable and favorable tolerability profile. Importantly, there were lower mortality and a greater number of ventilator-free days, or VFD, and ICU-free days in the MultiStem-treated patient group compared to the placebo group. Average quality-of-life outcomes were higher in the MultiStem group compared to placebo through one year. In April 2020, in response to the COVID-19 pandemic, the FDA authorized the initiation of a Phase 2/3 pivotal study to assess the safety and efficacy of MultiStem therapy in subjects with moderate to severe ARDS, or the MACOVIA study. In September 2020, the MultiStem cell therapy received RMAT designation for the ARDS program. The MACOVIA study features an open-label lead-in followed by a double-blinded, randomized, placebo-controlled Phase 2 and 3 portions, and the study is presently designed to enroll up to approximately 400 patients at leading pulmonary critical care centers throughout the United States. During 2021, we amended the protocol with the FDA to adjust the scope of the MACOVIA study to include subjects with ARDS induced by pathogens other than COVID-19. Recently, we received approval from the FDA to use MultiStem product manufactured with our bioreactor-based technology in the study, an important development milestone. The scope and timing of our MACOVIA study may be adjusted to reflect rapidly changing standards of care for ARDS patients and depending on regulatory discussions and business considerations. We are currently reinitiating sites for enrollment with investigational product manufactured using our bioreactor technology. We are focused on enrolling the Phase 2 part of the MACOVIA trial as soon as possible, but the timing of completion will depend on the speed of the reinitiation and addition of sites and the incidence of COVID-ARDS, among other factors.
Further, in 2019, Healios initiated the ONE-BRIDGE study in Japan for patients with pneumonia-induced and COVID-induced ARDS and, in August 2021, Healios reported top-line data from the ONE-BRIDGE study. We and Healios have conducted thorough analyses of the data from the MUST-ARDS and ONE-BRIDGE studies. The studies had comparable patient populations receiving the same MultiStem dose amount shortly following an ARDS diagnosis. Between the studies, excluding the COVID-ARDS cohort in the ONE-BRIDGE study, 60 ARDS subjects were enrolled in the studies, 40 receiving MultiStem treatment and the remaining 20 receiving placebo or standard of care. On a pooled basis, strong trends were observed in VFD survival, improved quality-of-life and reduction of key inflammatory biomarkers. For example, MultiStem-treated subjects had, on average, 5.5 more VFD in the first 28 days following diagnosis than non-treated subjects (p=0.07) and, on a median basis, 10.5 more VFD. In April 2022, Healios announced that while the PMDA did not disagree with the efficacy and safety conclusions of the ONE-BRIDGE study, the PMDA advised Healios that additional supporting data is necessary for application for approval of MultiStem treatment for the ARDS indication in Japan. As a result of the guidance from the PMDA, Healios disclosed that it will continue discussions with PMDA and work toward early application, and while it is undetermined at this time, it is expected that the application for approval is unlikely to take place in the current fiscal year.
Trauma: In April 2020, the FDA authorized the initiation of a Phase 2 clinical trial evaluating MultiStem cell therapy for the early treatment of traumatic injuries and the subsequent complications that result following severe trauma. The trial is being conducted by The University of Texas Health Science Center at Houston, or UTHealth, at the Memorial Hermann-Texas Medical Center in Houston, Texas, one of the busiest Level 1 trauma centers in the United States. This study is being supported under a grant awarded to the McGovern Medical School at UTHealth from the Medical Technology Enterprise Consortium, and the Memorial Hermann Foundation is providing additional funding. We are providing the investigational clinical product manufactured with our bioreactor-based technology for the trial as well as regulatory and operational support.
We are engaged in preclinical development and evaluation of MultiStem cell therapy in other indications for human health, as well as certain indications in the animal health field, and we conduct such work both through our own internal research efforts and through a broad global network of collaborators. We also engage in discussions with third parties about collaborating in the development of MultiStem cell therapy for various programs and/or various geographic territories and may enter into one or more business partnerships to advance these programs over time. We may also elect to develop certain programs independently.
While the MultiStem product platform continues to advance, we are engaged in process development initiatives intended to increase manufacturing scale, reduce production costs and enhance process controls and product quality, among other things. These initiatives are being conducted both internally and outsourced to select contractors, and the related investments are meant to enable us to meet potential commercial demand in the event of eventual regulatory approval. We have been developing a bioreactor-based manufacturing platform for such commercialization, for which we now have FDA approval for use in our
14

ARDS and trauma clinical trials in the United States. Until such time as we are able to manufacture products ourselves in accordance with good manufacturing practices, we will continue to rely on third-party manufacturers to make our MultiStem product for clinical trials and eventual commercial sales. These third parties may not deliver sufficient quantities of our MultiStem product, manufacture MultiStem product in accordance with specifications, or comply with applicable government regulations. From time to time, such third-party manufacturers, or their material suppliers, may experience production delays, stoppages or interruptions in supply, which may affect the initiation, execution and timing of completion of our and our partners’ clinical trials or potential commercial activities.
In addition to our manufacturing efforts, in other areas we are stepping up our planning and preparations for the potential commercialization of our MultiStem product candidate. We are advancing our strategies for market access and reimbursement, working with third-party experts to plan and undertake initiatives to position the product appropriately and effectively communicate to payors its value to them and patients. We are developing our go-to-market strategies, which could include third-party marketing partners in certain areas and the creation of a commercial sales force in other areas. We are also working with outside experts to develop proprietary solutions to the unique requirements related to the cell therapy supply chain and clinical site logistics. For example, working with an outside partner, we have been developing a proprietary cryogenic system designed to securely store and dispense our product in hospital pharmacies or other suitable clinical locations. Our intention is to be prepared to enable commercialization as soon as reasonably possible following potential successful completion of pivotal studies, application and approval by regulators.
Financial
We have entered into a series of agreements with Healios, currently our largest stockholder. Under the collaboration that began in 2016, Healios is responsible for the development and commercialization of the MultiStem product for the licensed fields in the licensed territories, and we provide services to Healios for which we are compensated. Each license agreement with Healios has defined economic terms, and we may receive success-based milestone payments, some of which may be subject to credits.
In August 2021, we entered into a Comprehensive Framework Agreement for Commercial Manufacturing and Ongoing Support, or the Framework Agreement, with Healios, which provides for resolution of certain issues under the existing agreements between the parties and reframes our collaboration to set the stage for productive efforts as Healios and our collaboration move towards commercialization of MultiStem in Japan. It also provides Healios with the deferral of certain milestone payments during the expensive initial commercial launch period. Under the Framework Agreement, we are entitled to milestone payments in the amount of $3.0 million in June 2022 and $5.0 million upon successful completion of certain commercial manufacturing activities. Also, we are entitled to receive tiered royalties on net product sales, as defined in the license agreements.
In March 2018, we entered into an investor rights agreement, or the Investor Rights Agreement, with Healios, which governs certain of our and Healios’ rights relating to Healios’ ownership of our common stock. Under the Investor Rights Agreement, Healios is permitted to participate in certain equity issuances as a means to maintain its proportional ownership of our common stock as of the time of issuance, which participation right was extended under the Framework Agreement until our 2023 annual meeting of stockholders.
We have had equity purchase agreements in place since 2011 with Aspire Capital Fund, LLC, or Aspire Capital, that provide us the ability to sell shares to Aspire Capital from time to time. Currently, we have an agreement with Aspire Capital that was entered into in June 2021, or the 2021 Equity Facility, and includes Aspire Capital’s commitment to purchase up to an aggregate of $100.0 million of shares of our common stock over a defined timeframe. Our prior $100 million equity facility with Aspire Capital that was entered in 2019, or the 2019 Equity Facility, was fully utilized and terminated during the third quarter of 2021. During the quarter ended March 31, 2022, we sold 6,800,000 shares of our common stock to Aspire Capital at an average price of $0.71 per share. During the quarter ended March 31, 2021, we sold 15,200,000 shares of our common stock to Aspire Capital at an average price of $2.01 per share.
15

Results of Operations
Since our inception, our revenues have consisted of license fees, contract revenues, royalties and milestone payments from our collaborators, and grant proceeds. We have not derived revenue from our commercial sale of therapeutic products to date since we are in clinical development. Research and development expenses consist primarily of external clinical and preclinical study fees, manufacturing and process development costs, salaries and related personnel costs, legal expenses resulting from intellectual property prosecution processes, facility costs, and laboratory supply and reagent costs. We expense research and development costs as they are incurred. We expect to continue to make significant investments in research and development to enhance our technologies, advance clinical trials of our product candidates, expand our regulatory affairs and product development capabilities, conduct preclinical studies of our product, manufacture our product candidates, improve our manufacturing and process development and prepare for potential commercialization of our MultiStem cell therapy product. General and administrative expenses consist primarily of salaries and related personnel costs, professional fees and other corporate expenses. We expect to continue to incur substantial losses through at least the next several years.
Three Months Ended March 31, 2022 and 2021
Revenues. Revenues for the three months ended March 31, 2022 were $2.9 million compared to no revenues for the three months ended March 31, 2021. The revenues in the first quarter of 2022 are associated with services provided under the Framework Agreement. Our collaboration revenues will fluctuate from period-to-period based on the services provided under our arrangement with Healios. We expect our collaboration revenues to vary over time as we contract with Healios to perform support services and as we potentially enter into new collaborations.
Research and Development Expenses. Research and development expenses are $20.9 million for the three months ended March 31, 2022 from $17.5 million for the comparable period in 2021. The $3.4 million increase is associated with increases in clinical trial and manufacturing process development costs of $1.8 million, personnel costs of $0.8 million, outside service costs of $0.7 million and internal research supplies of $0.4 million. These increases were partially offset by decreases in other research and development costs of $0.3 million. Our clinical development, clinical manufacturing and manufacturing process development expenses vary over time based on the timing and stage of clinical trials underway, manufacturing campaigns for clinical trials and manufacturing process development projects. These variations in activity level may also impact our accounts payable, accrued expenses, prepaid expenses and deposits balances from period to period. Other than external expenses for our clinical and preclinical programs, we generally do not track our research expenses by project; rather, we track such expenses by the type of cost incurred.
General and Administrative Expenses. General and administrative expenses were $4.1 million for the three months ended March 31, 2022, which was lower than the $8.8 million for the comparable period in 2021. The decrease is primarily related to legal expenses incurred in connection with the complaint filed by Dr. Kagimoto against the Company, its settlement, and the expenses associated with Dr. Van Bokkelen’s separation letter agreement, including $2.3 million of one-time non-cash stock compensation expense in the first quarter of 2021.
Depreciation. Depreciation expense remained consistent at $0.2 million for the three months ended March 31, 2022 and for the comparable period in 2021. We expect that our annual depreciation will increase in 2022 compared to 2021.
Other Income, net. Other income, net, generally includes net foreign currency gains and losses, and net interest income and expense.
Liquidity and Capital Resources
Our sources of liquidity include our cash balances and equity purchase agreement with Aspire Capital. At March 31, 2022, we had $21.8 million in cash and cash equivalents. We have primarily financed our operations through business collaborations, grant funding and equity financings, including through our equity facility. We conduct all of our operations through our subsidiary, ABT Holding Company. Consequently, our ability to fund our operations depends on ABT Holding Company’s financial condition and its ability to make dividend payments or other cash distributions to us. There are no restrictions such as government regulations or material contractual arrangements that restrict the ability of ABT Holding Company to make dividend and other payments to us.
We have prepared our unaudited condensed consolidated financial statements on a going concern basis, which assumes that we will realize our assets and satisfy our liabilities in the normal course of business. However, we have incurred losses since inception of our operations in 1995, have negative operating cash flows, including in each of the last three years, and had an accumulated deficit of $605.6 million at March 31, 2022. Our losses have resulted principally from costs incurred in research and development, clinical and preclinical product development, manufacturing and process development, acquisition and licensing costs, and general and administrative costs associated with our operations. These circumstances raise substantial doubt
16

about our ability to continue as a going concern. The accompanying unaudited condensed financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning our ability to continue as a going concern.
We plan to raise additional capital through the use of our equity purchase agreement with Aspire Capital and, depending on market conditions, through equity offerings. We are entitled to receive potential milestones payments, subject to certain credits, and royalties from Healios under our licensed programs. Under the Framework Agreement, we are entitled to a new milestone payment in the amount of $3.0 million in June 2022. We receive payments from Healios for certain manufacturing support services. Certain proceeds from Healios may be used by Healios to offset milestone payments that may become due in the future. Additionally, we have the ability to defer certain spending and potentially defer and delay certain non-core programs. While we believe this plan to generate additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within our control and cannot be assessed as being probable of occurring. For the foreseeable future, our ability to continue our operations is dependent upon our ability to obtain additional capital.
We have had equity purchase agreements in place with Aspire Capital since 2011 that provide us the ability to sell shares to Aspire Capital from time to time. Currently, we are party to the 2021 Equity Facility, which includes Aspire Capital’s commitment to purchase up to an aggregate of $100.0 million of shares of our common stock over a defined timeframe. The terms of the 2021 Equity Facility are similar to the previous equity purchase agreement, and we filed a registration statement for the resale of 40,000,000 shares of our common stock. The 2019 Equity Facility was fully utilized and terminated during the third quarter of 2021. During the quarter ended March 31, 2022, we sold 6,800,000 shares of our common stock to Aspire Capital at an average price of $0.71 per share. During the quarter ended March 31, 2021, we sold 15,200,000 shares of our common stock to Aspire Capital at an average price of $2.01.
We will require substantial additional funding in order to continue our research and product development programs, including clinical trials of our product candidates and process development and manufacturing projects, and to prepare for possible regulatory approval and commercial activities. We have agreements with several contract manufacturing organizations for the manufacture of our MultiStem product candidate to supply our planned and ongoing clinical trials. These agreements represent significant financial commitments, including deposits prior to commencement of manufacturing and progress payments through the course of the manufacturing process.
We intend to meet our short-term liquidity needs with available cash, including available proceeds from our existing equity facility, potential delays in certain non-core programs, and our ability to defer certain spending. Furthermore, we are actively pursuing new collaborative opportunities and other potential sources of funding. which could reduce the current level of usage of our equity facility.
Importantly, we expect that the results of Healios’ TREASURE study, followed by the results of our MASTERS-2 clinical trial, will have a significant impact, favorable or unfavorable, on our ability to access capital from potential third-party commercial partners or the equity capital markets. Depending on the nature of these results, we may accelerate or may delay certain programs. In the long term, we will have to continue to generate additional capital to meet our needs until we would become cash flow positive as a result of the sales of our clinical products, if they are approved for marketing. Such capital would come from new and existing collaborations and the related license fees, milestones and potential royalties, the sale of equity securities from time to time including through our equity facility, grant-funding opportunities, deferral of certain discretionary costs and the staging of certain development costs, as needed.
Additionally, we may raise capital from time to time through our equity purchase arrangement with Aspire, subject to its volume and price limitations and equity offerings. We also manage our cash by deferring certain discretionary costs and staging certain development costs to extend our operational runway, as needed. Over time, we may consider borrowing from financing institutions or royalty financing arrangements.
Our capital requirements over time depend on a number of factors, including progress in our clinical development programs, preparing for potential commercialization of our product candidates, potential product launch, our clinical and preclinical pipeline of additional opportunities and their stage of development, additional external costs, such as payments to contract research organizations and contract manufacturing organizations, additional personnel costs and the costs of filing and prosecuting patent applications and enforcing patent claims. Furthermore, delays in product supply for our clinical trials may impact the timing and cost of such studies, and delays in product supply following Healios’ potential product launch may impact the timing of royalties that we may receive. The availability of funds impacts our ability to advance multiple clinical programs concurrently, and any shortfall in funding could result in our having to delay or curtail research and development efforts. Further, these requirements may change at any time due to technological advances, business development activity or competition from other companies. We cannot assure you that adequate funding will be available to us or, if available, that it will be available on acceptable terms.
17

We expect to continue to incur substantial losses through at least the next several years and may incur losses in subsequent periods. The amount and timing of our future losses are highly uncertain. Our ability to achieve and thereafter sustain profitability will be dependent upon, among other things, successfully developing, commercializing and obtaining regulatory approval or clearances for our technologies and products resulting from these technologies.
Cash Flow Analysis
Net cash used in operating activities was $20.2 million for the three months ended March 31, 2022 compared to $17.1 million for the three months ended March 31, 2021. Net cash used in operating activities may fluctuate significantly on a quarter-to-quarter basis, as it has over the past several years, primarily due to the receipt of fees from our collaborators and payment of clinical trial costs, such as clinical manufacturing campaigns, contract research organization costs and manufacturing process development projects. These variations in activity level may also impact our accounts receivable, accounts payable, accrued expenses, prepaid expenses and deposits balances from period to period.
Net cash used in investing activities was $0.2 million and $0.1 million for the three months ended March 31, 2022 and 2021, respectively. The fluctuations over the periods were due to the timing of additions to property and equipment primarily for our manufacturing process development activities.
Financing activities provided cash of $4.7 million and $29.9 million for the three months ended March 31, 2022 and 2021, respectively, primarily from the issuance of our common stock to Aspire Capital under our equity purchase agreements. Also included in financing activities for the three months ended March 31, 2022 and March 31, 2021 are shares retained for withholding tax payments on stock-based awards.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements.
Critical Accounting Policies and Management Estimates
The Securities and Exchange Commission, or the SEC, defines critical accounting policies as those that are, in management’s view, important to the portrayal of our financial condition and results of operations and demanding of management’s judgment. Our discussion and analysis of financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates on experience and on various assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. A description of these accounting policies and estimates is included in Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes in our accounting policies and estimates as described in our Annual Report on Form 10-K for the year ended December 31, 2021.
For additional information regarding our accounting policies, see Note B to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2021.
Cautionary Note on Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the timing of initiation of new clinical sites and patient enrollment in our clinical trials, the expected timetable for development of our product candidates, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “suggest,” “will,” or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. These forward-looking statements appear in a number of places in this Quarterly Report on Form 10-Q.
In addition, a number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face are the risks and uncertainties inherent in the process of discovering, developing, and commercializing products that are safe and effective for use as therapeutics, including the uncertainty regarding market acceptance of our product candidates and our ability to generate revenues. The following risks and
18

uncertainties may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements:
the possibility of unfavorable results from ongoing and additional clinical trials involving MultiStem;
the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in an early stage clinical trial may not be predictive of results in later stage or large scale clinical trials;
our ability to raise capital to fund our operations, including but not limited to, our ability to access our traditional financing sources and to continue as a going concern;
our ability to regain compliance with the requirement to maintain a minimum closing bid price of $1.00 per share as set forth in Nasdaq Listing Rule 5550(a)(2);
the timing and nature of results from MultiStem clinical trials, including the MASTERS-2 Phase 3 clinical trial evaluating the administration of MultiStem for the treatment of ischemic stroke, and the Healios TREASURE clinical trial in Japan, including the timing of the release of data by Healios from its clinical trial;
our ability to meet milestones and earn royalties under our collaboration agreements, including the success of our collaboration with Healios;
the success of our MACOVIA clinical trial evaluating the administration of MultiStem for the treatment of ARDS induced by COVID-19 and other pathogens, and the MATRICS-1 clinical trial being conducted with The University of Texas Health Science Center at Houston evaluating the treatment of patients with serious traumatic injuries;
the possibility that the COVID-19 pandemic could continue to delay clinical site initiation, clinical trial enrollment, regulatory review and potential receipt of regulatory approvals, payments of milestones under our license agreements and commercialization of one or more of our product candidates, if approved;
the availability of product sufficient to meet commercial demand shortly following any approval;
the impact on our business, results of operations and financial condition from the ongoing and global COVID-19 pandemic, or any other pandemic, epidemic or outbreak of infectious disease in the United States;
the possibility of delays in, adverse results of, and excessive costs of the development process;
our ability to successfully initiate and complete clinical trials of our product candidates;
the impact of the COVID-19 pandemic on the production capabilities of our contract manufacturing partners and our MultiStem trial supply chain;
the possibility of delays, work stoppages or interruptions in manufacturing by third parties or us, such as due to material supply constraints, contaminations, operational restrictions due to COVID-19 or other public health emergencies, labor constraints, regulatory issues or other factors that could negatively impact our trials and the trials of our collaborators;
uncertainty regarding market acceptance of our product candidates and our ability to generate revenues, including MultiStem cell therapy for neurological, inflammatory and immune, cardiovascular and other critical care indications;
changes in external market factors;
changes in our industry’s overall performance;
changes in our business strategy;
our ability to protect and defend our intellectual property and related business operations, including the successful prosecution of our patent applications and enforcement of our patent rights, and operate our business in an environment of rapid technology and intellectual property development;
our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies;
our collaborators’ ability to continue to fulfill their obligations under the terms of our collaboration agreements and generate sales related to our technologies;
the success of our efforts to enter into new strategic partnerships and advance our programs;
our possible inability to execute our strategy due to changes in our industry or the economy generally;
19

changes in productivity and reliability of suppliers;
the success of our competitors and the emergence of new competitors; and
the risks described in our Annual Report on Form 10-K for the year ended December 31, 2021 under Item 1A, “Risk Factors.” and our other filings with the SEC.
Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events and is subject to these other risks, uncertainties and assumptions relating to our operations, operating results, growth strategy and liquidity. Although we currently believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee our future results, levels of activity or performance. We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law. You are advised, however, to consult any further disclosures we make on related subjects in our reports on Forms 10-Q, 8-K and 10-K furnished to the SEC. You should understand that it is not possible to predict or identify all risk factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.
Item 3.    Quantitative and Qualitative Disclosures About Market Risk.
There were no material changes in our exposure to market risk since the disclosure included in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2021.
Item 4.    Controls and Procedures.
Disclosure controls and procedures
Our management, under the supervision of and with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective.
Changes in internal control over financial reporting
During the last fiscal quarter covered by this Quarterly Report on Form 10-Q, there has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION 

Item 1A.    Risk Factors.
In addition to the other information set forth elsewhere in this Quarterly Report on Form 10-Q, you should carefully consider the risk factor set forth below and the other risk factors discussed in Part I, Item 1A “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Those factors, if they were to occur, could cause our actual results to differ materially from those expressed in our forward-looking statements in this report, and materially adversely affect our financial condition or future results. Although we are not aware of any other factors that we currently anticipate will cause our forward-looking statements to differ materially from our future actual results, or materially affect the Company’s financial condition or future results, additional risks and uncertainties not currently known to us or that we currently deem to be immaterial might materially adversely affect our actual business, financial condition and/or operating results.
We are not currently in compliance with Nasdaq’s continued listing requirements. If we are unable to comply with Nasdaq’s continued listing requirements, our common stock could be delisted, which could affect the price of our common stock and liquidity and reduce our ability to raise capital.
Our common stock is currently listed on the Nasdaq Capital Market. The NASDAQ Capital Market has established certain quantitative criteria and qualitative standards that companies must meet to remain listed for trading on this market.
20

On March 18, 2022, we received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”), because the closing bid price of our common stock was below $1.00 per share for 30 consecutive business days. The Notice does not impact the listing of our common stock on the Nasdaq Capital Market at this time.
The Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of the Notice, or until September 14, 2022, to regain compliance with the Bid Price Requirement. During this period, our common stock will continue to trade on the Nasdaq Capital Market. However, there can be no assurance that the Company will be able to regain compliance with the rule or will otherwise be in compliance with other Nasdaq listing criteria.
If we are unable to regain compliance, Nasdaq may make a determination to delist our common stock. Any delisting of our common stock could adversely affect the market liquidity of our common stock and the market price of our common stock could decrease. Furthermore, if our common stock were delisted it could adversely affect our ability to obtain financing for the continuation of our operations and our ability to attract and retain employees by means of equity compensation and/or result in the loss of confidence by investors.

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds.
Aspire Capital Equity Purchase Agreement
During the quarter ended March 31, 2022, we sold 6,800,000 shares of our common stock, in the aggregate, to Aspire Capital under the 2021 Equity Facility generating proceeds of $4.8 million. Each issuance of these unregistered shares qualifies as an exempt transaction pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). Each issuance qualified for exemption under Section 4(a)(2) of the Securities Act because it did not involve a public offering. Each offering was not a public offering due to the number of persons involved, the manner of the issuance and the number of securities issued. In addition, Aspire Capital had the necessary investment intent.

Item 6.    Exhibits.

Exhibit No.Description
10.1*†
10.2*†
10.3†
31.1
31.2
32.1
101
The following materials from Athersys’ Quarterly Report on Form 10-Q for the period ended March 31, 2022, are formatted in Inline XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations and Comprehensive Loss; (iii) the Condensed Consolidated Statements of Stockholders’ Equity; (iv) the Condensed Consolidated Statements of Cash Flows; (v) Notes to Unaudited Condensed Consolidated Financial Statements; and (vi) document and entity information.
104Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).
*Filed herewith.
Indicates management contract or compensatory plan, contract or arrangement in which one or more director or executive officers of the registrant maybe be participants.
21

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
ATHERSYS, INC.
 
Date: May 6, 2022/s/ Ivor Macleod
Ivor Macleod
Chief Financial Officer and Duly Authorized Officer
22
EX-10.1 2 ex10120220331.htm EX-10.1 Document
EXHIBIT 10.1

image_0a.jpg


CONFIDENTIAL
Sent by e-mail

January 13, 2022

Daniel Camardo
c/o Athersys, Inc.
3201 Carnegie Avenue
Cleveland, Ohio 44115

Dear Dan,

Speaking on behalf of our team, we have enjoyed our recent interactions with you. We believe that you could bring substantial leadership and experience to Athersys, Inc. (the “Company”) and build on our established foundation to help successfully prepare and position our operations for the next stage of growth and development. As such, we are pleased to extend to you an offer to join the Company as Chief Executive Officer, with a start date of March 1, 2022 (or such later date as mutually agreed to by you and the Company). In this role, you will report to the Board of Directors of the Company (the “Board”).

In your capacity as Chief Executive Officer, your compensation will include:

Base salary at the annual rate of $600,000, payable in monthly increments, with eligibility for annual merit increases at the discretion of the Board;
A cash signing bonus equal to $250,000, payable within 30 days of your employment start date, but if you voluntarily terminate your employment with the Company within 12 months of your employment start date, you must repay the full amount of the signing bonus within 30 days of your voluntary termination. You further acknowledge and agree that the Company may deduct from any amounts due to you from the Company (including without limitation any salary, bonuses, severance or separation pay, and expense reimbursements) up to the full amount of the signing bonus owed to the Company, subject to applicable law. If such deduction does not fully satisfy the amount of reimbursement due, or if the Company elects not to take such deduction, you agree to repay the remaining unpaid balance to the Company within 30 days of your separation from employment with the Company. By signing and returning this offer letter, you agree to repayment of the signing bonus as provided for in this paragraph, and you further agree
image_1a.jpg
Athersys, Inc. 3201 Carnegie Avenue, Cleveland, Ohio 44115-2634 Phone 216.431.9900 Fax 216.361.9495

EXHIBIT 10.1
to execute any documents that may be requested by the Company to memorialize any deductions that you have authorized herein;
Participation in the annual cash incentive compensation program on terms substantially similar as those that apply to other executive officers of the Company, with a target opportunity of 60% of your actually earned base salary during the year (and no guaranteed minimum payment), subject to company performance as designed annually for such program by the Board or its Compensation Committee. Each annual cash incentive award will be subject to the specific approval of the Board or its Compensation Committee. Any annual cash incentive payment you earn for 2022 will be based on full-year performance (in other words, it will not be pro-rated simply because you were not employed by the Company as of January 1, 2022);
A stock option award (the “Option Award”) to purchase 10,000,000 shares of Company common stock (the “Option Shares”), at a per share exercise price equal to the Grant Date closing price of a share of Company common stock, granted on (or as soon as practical after) your employment start date (the “Grant Date”). The Option Award is designed as an inducement material to your entry into employment with the Company, including for purposes of Nasdaq Listing Rule 5635(c)(4). Vesting of the Option Award shall generally occur as follows:
With respect to 4,000,000 of the Option Shares, vesting will generally occur after a one-year “cliff” for 1,000,000 of such Option Shares and the remainder of such shares vesting ratably in substantially equal installments over the subsequent 36 months;
With respect to 6,000,000 of the Option Shares, vesting will generally occur upon the achievement of certain milestones as provided on Appendix A;
Any unvested portion of the Option Award will accelerate and vest immediately upon a termination of your employment by the Company or its successor without “cause” following a change in control of the Company. The remaining terms of the Option Award will be based substantially on a form Company stock option agreement approved for the purposes of your Option Award. Notwithstanding the information described in the bullet points above, the Option Award will be subject to the specific approval of the Board or its Compensation Committee and the specific terms of the governing Company equity plan and award agreement (including key terms defined therein);
Beginning in 2022, participation during your employment on terms substantially similar to those that apply to other executive officers of the Company in the annual stock-based award program. These awards will be determined annually at the discretion of the Board or its Compensation Committee and will be subject to the specific approval of the Board or its Compensation Committee and the terms of the governing equity plan;
Certain severance benefits under the terms of an employment agreement to be entered into between you and the Company; and
Participation in the Company’s employee benefits plans then in effect.

image_1a.jpg
Athersys, Inc. 3201 Carnegie Avenue, Cleveland, Ohio 44115-2634 Phone 216.431.9900 Fax 216.361.9495

EXHIBIT 10.1
We reserve the right to change, alter or terminate any benefit plan or program in our sole discretion.

You are responsible for all federal, state, city or other taxes imposed on compensation and benefits provided pursuant to or otherwise related to your employment, and the Company is not obligated to guarantee any particular tax result for you with respect to any payment or benefit provided to you. The Company may withhold from any amounts payable to you under this letter or otherwise related to your employment all federal, state, city or other taxes as the Company or its affiliates is required to withhold pursuant to any applicable law, regulation or ruling.

This letter, including the at-will nature of the employment relationship between you and the Company, may be modified or terminated only in a writing signed by both you and an authorized representative of the Company.

Nothing in this letter prevents you from providing, without prior notice to the Company, information to governmental authorities regarding possible legal violations or otherwise testifying or participating in any investigation or proceeding by any governmental authorities regarding possible legal violations. Furthermore, no Company policy or individual agreement between the Company and you shall prevent you from providing information to government authorities regarding possible legal violations, participating in investigations, testifying in proceedings regarding the Company’s past or future conduct, engaging in any future activities protected under the whistleblower statutes administered by any government agency (e.g., EEOC, NLRB, SEC, etc.) or receiving a monetary award from a government-administered whistleblower award program for providing information directly to a government agency. The Company nonetheless asserts and does not waive attorney-client privilege over any information appropriately protected by privilege.

This offer of employment is valid through January 20, 2022, is contingent upon the Company’s receipt of your signed acceptance within that time and is revocable at any time at the discretion of the Company. This offer does not constitute a contract of employment, and your employment as Chief Executive Officer on these terms is subject to final Board approval and your entry into an Employment Agreement and other standard employment arrangements with the Company as may be appropriate, including those covering non-competition, confidentiality and other restrictive covenant arrangements.

We look forward to working together.

Sincerely,                        


/s/Dr. Ismail Kola                                        
Dr. Ismail Kola
Chairman of the Board of Directors
Athersys, Inc.
Accepted by:


/s/Daniel Camardo
Daniel Camardo
image_1a.jpg
Athersys, Inc. 3201 Carnegie Avenue, Cleveland, Ohio 44115-2634 Phone 216.431.9900 Fax 216.361.9495
EX-10.2 3 ex10220220331.htm EX-10.2 Document

EXHIBIT 10.2
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT, by and between Athersys, Inc., a Delaware corporation (the “Company”), and Daniel Camardo (“Executive”), is dated as of the 14th day of February, 2022 (the “Agreement”).
The Company wishes to employ Executive on the terms and conditions, and for the consideration, hereinafter set forth, and Executive desires to be employed by the Company on such terms and conditions and for such consideration.
In consideration of the promises provided for in this Agreement, the Company and Executive agree as follows:
1.Employment Period. This Agreement shall become effective as of February 14, 2022 (the “Effective Date”). The Company hereby agrees to employ Executive, and Executive hereby agrees to be employed by the Company, on an at-will basis on the terms and conditions set forth herein, for the period commencing on the Effective Date and ending on Executive’s Date of Termination (as defined in Section 3(f)) (the “Employment Period”).
2.Terms of Employment.
(a)Position and Duties.
(i)During the Employment Period, Executive shall serve as the Chief Executive Officer of the Company with such duties and responsibilities as are commensurate with such position, reporting to the Board of Directors of the Company (the “Board”). Except during such periods as otherwise agreed to from time to time by the Board, Executive shall perform Executive’s services at the Company’s principal executive offices in Cleveland, Ohio (subject to reasonable travel requirements commensurate with Executive’s position).
(ii)During the Employment Period, and excluding any periods of vacation, personal time off and/or sick leave to which Executive is entitled, Executive agrees to devote Executive’s full business time and attention to the business and affairs of the Company. During the Employment Period, it will not be a violation of this Agreement for Executive to (A) serve on civic or charitable boards or committees, (B) deliver lectures, fulfill speaking engagements or teach at educational institutions and (C) manage personal investments, so long as such activities described in clauses (A), (B) and (C) do not significantly interfere with the performance of Executive’s responsibilities as an employee of the Company in accordance with this Agreement.
(b)Compensation.
(i)Base Salary. During the Employment Period, Executive shall receive an annual base salary (“Annual Base Salary”) at a rate of $600,000 payable in accordance with the normal payroll practices of the Company as may be in effect from time to time, which Annual Base Salary shall be reviewed for merit increases from time to time at the discretion of the Compensation Committee (the “Compensation Committee”) of the Board.
(ii)Annual Incentive. During the Employment Period, beginning in 2022, Executive shall be eligible to participate in the Company’s annual cash incentive compensation program on terms and conditions substantially similar to those that apply to executive officers of the Company generally. Pursuant to such participation, Executive shall be eligible to earn an annual cash incentive payment (the “Annual Incentive Payment”) for each applicable calendar year, with a target Annual Incentive Payment opportunity equal to 60% of Annual Base Salary,
NAI-1525772552v3


based on the achievement of specified Company and/or individual performance goals (as determined annually by the Board or the Compensation Committee). Any Annual Incentive Payment opportunity will be subject to the terms and conditions of the Company’s annual cash incentive compensation program applicable thereto, including with respect to the timing of payment. Notwithstanding the foregoing, each Annual Incentive Payment opportunity granted to Executive shall be subject to the specific approval of the Board and/or the Compensation Committee. There is no guaranteed Annual Incentive Payment under this Agreement, and for each applicable year, Executive’s Annual Incentive Payment could be as low as zero or as high as the maximum Annual Incentive Payment opportunity established for such year.
(iii)Signing Bonus. During the Employment Period and within thirty (30) days following the Effective Date, the Company will make a lump sum payment to Executive in an amount equal to $250,000 (the “Signing Bonus”); provided, however, that if Executive voluntarily terminates Executive’s employment with the Company for any reason within the first twelve (12) months of the Employment Period, Executive agrees to repay the Signing Bonus to the Company within thirty (30) days following such termination in accordance with this Section 2(b)(iii). Executive acknowledges and agrees that the Company may deduct from any amounts due to Executive from the Company (including without limitation any salary, bonuses, severance or separation pay, and expense reimbursements) up to the full amount of the Signing Bonus owed to the Company in the event of Executive’s voluntary termination of employment within the first twelve (12) months of the Employment Period, subject to applicable law. If such deduction does not fully satisfy the amount of reimbursement due, or if the Company elects not to make such deduction, Executive agrees to repay the remaining unpaid balance to the Company within thirty (30) days following such termination of employment with the Company. By executing this Agreement, Executive agrees to repayment of the Signing Bonus as provided for in this paragraph, and Executive further agrees to execute any documents that may be requested by the Company to memorialize any deductions that Executive has authorized herein.
(iv)Annual Equity Grant. During the Employment Period, beginning in 2022, Executive shall be eligible to participate in the Company’s annual stock-based award program on terms and conditions substantially similar to those that apply to executive officers of the Company generally. The terms of such awards shall be determined annually at the discretion of the Board and/or the Compensation Committee and shall be subject to approval by the Board and/or the Compensation Committee. Such awards shall be granted in accordance with the Company’s policies, the applicable award agreements and the applicable equity compensation plans under which such awards are granted.
(v)Employee Benefits. During the Employment Period, Executive shall be eligible to participate in the employee benefit plans, programs, and policies, as may be in effect from time to time, for executive officers of the Company generally.
(vi)Vacation, Personal Time Off and Holidays. During the Employment Period, Executive shall be entitled to paid vacation and/or personal time off during each calendar year in accordance with the Company’s policies then applicable to executive officers, but in no event fewer than four (4) weeks per year (pro-rated for any partial year). Unused vacation and/or personal time off days will not carry over between calendar years unless otherwise expressly provided under the applicable Company policy. Executive shall be entitled to paid holidays in accordance with the Company’s policies.
(vii)Expenses. During the Employment Period, Executive shall be entitled to receive prompt reimbursement for all reasonable and customary expenses incurred by Executive in accordance with the performance of Executive’s duties under this Agreement and in accordance with the Company’s business expense reimbursement policy. In addition, during the Employment Period, Executive will be entitled to receive reimbursement for reasonable
NAI-1525772552v3    2




commuting expenses from Executive’s primary residence to Cleveland, Ohio that are incurred by Executive while performing Company-related work, which will include airfare, hotel and/or temporary housing in the Cleveland, Ohio area and local transportation, up to an annual maximum value of $50,000 for such period (to be paid in accordance with the applicable Company policies within 60 days after incurring such expense if evidence of such expense is provided to the Company within 30 days after incurring such expense).
3.Termination of Employment.
(a)Death or Disability. Executive’s employment shall terminate automatically if Executive dies during the Employment Period. If the Company determines in good faith that the Disability (as defined herein) of Executive has occurred during the Employment Period (pursuant to the definition of “Disability” set forth below), it may give to Executive written notice in accordance with Section 14(b) of its intention to terminate Executive’s employment. In such event, Executive’s employment with the Company shall terminate effective on the 30th day after receipt of such notice by Executive (the “Disability Effective Date”), provided that, within the thirty (30) days after such receipt, Executive shall not have returned to full-time performance of Executive’s duties. “Disability” means that in the written opinion of a qualified physician selected by the Company and agreed to by Executive (or if no agreement is reached within thirty (30) days of the commencement of discussions between the Company and Executive, then of a qualified physician agreed upon by the physician selected by the Company and a physician selected by Executive), Executive has become unable to perform his duties under this Agreement due to physical or mental illness.
(b)By the Company. The Company may terminate Executive’s employment during the Employment Period for any, or no, reason, with or without Cause. For purposes of this Agreement, “Cause” will be deemed to exist upon:
(i)the commission by Executive of an act of fraud, embezzlement, theft or other criminal act constituting a felony or involving moral turpitude;
(ii)Executive’s willful or wanton disregard of the rules or policies of the Company or its affiliates that results in a material loss, damage or injury to the Company or its affiliates;
(iii)the repeated failure of Executive to perform duties consistent with Executive’s position or to follow or comply with the reasonable directives of the Board after having been given notice thereof (e.g., the insubordination of Executive); or
(iv)Executive’s breach of any provision contained in Section 8 of this Agreement.
Notwithstanding the foregoing, Executive will not be deemed to have been terminated for Cause without (A) reasonable written notice to Executive specifying in detail the specific reasons for the Company’s intention to terminate for Cause, and (B) an opportunity for Executive to cure such condition constituting “Cause,” if curable, within thirty (30) days following the date on which the Company provides such notice to Executive.
(c)By Executive. Executive’s employment may be terminated during the Employment Period by Executive for Good Reason or by Executive without Good Reason. For purposes of this Agreement, “Good Reason shall mean, in the absence of the prior written consent of Executive:
NAI-1525772552v3    3




(i)a material diminution in Executive’s position, duties, responsibilities, authority, or reporting relationship (except during periods when Executive is unable to perform all or substantially all of Executive’s duties and/or responsibilities as a result of Executive’s illness (either physical or mental) or other incapacity);
(ii)a material reduction in Executive’s Annual Base Salary or annual cash incentive opportunity; provided, however, that if, at any time other than on (or during the twelve-month period following) a Change in Control (as defined below), such reduction is part of a broad-based reduction (A) in the annual base salaries and/or annual cash incentive opportunities of all executives of the Company at or above the senior vice president level, and (B) that applies substantially equally to all such executives in terms of percentage (and that constitutes less than a 15% reduction of such Annual Base Salary and/or annual cash incentive opportunity), such reduction shall not constitute Good Reason;
(iii)a change in the location where Executive is required to perform Executive’s services to the Company to a location that is greater than fifty (50) miles from such location as of the Effective Date; or
(iv)a material breach of this Agreement by the Company;
provided, however, that the circumstances described in clauses (i)–(iv) above shall not constitute Good Reason unless (A) Executive gives the Company notice of the existence of the applicable event described above within sixty (60) days following the occurrence thereof, (B) the Company does not remedy such event within thirty (30) days after receiving such notice, and (C) Executive terminates employment within sixty (60) days after the end of the cure period specified in clause (B) above.
(d)Notice of Termination. Any termination of Executive’s employment by the Company for Cause or without Cause, or by Executive for Good Reason or without Good Reason, shall be communicated by Notice of Termination to the other party hereto given in accordance with Section 14(b) of this Agreement. “Notice of Termination” means a written notice that (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive’s employment under the provision so indicated, and (iii) if the Date of Termination (as defined in Section 3(f)) is other than the date of receipt of such notice, specifies the Date of Termination. The failure by Executive or the Company to set forth in the Notice of Termination any fact or circumstance that contributes to a showing of Good Reason or Cause shall not waive any right of Executive or the Company, respectively, hereunder or preclude Executive or the Company, respectively, from asserting such fact or circumstance in enforcing Executive’s or the Company’s respective rights hereunder.
(e)Resignation. Upon any termination of Executive’s employment with the Company, Executive shall be deemed to resign from any position as an officer, director, or fiduciary of any Company-related entity. Executive hereby agrees to execute any documentation reasonably requested by the Company or any of its affiliates in order to effectuate any such resignation.
(f)Date of Termination. “Date of Termination” means (i) if Executive’s employment is terminated by the Company for Cause, or by Executive for Good Reason, the date of receipt of the Notice of Termination or such later date specified in the Notice of Termination, as the case may be (which, in the case of a termination by Executive for Good Reason shall be subject to Section 3(c) above), (ii) if Executive’s employment is terminated by the Company other than for Cause or Disability, the date on which the Company notifies Executive of such
NAI-1525772552v3    4




termination (or such later date as is set forth in such notification); (iii) if Executive resigns or terminates employment without Good Reason, the date on which Executive notifies the Company of such termination (or such later date as is set forth in such notification, provided that the Company may in such case accelerate such date of termination, and any such accelerated termination shall not be considered a termination by the Company), and (iv) if Executive’s employment is terminated by reason of death or Disability, the date of Executive’s death or the Disability Effective Date, as the case may be. Notwithstanding the foregoing, in no event shall the Date of Termination occur until Executive experiences a “separation from service” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and the date on which such separation from service takes place shall be the “Date of Termination.”
4.Obligations of the Company upon Termination.
(a)By Executive for Good Reason or by the Company other than for Cause, Death or Disability Not During the Change In Control Period. If, during the Employment Period, the Company terminates Executive’s employment other than for Cause, death or Disability, or Executive terminates Executive’s employment for Good Reason, and Section 4(b) does not apply, the Company will pay and provide to Executive the amounts and benefits specified in Section 4(a)(i)-(iv) herein:
(i)The Company shall pay to Executive, in a lump sum in cash within thirty (30) days after the Date of Termination (or earlier, if required by applicable law), the aggregate of the following amounts: the sum of (A) Executive’s Annual Base Salary earned through the Date of Termination to the extent not theretofore paid; (B) Executive’s business expenses that are reimbursable pursuant to Section 2(b)(vii) of this Agreement but have not been reimbursed by the Company as of the Date of Termination; (C) Executive’s Annual Incentive Payment earned for the fiscal year immediately preceding the fiscal year in which the Date of Termination occurs (to the extent not previously paid); and (D) any accrued vacation and/or personal time off pay to the extent not theretofore paid (the sum of the amounts described in subclauses (A), (B), (C) and (D), the “Accrued Obligations”);
(ii)Subject to Section 11(b), the Company shall continue to pay Executive the greater of (A) Executive’s Annual Base Salary at the rate in effect at the time of such termination or (B) Executive’s Annual Base Salary at the highest rate in effect for Executive during the nine (9) month period immediately preceding the Date of Termination, for a period of eighteen (18) months following such termination in accordance with the Company’s normal payroll practices; provided, however, that Executive executes and does not revoke the Release (as defined in Section 4(d)) as described in Section 4(d);
(iii)In addition, if Executive was enrolled in the Company’s medical plan at the time of termination of Executive’s employment, the Company shall pay Executive a lump sum amount equal to the monthly COBRA premium for the level of coverage Executive was receiving at the time of termination of employment multiplied by 18; provided, however, that Executive executes and does not revoke the Release as described in Section 4(d), and such lump sum shall be paid on the first payroll date following the date the applicable Release revocation period has expired without the signed Release being revoked; and
(iv)To the extent not theretofore paid or provided, the Company shall timely pay or provide to Executive any Other Benefits (as defined in Section 5) in accordance with the terms of the underlying plans or agreements.
NAI-1525772552v3    5




It is expressly understood that the Company’s obligations under Sections 4(a)(ii)-(iii) shall cease in the event Executive breaches any of the agreements in Section 8 hereof. Other than as set forth in this Section 4(a), in the event of a termination of Executive’s employment by the Company other than for Cause, death or Disability, or by Executive for Good Reason, the Company shall have no further obligation to Executive under this Agreement.

(b) By Executive for Good Reason or By the Company other than for Cause, Death, or Disability During the Change in Control Period. If, during the Employment Period, the Company terminates Executive’s employment other than for Cause, death or Disability, or Executive terminates Executive’s employment for Good Reason, during the twelve (12) month period after a Change in Control (as defined below) (the “Change in Control Period”), the Company will pay and provide to Executive the amounts and benefits specified in Section 4(b)(i)-(v) herein and in lieu of the amounts and benefits provided in Section 4(a).
(i)The Company shall pay to Executive, in a lump sum in cash within thirty (30) days after the Date of Termination (or earlier, if required by applicable law), the aggregate of the Accrued Obligations;
(ii)Subject to Section 11(b), the Company shall: (A) continue to pay Executive the greater of (1) Executive’s Annual Base Salary at the rate in effect at the time of such termination, or (2) Executive’s Annual Base Salary at the highest rate in effect for Executive during the nine (9) month period immediately preceding the Date of Termination, for a period of twenty-four (24) months following such termination in accordance with the Company’s normal payroll practices; provided, however, that Executive executes and does not revoke the Release as described in Section 4(d); and (B) pay Executive a lump sum amount equal to the target Annual Incentive Payment for the calendar year in which the Date of Termination occurs multiplied by 200%; provided, however, that Executive executes and does not revoke the Release as described in Section 4(d), and such lump sum shall be paid on the first payroll date following the date the applicable Release revocation period has expired without the signed Release being revoked;
(iii)In addition, subject to Section 11(b), the Company shall pay Executive a lump sum amount equal to the product of (A) the Annual Incentive Payment that Executive would have received for the calendar year in which the Date of Termination occurs, based on actual achievement of the applicable performance goals for the calendar year, assuming that Executive’s employment had not been terminated, multiplied by (B) a fraction (x) the numerator of which is the number of days that Executive remained employed during the calendar year in which such Date of Termination occurs and (y) the denominator of which is 365, which shall be paid by the Company to Executive at the time the Company pays the Annual Incentive Payment for such calendar year to similarly situated active employees; provided, however, that Executive executes and does not revoke the Release as described in Section 4(d);
(iv)In addition, if Executive was enrolled in the Company’s medical plan at the time of termination of Executive’s employment, the Company shall pay Executive a lump sum amount equal to the monthly COBRA premium for the level of coverage Executive was receiving at the time of termination of employment multiplied by twenty-four (24); provided, however, that Executive executes and does not revoke the Release as described in Section 4(d), and such lump sum shall be paid on the first payroll date following the date the applicable Release revocation period has expired without the signed Release being revoked; and
NAI-1525772552v3    6




(v)To the extent not theretofore paid or provided, the Company shall timely pay or provide to Executive any Other Benefits (as defined in Section 5) in accordance with the terms of the underlying plans or agreements.
It is expressly understood that the Company’s obligations under Sections 4(b)(ii)-(iv) shall cease in the event Executive breaches any of the agreements in Section 8 hereof. Other than as set forth in this Section 4(b), in the event of a termination of Executive’s employment during the Change in Control Period by the Company other than for Cause, death or Disability, or by Executive for Good Reason, the Company shall have no further obligation to Executive under this Agreement.

(c)Cause; Disability; Death; Other than for Good Reason. If Executive’s employment is terminated by the Company for Cause during the Employment Period, the Company shall provide Executive with Executive’s Annual Base Salary earned through the Date of Termination, and the timely payment or delivery of the Other Benefits in accordance with the terms of the underlying plans or agreements, and shall have no further obligations under this Agreement. If Executive voluntarily terminates employment other than for Good Reason during the Employment Period, the Company shall provide to Executive the Accrued Obligations and the timely payment or delivery of the Other Benefits in accordance with the terms of the underlying plans or agreements, and shall have no further obligations under this Agreement. If Executive’s employment is terminated by reason of Executive’s death or Disability during the Employment Period, the Company shall provide Executive (or Executive’s estate or beneficiaries, if applicable) with the Accrued Obligations and the timely payment or delivery of the Other Benefits in accordance with the terms of the underlying plans or agreements, and shall have no further obligations under this Agreement. The Accrued Obligations shall be paid to Executive or, in the event of death, Executive’s estate or beneficiaries, in a lump sum in cash within thirty (30) days of the applicable Date of Termination.
(d)Release. Notwithstanding anything herein to the contrary, the Company shall not be obligated to make any payment under Sections 4(a)(ii) or 4(a)(iii) or Sections 4(b)(ii), 4(b)(iii), or 4(b)(iv) of this Agreement unless (i) prior to the 60th day following the Date of Termination, Executive executes a release of claims against the Company and its affiliates in substantially the form attached hereto as Exhibit A, with updates as needed or desired to reflect changes in applicable law, (the “Release”), and (ii) any applicable revocation period has expired during such 60-day period without Executive revoking such Release. Any payments pursuant to Section 4(a)(ii) or 4(a)(iii) or Section 4(b)(ii), (iii), or (iv) that would have been made during the 60-day period following the Date of Termination (as described above) but that are not made because the Release has not yet been signed and become effective will be made in a lump sum on the first payroll date following the date the revocation period has expired without the signed Release being revoked. In the event that the period beginning on Executive’s Date of Termination and ending on the first payroll date following the 60th day after Executive’s Date of Termination begins in one taxable year of Executive, and ends in a second taxable year of Executive, then, to the extent necessary to comply with Section 409A of the Code, the payments that would have otherwise been made pursuant to Sections 4(a)(ii) or 4(a)(iii) or Sections 4(b)(ii), 4(b)(iii), or 4(b)(iv) in the first taxable year shall not be made until the second taxable year. Each payment under Sections 4(a)(ii) or 4(a)(iii) or Sections 4(b)(ii), 4(b)(iii), or 4(b)(iv) shall be considered a separate payment and not one of a series of payments for purposes of Section 409A of the Code.
(e)Change in Control. “Change in Control” means the occurrence of any of the following events:
(i)any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended from time to time (the
NAI-1525772552v3    7




Exchange Act”)) (a “Person”) is or becomes the beneficial owner (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of more than 50% of the combined voting power of the then-outstanding securities entitled to vote generally in the election of members of the Board (the “Voting Stock”) of the Company; provided, however, that:
(A)for purposes of this Section 4(e), the following acquisitions shall not constitute a Change in Control: (1) any acquisition of Voting Stock of the Company directly from the Company that is approved by a majority of the Incumbent Directors (as defined below), (2) any acquisition of Voting Stock of the Company by the Company or any Subsidiary (as defined below), (3) any acquisition of Voting Stock of the Company by the trustee or other fiduciary holding securities under any employee benefit plan (or related trust) sponsored or maintained by the Company or any Subsidiary, and (4) any acquisition of Voting Stock of the Company by any Person pursuant to a Business Transaction (as defined below) that complies with clauses (A), (B) and (C) of Section 4(e)(ii) below;
(B)a Change in Control will not be deemed to have occurred if a Person is or becomes the beneficial owner of more than 50% of the Voting Stock of the Company as a result of a reduction in the number of shares of Voting Stock of the Company outstanding pursuant to a transaction or series of transactions that is approved by a majority of the Incumbent Directors unless and until such Person thereafter becomes the beneficial owner of any additional shares of Voting Stock of the Company representing 1% or more of the then-outstanding Voting Stock of the Company, other than as a result of a stock dividend, stock split or similar transaction effected by the Company in which all holders of Voting Stock are treated equally; and
(C)if at least a majority of the Incumbent Directors determine in good faith that a Person has acquired beneficial ownership of more than 50% of the Voting Stock of the Company inadvertently, and such Person divests as promptly as practicable but no later than the date, if any, set by the Incumbent Board a sufficient number of shares so that such Person beneficially owns 50% or less of the Voting Stock of the Company, then no Change in Control shall have occurred as a result of such Person’s acquisition; or
(ii)the consummation of a reorganization, merger or consolidation, or sale or other disposition of all or substantially all of the assets of the Company or the acquisition of the stock or assets of another corporation, or other transaction (each, a “Business Transaction”), unless, in each case, immediately following such Business Transaction (A) the Voting Stock of the Company outstanding immediately prior to such Business Transaction continues to represent (either by remaining outstanding or by being converted into Voting Stock of the surviving entity or any parent thereof), more than 60% of the combined voting power of the then outstanding shares of Voting Stock of the entity resulting from such Business Transaction (including, without limitation, an entity which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries), (B) no Person (other than the Company, such entity resulting from such Business Transaction or any employee benefit plan (or related trust) sponsored or maintained by the Company, any Subsidiary or such entity resulting from such Business Transaction) beneficially owns, directly or indirectly, more than 50% of the combined voting power of the then outstanding shares of Voting Stock of the entity resulting from such Business Transaction, and (C) at least a majority of the members of the Board of Directors of the entity resulting from such Business Transaction were Incumbent Directors at the time of
NAI-1525772552v3    8




the execution of the initial agreement or of the action of the Board providing for such Business Transaction; or
(iii)approval by the stockholders of the Company of a complete liquidation or dissolution of the Company, except pursuant to a Business Transaction that complies with clauses (A), (B) and (C) of Section 4(e)(ii) above.
(f)Incumbent Directors” means the individuals who, as of the Effective Date, are members of the Board (“Directors”) of the Company and any individual becoming a Director subsequent to the Effective Date whose election, nomination for election by the Stockholders (as defined below), or appointment was approved by a vote of at least two-thirds of the then Incumbent Directors (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director, without objection to such nomination); provided, however, that an individual shall not be an Incumbent Director if such individual’s election or appointment to the Board occurs as a result of an actual or threatened election contest with respect to the election or removal of Directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board.
(g)Stockholder” means an individual or entity that owns one or more shares of common stock, par value $0.001 per share, of the Company.
(h)Subsidiary” means a corporation, company or other entity (i) more than 50% of whose outstanding shares or securities (representing the right to vote for the election of directors or other managing authority) are, or (ii) which does not have outstanding shares or securities (as may be the case in a partnership, joint venture, limited liability company, unincorporated association or other similar entity), but more than 50% of whose ownership interest representing the right generally to make decisions for such other entity is, now or hereafter, owned or controlled, directly or indirectly, by the Company.
5.Non-Exclusivity of Rights. Amounts that Executive is otherwise entitled to receive under any plan, policy, practice or program of or any other contract or agreement with the Company at or subsequent to the Date of Termination (“Other Benefits”) shall be payable in accordance with such plan, policy, practice or program or contract or agreement, except as explicitly modified by this Agreement. Notwithstanding the foregoing, Executive shall not be eligible to participate in any other severance plan, program or policy of the Company.
6.Set-off; No Mitigation. The Company’s obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall be subject to set-off, counterclaim, recoupment, defense, or other claim, right or action that the Company may have against Executive to the extent such set-off or other action does not violate Section 409A of the Code. Executive shall not be required to mitigate the amount of any payment or benefit provided for in Sections 4(a)(ii) or 4(a)(iii) or Sections 4(b)(ii), 4(b)(iii), or 4(b)(iv) by seeking other employment or otherwise.
7.Limitations on Payments Under Certain Circumstances. Notwithstanding any provision of any other plan, program, arrangement or agreement to the contrary, in the event that it shall be determined that any payment or benefit to be provided by the Company to Executive pursuant to the terms of this Agreement or any other payments or benefits received or to be received by Executive (a “Payment”) in connection with or as a result of any event which is deemed by the U.S. Internal Revenue Service or any other taxing authority to constitute a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the assets of the Company and subject to the tax (the “Excise Tax”) imposed by Section 4999 (or any successor section) of the Code, the Payments, whether under this Agreement or otherwise, shall be reduced so that the Payment, in the aggregate, is reduced to the greatest
NAI-1525772552v3    9




amount that could be paid to Executive without giving rise to any Excise Tax; provided that in the event that Executive would be placed in a better after-tax position after receiving all Payments and not having any reduction of Payments as provided hereunder, Executive shall, notwithstanding the provisions of any other plan, program, arrangement or agreement to the contrary, receive all Payments and pay any applicable Excise Tax. All determinations under this Section 7 shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”). Without limiting the generality of the foregoing, any determination by the Accounting Firm under this Section 7 shall take into account the value of any reasonable compensation for services to be rendered by Executive (or for holding oneself out as available to perform services and refraining from performing services (such as under a covenant not to compete)). If the Payments are to be reduced pursuant to this Section 7, the Payments shall be reduced in the following order: (a) Payments which do not constitute “nonqualified deferred compensation” subject to Section 409A of the Code shall be reduced first; and (b) all other Payments shall then be reduced, in each case as follows: (i) cash payments shall be reduced before non-cash payments and (ii) payments to be made on a later payment date shall be reduced before payments to be made on an earlier payment date.
8.Restrictive Covenants.
(a)Acknowledgements and Agreements. Executive hereby acknowledges and agrees that in the performance of Executive’s duties to the Company during the Employment Period, Executive shall be brought into frequent contact with existing and potential customers of the Company throughout the world. Executive also agrees that trade secrets and confidential information of the Company, more fully described in Section 8(i) gained by Executive during Executive’s association with the Company, have been developed by the Company through substantial expenditures of time, effort and money and constitute valuable and unique property of the Company. Executive further understands and agrees that the foregoing makes it necessary for the protection of the Company’s business that Executive not compete with the Company during Executive’s employment with the Company and not compete with the Company for a reasonable period thereafter, as further provided in the following sections.
(b)Competitive Activity During Employment. Executive will not compete with the Company anywhere in the world during Executive’s employment with the Company, including, without limitation:
(i)entering into or engaging in any business which competes with the Company’s Business (as defined below);
(ii)soliciting customers, business, patronage or orders for, or selling, any products or services in competition with, or for any business that competes with, the Company’s Business;
(iii)diverting, enticing or otherwise taking away any customers, business, patronage or orders of the Company or attempting to do so; or
(iv)promoting or assisting, financially or otherwise, any person, firm, association, partnership, corporation or other entity engaged in any business which competes with the Company’s Business.
(c)Following Termination. For a period of twelve (12) months following Executive’s termination of employment with the Company, Executive will not:
(i) enter into or engage in any business which competes with the Company’s Business within the Restricted Territory (as hereinafter defined);
NAI-1525772552v3    10




(ii)solicit customers, business, patronage or orders for, or sell, any products or services in competition with, or for any business, wherever located, that competes with, the Company’s Business within the Restricted Territory;
(iii) divert, entice or otherwise take away any customers, business, patronage or orders of the Company within the Restricted Territory, or attempt to do so; or
(iv) promote or assist, financially or otherwise, any person, firm, association, partnership, corporation or other entity engaged in any business which competes with the Company’s Business within the Restricted Territory.

For the purposes of
Sections 8(a), (b), and (c) above and Section 8(h) below, inclusive, but without limitation thereof, Executive will be in violation thereof if Executive engages in any or all of the activities set forth therein directly as an individual on Executive’s own account, or indirectly as a partner, joint venturer, employee, agent, salesperson, consultant, officer and/or director of any firm, association, partnership, corporation or other entity, or as a stockholder of any corporation in which Executive or Executive’s spouse, child or parent owns, directly or indirectly, individually or in the aggregate, more than 5% of the outstanding stock.
(d)The “Company.” For the purposes of this Section 8, the “Company” shall include any and all direct and indirect subsidiaries, parents, and affiliated, or related companies of the Company for which Executive worked or had responsibility, or to which Executive had access to confidential or trade secret information, at the time of termination of Executive’s employment and at any time during the two year period prior to such termination.
(e)The Company’s “Business.” For the purposes of this Section 8, the Company’s Business is defined to be the business of researching, developing, marketing, or selling bone marrow-derived, stromal cell-based therapies, and any technology directly related thereto, including any such technology that is part of the Company’s intellectual property portfolio or that is substantially similar to that researched, developed, marketed or sold or contemplated to be researched, developed, marketed or sold by the Company prior to the Date of Termination, as evidenced by the books and records of the Company.
(f)“Restricted Territory.” For the purposes of this Section 8, the Restricted Territory shall be defined as and limited to any geographic areas in the United States or any countries outside the United States where the Company has researched, developed, marketed or sold such technologies, or has plans to expand into, as evidenced by the business and marketing plans of the Company, prior to the Date of Termination.
(g)Extension. If it shall be judicially determined that Executive has violated any of Executive’s obligations under Section 8(b) or 8(c), then the period applicable to each obligation that Executive shall have been determined to have violated shall automatically be extended by a period of time equal in length to the period during which such violation(s) occurred.
(h)Non-Solicitation. Executive shall not, directly or indirectly, at any time during Executive’s employment with the Company and for a period of twelve (12) months following Executive’s termination of employment with the Company for any reason, solicit or induce or attempt to solicit or induce any employee(s), sales representative(s), agent(s) or consultant(s) of the Company and/or of its parents, or its other subsidiaries or affiliated or related companies to terminate their employment, representation or other association with the Company and/or its parent or its other subsidiary or affiliated or related companies.
NAI-1525772552v3    11




(i)Further Covenants. (i) Executive shall not, directly or indirectly, at any time during or after Executive’s employment with the Company, disclose, furnish, disseminate, make available or, except in the course of performing Executive’s duties of employment, use any trade secrets or confidential business and technical information of the Company or its customers or vendors, including without limitation as to when or how Executive may have acquired such information. Such confidential information shall include, without limitation, the Company’s unique selling, manufacturing and servicing methods and business techniques, training, service and business manuals, promotional materials, training courses and other training and instructional materials, vendor and product information, information about employee performance and employee evaluations, customer and prospective customer lists, other customer and prospective customer information and other business information. Executive specifically acknowledges that all such confidential information, whether reduced to writing, maintained on any form of electronic media, or maintained in Executive’s mind or memory and whether compiled by the Company, and/or Executive, derives independent economic value from not being readily known to or ascertainable by proper means by others who can obtain economic value from its disclosure or use, that reasonable efforts have been made by the Company to maintain the secrecy of such information, that such information is the sole property of the Company and that any retention and use of such information by Executive during Executive’s employment with the Company (except in the course of performing Executive’s duties and obligations to the Company) or after the termination of Executive’s employment shall constitute a misappropriation of the Company’s trade secrets. Upon termination of Executive’s employment with the Company, for any reason, Executive shall return to the Company, in good condition, all property of the Company, including without limitation, the originals and all copies of any materials which contain, reflect, summarize, describe, analyze or refer or relate to any items of information listed in this Section 8(i).
(ii)    The U.S. Defend Trade Secrets Act of 2016 (“DTSA”) provides that an individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (A) is made in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, the DTSA provides that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order.
(j)Discoveries and Inventions. Executive does hereby assign to the Company, its successors, assigns or nominees, all of Executive’s rights to any intellectual property, discoveries, inventions and improvements, whether patentable or not, made, conceived or suggested, either solely or jointly with others, by Executive while in the Company’s employ, whether in the course of Executive’s employment with the use of the Company’s time, material or facilities or that is in any way within or related to the existing or contemplated scope of the Company’s business. Any discovery, invention or improvement relating to any subject matter with which the Company was concerned during Executive’s employment and made, conceived or suggested by Executive, either solely or jointly with others, within one (1) year following termination of Executive’s employment under this Agreement or any successor agreements shall be irrebuttably presumed to have been so made, conceived or suggested in the course of such employment with the use of the Company’s time, materials or facilities. Upon request by the Company with respect to any such discoveries, inventions or improvements, Executive will
NAI-1525772552v3    12




execute and deliver to the Company, at any time during or after Executive’s employment, all appropriate documents for use in applying for, obtaining and maintaining such domestic and foreign patents as the Company may desire, and all proper assignments therefor, when so requested, at the expense of the Company, but without further or additional consideration.
(k)In order to determine the rights of Executive and the Company in any idea, discovery, invention, improvement, software, writing or other material, and to insure the protection of the same, Executive agrees that during Executive’s employment, and for one (1) year after termination of Executive’s employment with the Company, Executive will disclose immediately and fully to the Company any idea, discovery, invention, improvement, software, writing or other material or design conceived, made or developed by Executive solely or jointly with others that relates, in any way, to the Company’s Business. The Company agrees to keep any such disclosures confidential. Executive also agrees to record descriptions of all work in the manner directed by the Company and agrees that all such records and copies, samples and experimental materials will be the exclusive property of the Company. Executive agrees that at the request of and without charge to the Company, but at the Company’s expense, Executive will execute a written assignment of the idea, discovery, invention, improvement, software, writing or other material or design to the Company and will assign to the Company any application for letters patent or for trademark registration made thereon, and to any common-law or statutory copyright therein; and that Executive will do whatever may be necessary or desirable to enable the Company to secure any patent, trademark, copyright, or other property right therein in the United States and in any foreign country, and any division, renewal, continuation, or continuation in part thereof, or for any reissue of any patent issued thereon. In the event the Company is unable, after reasonable effort, and in any event after ten (10) business days, to secure Executive’s signature on a written assignment to the Company of any application for letters patent or to any common-law or statutory copyright or other property right therein, whether because of Executive’s physical or mental incapacity or for any other reason whatsoever, Executive irrevocably designates and appoints the Corporate Secretary of the Company as Executive’s attorney-in-fact to act on Executive’s behalf to execute and file any such application and to do all other lawfully permitted acts to further the prosecution and issuance of such letters patent, copyright or trademark.
(l)The Executive’s assignment of intellectual property rights pursuant to this Agreement includes (i) all rights of attribution, paternity, integrity, disclosure and withdrawal, and (ii) all other rights throughout the world sometimes referred to as “moral rights” (collectively “Moral Rights”). To the extent that Moral Rights cannot be assigned under applicable law, the Executive hereby waives such Moral Rights to the extent permitted under applicable law and consents to any and all actions of Company that would otherwise violate such Moral Rights.
(m)Work Made For Hire. Executive acknowledges that, to the extent permitted by law, all work papers, reports, documentation, drawings, photographs, negatives, tapes and masters therefore, prototypes and other materials (hereinafter, “Items”), including without limitation, any and all such Items generated and maintained on any form of electronic media, generated by Executive during Executive’s employment with the Company shall be considered a “work made for hire” and that ownership of any and all copyrights in any and all such Items shall belong to the Company. The Item will recognize the Company as the copyright owner, will contain all proper copyright notices, e.g., “(creation date) Athersys, Inc., All Rights Reserved,” and will be in condition to be registered or otherwise placed in compliance with registration or other statutory requirements throughout the world.
(n)Remedies. The parties acknowledge and agree that any breach by Executive of the terms of this Agreement may cause the Company irreparable harm and injury for which money damages would be inadequate. Accordingly, the Company, in addition to any other remedies available at law or equity, shall be entitled, as a matter of right, to injunctive
NAI-1525772552v3    13




relief in any court of competent jurisdiction. The parties agree that such injunctive relief may be granted without the necessity of proving actual damages. Nothing in this Agreement shall limit the Company’s remedies under state for federal law or elsewhere.
(o)Reasonableness. Executive acknowledges that Executive’s obligations under this Section 8 are reasonable in the context of the nature of the Company’s Business and the competitive injuries likely to be sustained by the Company if Executive were to violate such obligations. Executive further acknowledges that this Agreement is made in consideration of, and is adequately supported by, the agreement of the Company to perform its obligations under this Agreement and by other consideration, which Executive acknowledges constitutes good, valuable and sufficient consideration.
(p)Additional Acknowledgements. Executive acknowledges and agrees that, in the event that Executive becomes subject to any other contractual arrangements with the Company regarding competition with the Company, the restrictive covenants set forth in this Agreement were executed first and shall be deemed supplemented, and in no event diminished or replaced, by such other contractual arrangements.
9.Successors.
(a)This Agreement is personal to Executive and without the prior written consent of the Company shall not be assignable by Executive otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of, and be enforceable by, Executive’s legal representatives.
(b)This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns. As used in this Agreement, “Company” shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law, or otherwise.
10.Indemnification. The Company shall indemnify Executive to the maximum extent permitted under applicable law for acts taken within the scope of Executive’s employment and Executive’s service as an officer or director of the Company or any of its subsidiaries or affiliates. To the extent that the Company obtains coverage under a director and officer indemnification policy, Executive will be entitled to such coverage on a basis that is no less favorable than the coverage provided to any other officer or director of the Company.
11.Section 409A of the Code.
(a)The intent of the parties is that payments and benefits under this Agreement comply with, or be exempt from, Section 409A of the Code and the regulations and guidance promulgated thereunder (collectively “Section 409A”) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.
(b)Notwithstanding any provision of this Agreement to the contrary, in the event that Executive is a “specified employee” within the meaning of Section 409A (as determined in accordance with the methodology established by the Company as in effect on the Date of Termination) (a “Specified Employee”), any payments or benefits that are considered non-qualified deferred compensation under Section 409A payable under this Agreement on account of a “separation from service” during the six-month period immediately following the Date of Termination shall, to the extent necessary to comply with Section 409A, instead be paid, or provided, as the case may be, on the first business day after the date that is six months following Executive’s “separation from service” within the meaning of Section 409A. For purposes of Section 409A, Executive’s right to receive any installment payments pursuant to this
NAI-1525772552v3    14




Agreement shall be treated as a right to receive a series of separate and distinct payments. In no event may Executive, directly or indirectly, designate the calendar year of any payment to be made under this Agreement that is considered nonqualified deferred compensation subject to Section 409A.
(c)With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits that are deferred compensation subject to Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year and (iii) such payments shall be made on or before the last day of Executive’s taxable year following the taxable year in which the expense occurred.
12.Compensation Recovery Policy. Notwithstanding anything in this Agreement to the contrary, Executive acknowledges and agrees that this Agreement and any compensation described herein are subject to the terms and conditions of the Company’s clawback policy (if any) as may be in effect from time to time, including specifically to implement Section 10D of the Securities Exchange Act of 1934, as amended, and any applicable rules or regulations promulgated thereunder (including applicable rules and regulations of any national securities exchange on which the shares of the Company’s common stock may be traded) (the “Compensation Recovery Policy”), and that applicable sections of this Agreement and any related documents shall be deemed superseded by and subject to the terms and conditions of the Compensation Recovery Policy from and after the effective date thereof.
13.Complete Agreement. This Agreement sets forth the entire agreement of the parties hereto in respect of the subject matter contained herein, and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party hereto in respect of the subject matter contained herein (including, but not limited to, the offer letter between the Company and Executive, dated January 14, 2022); provided, however, that this Section 13 shall not apply to any provisions that are (or may be) contained in any other type of agreement between the Company and Executive that pertain to non-competition, confidentiality, non-disclosure, or other restrictive covenants to which Executive is or may be bound.
14.Miscellaneous.
(a)This Agreement shall be governed by and construed in accordance with the laws of the State of Ohio, without reference to principles of conflict of laws. Executive agrees that the state and federal courts located in the State of Ohio shall have jurisdiction in any action, suit or proceeding against Executive based on or arising out of this Agreement and Executive hereby: (i) submits to the personal jurisdiction of such courts; (ii) consents to service of process in connection with any action, suit or proceeding against Executive; and (iii) waives any other requirement (whether imposed by statute, rule of court or otherwise) with respect to personal jurisdiction, venue or service of process. The captions of this Agreement are not part of the provisions hereof and shall have no force or effect. This Agreement may not be amended or modified otherwise than by a written agreement executed by the parties hereto or their respective successors and legal representatives.
(b)All notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other party or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows:
NAI-1525772552v3    15




If to Executive:    At the most recent address
on file at the Company.
If to the Company:    Athersys, Inc.
3201 Carnegie Avenue
Cleveland, Ohio 44115-2634

or to such other address as either party shall have furnished to the other in writing in accordance herewith (including via electronic mail). Notice and communications shall be effective when actually received by the addressee.
(c)    The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement.
(d)    The Company, its subsidiaries and affiliates may withhold from any amounts payable under this Agreement such Federal, state, local or foreign taxes or social security charges as shall be required to be withheld pursuant to any applicable law or regulation. None of the Company, its subsidiaries or affiliates guarantees any tax result with respect to payments or benefits provided hereunder. Executive is responsible for all taxes owed with respect to all such payments and benefits.
(e)    Subject to any limits on applicability contained therein, Section 8 of this Agreement shall survive and continue in full force in accordance with its terms notwithstanding any termination of the Employment Period.
(f)    This Agreement may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.
(g)    Executive’s or the Company’s failure to insist upon strict compliance with any provision of this Agreement or the failure to assert any right Executive or the Company may have hereunder shall not be deemed to be a waiver of such provision or right, or any other provision or right of this Agreement.    
(h)    With respect to any controversy or claim arising out of or relating to or concerning injunctive relief for Executive’s breach or purported breach of Section 8 of this Agreement, the Company shall have the right, in addition to any other remedies it may have, to seek specific performance and injunctive relief with a court of competent jurisdiction, without the need to post a bond or other security.
15.Other Acknowledgements. Nothing in this Agreement prevents Executive from providing, without prior notice to the Company, information to governmental authorities regarding possible legal violations or otherwise testifying or participating in any investigation or proceeding by any governmental authorities regarding possible legal violations.
[Remainder of page intentionally left blank.]

NAI-1525772552v3    16





IN WITNESS WHEREOF, Executive and the Company have executed this Agreement on the date first above written.

EXECUTIVE


/s/Daniel Camardo    
Daniel Camardo


ATHERSYS, INC.


By: /s/Ismail Kola    
Name: Ismail Kola
Title: Chairman of the Board

NAI-1525772552v3
EX-31.1 4 ex31120220331.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATIONS
I, Daniel Camardo., certify that:
1.I have reviewed this quarterly report on Form 10-Q of Athersys, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have 
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): 
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 6, 2022
/s/ Daniel Camardo
Daniel Camardo
Chief Executive Officer


EX-31.2 5 ex31220220331.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATIONS
I, Ivor Macleod, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Athersys, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have 
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): 
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 6, 2022
/s/ Ivor Macleod
Ivor Macleod
Chief Financial Officer

EX-32.1 6 ex32120220331.htm EX-32.1 Document

EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Athersys, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to such officer’s knowledge:
 
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.
Date: May 6, 2022 
 /s/ Daniel Camardo
 Name: Daniel Camardo
 Title: Chief Executive Officer
 
 /s/ Ivor Macleod
 Name: Ivor Macleod
 Title: Chief Financial Officer
The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

EX-101.SCH 7 athx-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Background and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Background and Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Going Concern (Details) link:presentationLink link:calculationLink link:definitionLink 2105103 - Disclosure - Accounting Standards Not Yet Adopted link:presentationLink link:calculationLink link:definitionLink 2206201 - Disclosure - Accounting Standards Not Yet Adopted (Policies) link:presentationLink link:calculationLink link:definitionLink 2107104 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Net Loss per Share - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2109105 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 2112106 - Disclosure - Collaborative Arrangements and Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 2313302 - Disclosure - Collaborative Arrangements and Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 2414405 - Disclosure - Collaborative Arrangements and Revenue Recognition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2415406 - Disclosure - Collaborative Arrangements and Revenue Recognition - Schedule of Contract Revenues Disaggregated by Timing of Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2116107 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 2417407 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2118108 - Disclosure - Stockholders’ Equity and Warrants link:presentationLink link:calculationLink link:definitionLink 2419408 - Disclosure - Stockholders’ Equity and Warrants - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2120109 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 athx-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 athx-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 athx-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Revenue recognized from performance obligations satisfied in previous periods Contract with Customer, Performance Obligation Satisfied in Previous Period Regulatory and sales milestones Regulatory And Sales Milestones [Member] Regulatory and sales milestones. Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Operating lease liabilities, non-current Operating Lease, Liability, Noncurrent Net loss Net Income (Loss) Attributable to Parent Consolidated Entities [Axis] Consolidated Entities [Axis] Healios Framework Agreement Healios Framework Agreement [Member] Healios Framework Agreement Operating right-of-use assets, net Operating Lease, Right-of-Use Asset Healios Healios License Agreement [Member] Healios license agreement. Insurance reimbursement amount Proceeds from Litigation Insurance Reimbursement Proceeds from Litigation Insurance Reimbursement Preferred stock, shares outstanding (in shares) Preferred stock shares, beginning balance (in shares) Preferred stock shares, ending balance (in shares) Preferred Stock, Shares Outstanding Accrued compensation and related benefits Employee-related Liabilities, Current Statistical Measurement [Domain] Statistical Measurement [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit) Deposits and other Deposits And Other Assets Non Current Deposits And Other Assets Non Current Share-based Payment Arrangement Share-based Payment Arrangement [Member] Award expiration period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Litigation Case [Domain] Litigation Case [Domain] RSUs Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Entity Filer Category Entity Filer Category Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Tranche Two Share-based Payment Arrangement, Tranche Two [Member] Income Statement [Abstract] Income Statement [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Entity Registrant Name Entity Registrant Name Accounting Policies And General Information [Table] Accounting Policies And General Information [Table] Accounting Policies And General Information [Table] Accounting Standards Not Yet Adopted Accounting Standards Update and Change in Accounting Principle [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Shares available for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Cash retention bonus granted Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount (Decrease) Increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity File Number Entity File Number Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Number of material performance obligations Number Of Material Performance Obligations Number Of Material Performance Obligations Accounts receivable from Healios Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Equity Components [Axis] Equity Components [Axis] Entity Tax Identification Number Entity Tax Identification Number Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain] Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Deferred Bonus Deferred Bonus [Member] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Over Time Transferred over Time [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Stock-based awards (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Revenue recognized Contract with Customer, Liability, Revenue Recognized Common stock registered for resale (in shares) Common Stock Shares Registered For Resale Common stock shares registered for resale. Product and Service [Axis] Product and Service [Axis] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Chief Executive Officer Chief Executive Officer [Member] Equity Component [Domain] Equity Component [Domain] Title of Individual [Domain] Title of Individual [Domain] Issuance of common stock under equity compensation plan (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Award Type [Domain] Award Type [Domain] Local Phone Number Local Phone Number Assets Assets [Abstract] Severance payments and benefits, period (in months) Supplemental Unemployment Benefits, Period Supplemental Unemployment Benefits, Period Statement [Line Items] Statement [Line Items] Litigation Case [Axis] Litigation Case [Axis] Accounts payable to healios Accounts Payable, Related Parties, Noncurrent Deferred revenue - Healios Increase (Decrease) in Contract with Customer, Liability Shares of common stock outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Common Stock, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Common Stock, Outstanding, Number Preferred stock, at stated value; 10,000,000 shares authorized, and no shares issued and outstanding at March 31, 2022 and December 31, 2021 Preferred Stock, Value, Issued Issuance of common stock under equity compensation plan Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Section 220 Litigation Section 220 Litigation [Member] Section 220 Litigation Consolidated entity, excluding related party Consolidated Entity Excluding Related Party [Member] Consolidated Entity Excluding Related Party [Member] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Axis] Accumulated Deficit Retained Earnings [Member] Counterparty Name [Domain] Counterparty Name [Domain] Prepaid expenses, deposits and other Increase (Decrease) in Prepaid Expense and Other Assets Lump sum payment Supplemental Unemployment Benefits, Severance Benefits Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Advance from Healios Contract with Customer, Liability, Noncurrent Accounts payable to Healios Accounts Payable, Related Parties, Current Related Party [Axis] Related Party [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] Stock options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Equity purchase agreement, value Stock Issuable During Period Value Equity Purchase Agreement Stock issuable during period value equity purchase agreement. Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Vesting percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting [Axis] Vesting [Axis] Title of 12(b) Security Title of 12(b) Security Proceeds from issuance of common stock, net Net proceeds from sales of common stock Proceeds from Issuance of Common Stock Total assets Assets Plan Name [Domain] Plan Name [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Accounts receivable, payments due within period of invoicing Contract with Customer, Asset, Threshold Period Past Due Number of business segments Number of Operating Segments Net loss per share, basic (in dollars per share) Earnings Per Share, Basic Title of Individual [Axis] Title of Individual [Axis] Document Type Document Type Product and Service [Domain] Product and Service [Domain] Research and development Research and Development Expense 2019 Equity And Incentive Compensation Plan 2019 Equity And Incentive Compensation Plan [Member] 2019 Equity And Incentive Compensation Plan [Member] Exercise period (in days) Class Of Warrant Or Right, Exercise Period Class Of Warrant Or Right, Exercise Period Schedule of Contract Revenues Disaggregated by Timing of Revenue Recognition Disaggregation of Revenue [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Litigation Status [Axis] Litigation Status [Axis] Common stock authorized for equity incentive plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] The Inducement Award, Four-Year Vesting The Inducement Award, Four-Year Vesting [Member] The Inducement Award, Four-Year Vesting Weighted average shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Net loss per share, diluted (in dollars per share) Earnings Per Share, Diluted Vesting [Domain] Vesting [Domain] Plan Name [Axis] Plan Name [Axis] Net loss and comprehensive loss Net comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Small Business Entity Small Business Awards vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Total liabilities and stockholders’ equity Liabilities and Equity Pending Litigation Pending Litigation [Member] Accounting Policies And General Information [Line Items] Accounting Policies And General Information [Line Items] Accounting Policies And General Information [Line Items] Tranche One Share-based Payment Arrangement, Tranche One [Member] Deferred revenue - Healios Remaining transaction price for the performance obligations that were not yet delivered Contract with Customer, Liability, Current Accounts payable Accounts Payable, Current Service revenue Service [Member] Additional Employees Additional Employees [Member] Additional Employees Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Going Concern Substantial Doubt about Going Concern [Text Block] Common stock, shares outstanding (in shares) Common stock, beginning balance (in shares) Common stock, ending balance (in shares) Common Stock, Shares, Outstanding Timing of Transfer of Good or Service [Domain] Timing of Transfer of Good or Service [Domain] Net Loss per Share Earnings Per Share [Text Block] Entity Interactive Data Current Entity Interactive Data Current Revenues Revenues [Abstract] Severance payments and benefits Supplemental Unemployment Benefits Minimum Minimum [Member] Document Period End Date Document Period End Date Background and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Entity Central Index Key Entity Central Index Key Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Healios Healios Affiliated Entity [Member] Inducement Awards Plan Inducement Awards Plan [Member] Inducement Awards Plan [Member] Consolidated Entities [Domain] Consolidated Entities [Domain] Schedule of Property and Equipment, net Property, Plant and Equipment [Table Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Stock options and RSUs granted (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Grants In Period, Gross Share-Based Compensation Arrangement By Share-Based Payment Award, Grants In Period, Gross Entity Address, State or Province Entity Address, State or Province Fees and expenses sought by plaintiff Loss Contingency, Damages Sought, Value Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Issuance of common stock Stock Issued During Period, Value, New Issues General and administrative General and Administrative Expense Trading Symbol Trading Symbol Earnings Per Share [Abstract] Earnings Per Share [Abstract] Stock-based Compensation Share-based Payment Arrangement [Text Block] Property and equipment, gross Property, Plant and Equipment, Gross Accounting Policies [Abstract] Accounting Policies [Abstract] Total revenues Revenues Exercise price of warrant (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Laboratory equipment Equipment [Member] Issuance of common stock (in shares) Issuance of common stock, new issues (in shares) Stock Issued During Period, Shares, New Issues Document Transition Report Document Transition Report Common stock, $0.001 par value; 600,000,000 shares authorized with 249,792,791 and 242,844,180 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Costs and expenses Costs and Expenses [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Award exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price Stock-based compensation expense Share-based Payment Arrangement, Expense Entity Emerging Growth Company Entity Emerging Growth Company Entity Current Reporting Status Entity Current Reporting Status Equipment and leasehold improvements not yet in service Equipment And Leasehold Improvement Not Yet In Service [Member] Equipment And Leasehold Improvement Not Yet In Service Aspire Capital Aspire [Member] Aspire. Warrant One Warrant One [Member] Warrant One Counterparty Name [Axis] Counterparty Name [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Cover [Abstract] Cash and cash equivalents at beginning of the period Cash and cash equivalents at end of the period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Total costs and expenses Costs and Expenses Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Current assets: Assets, Current [Abstract] Warrants outstanding (in shares) Warrants issued (in shares) Class of Warrant or Right, Outstanding Unbilled accounts receivable from Healios Unbilled Receivables, Current Entity Address, Postal Zip Code Entity Address, Postal Zip Code Prepaid expenses and other Prepaid Expense and Other Assets, Current Accounts receivable from Healios - billed and unbilled Increase (Decrease) in Accounts Receivable, Related Parties Weighted average shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Accrued expenses and other Accrued Liabilities, Current Contract revenue from Healios Total disaggregated revenues Revenue from Contract with Customer, Excluding Assessed Tax Income Taxes Income Tax Disclosure [Text Block] Related Party [Domain] Related Party [Domain] Point in Time Transferred at Point in Time [Member] Stockholders’ Equity and Warrants Stockholders' Equity Note Disclosure [Text Block] Stock Options Share-based Payment Arrangement, Option [Member] Sale of additional shares at an average price (in dollars per share) Issuance Of Stock Price Per Share Issuance of stock price per share. Equity [Abstract] Equity [Abstract] Document Quarterly Report Document Quarterly Report Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Common Stock Common Stock [Member] Entity Address, Address Line One Entity Address, Address Line One Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Loss from operations Operating Income (Loss) Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Entity Shell Company Entity Shell Company Operating lease liabilities, current Operating Lease, Liability, Current Collaborative Arrangements and Revenue Recognition Collaborative Arrangement Disclosure [Text Block] Total current liabilities Liabilities, Current Shares retained for withholding tax payments on stock-based awards Payment, Tax Withholding, Share-based Payment Arrangement Document Fiscal Year Focus Document Fiscal Year Focus Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Property, Plant and Equipment [Abstract] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Litigation Status [Domain] Litigation Status [Domain] Depreciation Depreciation Current Fiscal Year End Date Current Fiscal Year End Date Number of future milestones achieved Number of Future Milestones Achieved Number of future milestones achieved. Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Shares called by warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrant Two Warrant Two [Member] Warrant Two Other income, net Other Nonoperating Income (Expense) Statement [Table] Statement [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Recently Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Potential revenue from milestones Revenue From Contract With Customer, Potential Revenue From Milestones Revenue From Contract With Customer, Potential Revenue From Milestones Unrecognized compensation cost of unvested stock awards Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] Subsequent Event Subsequent Event [Member] Purchases of equipment Payments to Acquire Machinery and Equipment The Inducement Award The Inducement Award [Member] The Inducement Award Former Chief Executive Officer Former Chief Executive Officer [Member] Former Chief Executive Officer Award Type [Axis] Award Type [Axis] Preferred Stock Preferred Stock [Member] Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Common stock, shares issued (in shares) Common Stock, Shares, Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued City Area Code City Area Code Accounts payable, accrued expenses and other Increase (Decrease) in Accounts Payable and Accrued Liabilities Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Ownership percentage in common stock for exercise cap to be triggered Class Of Warrant Or Right, Common Stock Ownership Percentage Triggered Class Of Warrant Or Right, Common Stock Ownership Percentage Triggered The Inducement Award, Performance Based Vesting The Inducement Award, Performance Based Vesting [Member] The Inducement Award, Performance Based Vesting Subsequent Event Type [Axis] Subsequent Event Type [Axis] Office equipment and leasehold improvements Office Equipment And Leasehold Improvements [Member] Office equipment and leasehold improvements. Accrued clinical trial related costs Accrued Clinical Trial Costs Current Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to clinical trial services received from vendors, such as accrued contract research organization costs, patient costs, clinical site costs and clinical product cost. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Entity Address, City or Town Entity Address, City or Town Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Potential revenue from completion of certain manufacturing activities Revenue From Contract With Customer, Potential Revenue From Completion Of Certain Manufacturing Activities Revenue From Contract With Customer, Potential Revenue From Completion Of Certain Manufacturing Activities EX-101.PRE 11 athx-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 image_0a.jpg begin 644 image_0a.jpg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end GRAPHIC 13 image_1a.jpg begin 644 image_1a.jpg MB5!.1PT*&@H -24A$4@ #-< '" ( >.]T* C4E$051X7NW: ML0T ,0@$04IWY_Z(Y)#]DN-9308E7-4J N-N'\@\ M "F7)]U^0< !3KL^Z_ , ( IUV?=\2!)DB1)DB1) MDB1)DB1)TF]6:)(D29(D29(D29(D29*D]ZS0)$F2)$F2)$F2)$F2)$GO?5@R 2(55IN3P1 $E%3D2N0F"" end XML 14 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover Page - shares
3 Months Ended
Mar. 31, 2022
Apr. 29, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2022  
Document Transition Report false  
Entity File Number 001-33876  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 20-4864095  
Entity Address, Address Line One 3201 Carnegie Avenue,  
Entity Address, City or Town Cleveland,  
Entity Address, State or Province OH  
Entity Address, Postal Zip Code 44115-2634  
City Area Code 216  
Local Phone Number 431-9900  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol ATHX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   251,967,791
Amendment Flag false  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q1  
Entity Registrant Name ATHERSYS, INC / NEW  
Entity Central Index Key 0001368148  
Current Fiscal Year End Date --12-31  
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 21,797 $ 37,407
Prepaid expenses and other 4,661 4,206
Total current assets 31,101 46,027
Operating right-of-use assets, net 8,707 8,960
Property and equipment, net 3,631 3,692
Deposits and other 1,520 1,505
Total assets 44,959 60,184
Current liabilities:    
Operating lease liabilities, current 1,031 1,011
Accrued compensation and related benefits 3,345 4,133
Accrued clinical trial related costs 5,770 3,773
Accrued expenses and other 727 704
Total current liabilities 30,965 29,861
Operating lease liabilities, non-current 8,488 8,755
Stockholders’ equity:    
Preferred stock, at stated value; 10,000,000 shares authorized, and no shares issued and outstanding at March 31, 2022 and December 31, 2021 0 0
Common stock, $0.001 par value; 600,000,000 shares authorized with 249,792,791 and 242,844,180 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively 250 243
Additional paid-in capital 605,617 599,470
Accumulated deficit (605,560) (583,344)
Total stockholders’ equity 307 16,369
Total liabilities and stockholders’ equity 44,959 60,184
Consolidated entity, excluding related party    
Current liabilities:    
Accounts payable 16,771 15,781
Healios    
Current assets:    
Accounts receivable from Healios 1,643 1,414
Unbilled accounts receivable from Healios 3,000 3,000
Current liabilities:    
Accounts payable to Healios 1,119 1,119
Deferred revenue - Healios 2,202 3,340
Advance from Healios $ 5,199 $ 5,199
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Stockholders’ equity:    
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 600,000,000 600,000,000
Common stock, shares issued (in shares) 249,792,791 242,844,180
Common stock, shares outstanding (in shares) 249,792,791 242,844,180
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenues    
Total revenues $ 2,912 $ 0
Costs and expenses    
Research and development 20,944 17,508
General and administrative 4,099 8,837
Depreciation 247 244
Total costs and expenses 25,290 26,589
Loss from operations (22,378) (26,589)
Other income, net 162 121
Net loss and comprehensive loss $ (22,216) $ (26,468)
Net loss per share, basic (in dollars per share) $ (0.09) $ (0.13)
Net loss per share, diluted (in dollars per share) $ (0.09) $ (0.13)
Weighted average shares outstanding, basic (in shares) 244,197 208,192
Weighted average shares outstanding, diluted (in shares) 244,197 208,192
Healios    
Revenues    
Contract revenue from Healios $ 2,912 $ 0
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Consolidated entity, excluding related party
Consolidated entity, excluding related party
Common Stock
Consolidated entity, excluding related party
Additional Paid-in Capital
Preferred stock shares, beginning balance (in shares) at Dec. 31, 2020   0            
Beginning balance at Dec. 31, 2020 $ 31,362 $ 0 $ 202 $ 527,549 $ (496,389)      
Common stock, beginning balance (in shares) at Dec. 31, 2020     201,973,582          
Stock-based compensation 3,903     3,903        
Issuance of common stock (in shares)             15,200,000  
Issuance of common stock           $ 30,495 $ 15 $ 30,480
Issuance of common stock under equity compensation plan (in shares)     437,925          
Issuance of common stock under equity compensation plan (611)   $ 1 (612)        
Net comprehensive loss (26,468)       (26,468)      
Preferred stock shares, ending balance (in shares) at Mar. 31, 2021   0            
Ending balance at Mar. 31, 2021 $ 38,681 $ 0 $ 218 561,320 (522,857)      
Common stock, ending balance (in shares) at Mar. 31, 2021     217,611,507          
Preferred stock shares, beginning balance (in shares) at Dec. 31, 2021 0 0            
Beginning balance at Dec. 31, 2021 $ 16,369 $ 0 $ 243 599,470 (583,344)      
Common stock, beginning balance (in shares) at Dec. 31, 2021 242,844,180   242,844,180          
Stock-based compensation $ 1,410     1,410        
Issuance of common stock (in shares)             6,800,000  
Issuance of common stock           $ 4,802 $ 7 $ 4,795
Issuance of common stock under equity compensation plan (in shares)     148,611          
Issuance of common stock under equity compensation plan (58)   $ 0 (58)        
Net comprehensive loss $ (22,216)       (22,216)      
Preferred stock shares, ending balance (in shares) at Mar. 31, 2022 0 0            
Ending balance at Mar. 31, 2022 $ 307 $ 0 $ 250 $ 605,617 $ (605,560)      
Common stock, ending balance (in shares) at Mar. 31, 2022 249,792,791   249,792,791          
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating activities    
Net loss $ (22,216) $ (26,468)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 247 244
Stock-based compensation 1,410 3,903
Changes in operating assets and liabilities:    
Prepaid expenses, deposits and other (217) (45)
Net cash used in operating activities (20,168) (17,093)
Investing activities    
Purchases of equipment (186) (114)
Net cash used in investing activities (186) (114)
Financing activities    
Shares retained for withholding tax payments on stock-based awards (58) (622)
Net cash provided by financing activities 4,744 29,884
(Decrease) Increase in cash and cash equivalents (15,610) 12,677
Cash and cash equivalents at beginning of the period 37,407 51,546
Cash and cash equivalents at end of the period 21,797 64,223
Consolidated entity, excluding related party    
Changes in operating assets and liabilities:    
Accounts payable, accrued expenses and other 1,975 5,273
Financing activities    
Proceeds from issuance of common stock, net 4,802 30,506
Healios    
Changes in operating assets and liabilities:    
Accounts receivable from Healios - billed and unbilled (229) 0
Deferred revenue - Healios $ (1,138) $ 0
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Background and Basis of Presentation
3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Background and Basis of Presentation Background and Basis of Presentation
Background
Athersys, Inc., including its consolidated subsidiaries (collectively, “we,” “us,” “our,” “Athersys,” and the “Company”), is a biotechnology company focused in the field of regenerative medicine and operates in one business segment. Our operations consist of research, clinical development activities, manufacturing and manufacturing process development activities, and our most advanced program is in a pivotal Phase 3 clinical trial.
We expect that the results of the TREASURE study, the clinical trial of our partner in Japan, HEALIOS K.K. (“Healios”), followed by the results of our MASTERS-2 clinical trial, will have a significant impact, favorable or unfavorable, on our ability to access capital from potential third-party commercial partners or the equity capital markets. Depending on the nature of these results, we may accelerate or may delay certain programs. In the long term, we will have to continue to generate additional capital to meet our needs until we become cash flow positive as a result of the sales of our clinical products, if they are approved for marketing. Such capital would come from new and existing collaborations and the related license fees, milestones and potential royalties and the sale of equity securities from time to time including through our equity facility and grant-funding opportunities.
Healios Framework Agreement
On August 5, 2021, we expanded our partnership with Healios by entering into the Comprehensive Framework Agreement for Commercial Manufacturing and Ongoing Support (the “Framework Agreement”). The Framework Agreement provides for planned investment by Healios in certain manufacturing preparation activities. We have agreed to defer certain milestone payments and potentially adjust royalty payments during the initial commercial launch period. Refer to Note 6 for additional information on the Framework Agreement.
On February 16, 2021, the Company, Healios and Dr. Hardy TS Kagimoto, the Chairman and Chief Executive Officer of Healios and a member of the Company’s board of directors (the “Board”), entered into a cooperation agreement (the “Cooperation Agreement”). The Cooperation Agreement provided for the parties’ cooperation on certain commercial matters, including a commitment to work in good faith to finalize negotiations on all aspects of their supply, manufacturing, information provision and regulatory support relationship.
The Cooperation Agreement also provided for, among related matters, the dismissal with prejudice of the complaint filed by Dr. Kagimoto against the Company seeking the inspection of the Company’s books and records in the Court of Chancery of the State of Delaware on November 21, 2020 (the “Section 220 Litigation”). Pursuant to the Cooperation Agreement, in April 2021, the Company reimbursed Healios and Dr. Kagimoto for reasonable out-of-pocket fees and expenses, including legal expenses, incurred in connection with the Section 220 Litigation, which were not to exceed $0.5 million in the aggregate. In April 2022, the Company received an insurance reimbursement of $0.4 million for legal costs incurred in connection with the Section 220 Litigation.
In connection with the execution of the Framework Agreement, certain issues as contemplated by the Cooperation Agreement were resolved and the Cooperation Agreement was amended to extend certain customary standstill provisions until the conclusion of our 2023 annual meeting of stockholders.
Retention Program
In the first quarter of 2021, we entered into retention letter agreements (“Retention Agreements”) with our executive officers and certain other employees in leadership positions. Each Retention Agreement provides for, among other things, a cash retention bonus and a stock option award, each with vesting tied to continued employment. The cash retention bonuses generally represent a percentage of the employee’s annual compensation and generally vest in full if employed on May 1, 2022. The stock option awards generally vest one-third on May 1, 2022 with the remainder vesting on May 1, 2023 and include a provision for accelerated vesting upon termination without cause. The total stock compensation expense related to the stock option awards is approximately $2.7 million and is being expensed ratably over the vesting period. In April 2021, we expanded the retention program to all then-current employees of the Company, providing for a cash retention bonus with vesting also tied to continued employment through May 1, 2022. The total cash retention bonus is approximately $2.5 million, which is being expensed ratably over the respective vesting periods.
Chief Executive Officer Separation Letter Agreement
Effective February 15, 2021, Dr. Gil Van Bokkelen was terminated from his position as the Company’s Chief Executive Officer and Chairman of the Board. In connection with his cessation of service, the Company and Dr. Van Bokkelen entered into a separation letter agreement (the “Separation Letter”) entitling him to severance payments and benefits with an aggregate value of approximately $1.0 million payable in installments over an 18-month period, and providing for a total lump sum payment of approximately $0.2 million. At March 31, 2022, we recorded a liability in the amount of $0.2 million, which represents the remaining installments payable to Dr. Van Bokkelen. The lump sum payment was made to Dr. Van Bokkelen in March 2021. The related expense is recorded in general and administrative expense on the unaudited condensed consolidated statements of operations and comprehensive loss.
The terms of the Separation Letter also provide for the accelerated vesting of Dr. Van Bokkelen’s outstanding restricted stock units (“RSUs”) and the modification of his stock option awards by providing for accelerated vesting of his unvested stock options and the extension of time during which certain vested stock options can be exercised. In the first quarter of 2021, following the evaluation of the modification, we recorded stock compensation expense of approximately $1.4 million related to the accelerated vesting of Dr. Van Bokkelen’s stock options and $0.9 million related to the accelerated vesting of his RSUs.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and Regulation S-X. Accordingly, since they are interim statements, the accompanying financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments and disclosures that are, in the opinion of management, necessary for a fair presentation of financial position and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Our critical accounting policies, estimates and assumptions are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which is included in this Quarterly Report on Form 10-Q.
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Going Concern
3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern Going Concern
We have prepared our unaudited condensed consolidated financial statements on a going concern basis, which assumes that we will realize our assets and satisfy our liabilities in the normal course of business. However, we have incurred net losses since our inception in 1995 and have negative operating cash flows. These factors, among others, raise substantial doubt about our ability to continue as a going concern within one year after the date that these financial statements are issued.
The accompanying unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of the uncertainty concerning our ability to continue as a going concern.
At March 31, 2022, we had cash and cash equivalents of $21.8 million. We will require significant additional capital to continue our research and development programs, including progressing our clinical product candidates to potential commercialization and preparing for commercial-scale manufacturing and sales. We expect that the results of the TREASURE study, followed by the results of our MASTERS-2 clinical trial, will have a significant impact, favorable or unfavorable, on our ability to access capital from potential third-party commercial partners or the equity capital markets.
In the long term, we will have to continue to generate additional capital to meet our needs until we become cash flow positive as a result of the sales of our clinical products, if they are approved for marketing. Such capital would come from new and existing collaborations and the related license fees, milestones and potential royalties. Management plans to raise additional capital through the use of our equity purchase agreement with Aspire Capital Fund, LLC (“Aspire Capital”) and, depending on market conditions, through equity offerings. We are entitled to a new milestone payment from Healios in the amount of $3.0 million in June 2022. While management believes this plan to generate additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. For the foreseeable future, our ability to continue our operations is dependent upon the ability to obtain additional capital.
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Accounting Standards Not Yet Adopted
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Accounting Standards Not Yet Adopted Accounting Standards Not Yet AdoptedIn June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326). This ASU replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Subsequent to issuing ASU 2016-13, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326): Effective Dates, delaying the effective date for smaller reporting companies until January 2023. We are currently evaluating the potential impact of adoption of this standard on our consolidated financial statements and disclosures, and we do not intend to adopt this standard earlier than required.
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Net Loss per Share
3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Net Loss per Share Net Loss per Share
Basic and diluted net loss per share have been computed using the weighted-average number of shares of our common stock outstanding during the period. Stock-based awards of approximately 28,355,351 and 21,788,078 for the three months ended March 31, 2022 and 2021, respectively, were excluded from the calculation of diluted net loss per share because their effects would be antidilutive.
We have two warrants outstanding to purchase an aggregate of 10,000,000 shares of our common stock that were issued to Healios in August 2021 and are excluded from the calculation of diluted net loss per share, as the underlying performance condition associated with each warrant has not been satisfied and is not yet considered probable by the end of the reporting period. Refer to Note 8 for additional information.
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment, net
3 Months Ended
Mar. 31, 2022
Property, Plant and Equipment [Abstract]  
Property and Equipment, net Property and Equipment, net
For the periods ended
Property and equipment consists of (in thousands):March 31,
2022
December 31,
2021
Laboratory equipment$9,535 $9,352 
Office equipment and leasehold improvements4,000 4,000 
Equipment and leasehold improvements not yet in service433 458 
13,968 13,810 
Accumulated depreciation and amortization(10,337)(10,118)
$3,631 $3,692 
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Collaborative Arrangements and Revenue Recognition
3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaborative Arrangements and Revenue Recognition Collaborative Arrangements and Revenue Recognition
Healios Collaboration
We have a licensing collaboration with Healios to primarily develop and commercialize our cell therapy technologies for certain disease indications in Japan, pursuant to which we received nonrefundable license fee payments and are entitled to royalties on net sales. We also have the right to receive development and commercial milestone payments from Healios, subject to certain potential credits that have been negotiated from time-to-time and are associated with modifications to the arrangement. Healios is responsible for the development and commercialization of the licensed products in the licensed territories, and we provide certain services to Healios for which we are paid.
In August 2021, the Company and Healios entered into the Framework Agreement, which provides for clarification under and modifies the existing agreements between the parties and reframes our collaboration to set the stage for productive efforts as Healios and our collaboration move towards commercialization of MultiStem in Japan. It also provides Healios with deferral of certain milestone payments during the expensive initial commercial launch period. We will be entitled to new milestone payments in the amount of $3.0 million in June 2022 and $5.0 million upon the successful completion of certain commercial manufacturing activities. Additionally, accounts payable to Healios have been reduced to $1.1 million and are due on or before December 31, 2022. In August 2021, we also issued two warrants (together, the “2021 Warrants”) to Healios in connection with the Framework Agreement to purchase up to a total of 10,000,000 shares of our common stock. The 2021 Warrants are being accounted for as consideration paid or payable to a customer according to Topic 606, Revenue from Contracts with Customers, and Topic 718, Compensation Stock Compensation, under which the recognition of such equity instruments is required at the time that the underlying performance conditions become probable or are satisfied. As of March 31, 2022, the 2021 Warrants have not been recorded as the underlying performance conditions have not been satisfied and are not yet considered probable. Refer to Note 8 for further information.
Healios Revenue Recognition
At the inception of the Healios arrangement and again each time that the arrangement is modified, all material performance obligations are identified, which currently include one performance obligation for services necessary for regulatory approvals, manufacturing readiness, and commercial launch in Japan. We determined the transaction price includes estimated payments for reimbursable services to be performed by us for Healios and the $3.0 million milestone payment due in June 2022. We allocated the total transaction price to this one performance obligation. We began recognizing this revenue beginning in the third quarter of 2021 as the services were being performed. We expect the services to be completed by the end of 2022. During our evaluation of variable consideration in the first quarter of 2022, we decreased our estimated transaction price due to changes in the estimated cost of the reimbursable services. The remaining transaction price for the performance obligation that was not yet satisfied is approximately $1.4 million at March 31, 2022. During the three months ended March 31, 2022, we recognized approximately $2.8 million of revenue associated with this performance obligation. We recognized no revenue for the three months ended March 31, 2022, and March 31, 2021 from performance obligations satisfied in previous periods.
Accounts receivable from Healios
Accounts receivable from Healios are related to our contracts and are recorded when the right to consideration is unconditional at the amount that management expects to collect. Accounts receivable from Healios do not bear interest if paid when contractually due, and payments are generally due within thirty to forty-five days of invoicing.
Unbilled Accounts Receivable
Unbilled accounts receivable from Healios represent amounts due to us under contractual arrangements and for which we have an unconditional right to consideration, but which we have not yet invoiced Healios. At March 31, 2022, the unbilled accounts receivable from Healios was $3.0 million, which represents a milestone payment owed to us under the Framework Agreement for which we are entitled to receive payment in June 2022.
Deferred Revenue - Healios
Amounts included in deferred revenue - Healios on the condensed consolidated balance sheets are considered a contract liability. During the three months ended March 31, 2022, revenue recognized from contract liabilities as of the beginning of the respective period was $1.1 million. No revenue was recognized from contract liabilities during the three months ended March 31, 2021. At March 31, 2022, the contract liability included in deferred revenue - Healios is classified as a current liability because the rights to consideration are expected to be satisfied, in all material respects, within one year.
Advance from Healios
In 2017, we amended the clinical trial supply agreement for the manufacturing of clinical product for TREASURE to clarify a cost-sharing arrangement. The proceeds from Healios that relate specifically to the cost-sharing arrangement may either (i) result in a reduction in the proceeds we receive from Healios upon the achievement of two potential milestones and an increase to a commercial milestone under the license agreement for stroke or (ii) be repaid to Healios at our election, as defined. The cost-sharing proceeds received are recognized in advance from Healios on the unaudited condensed consolidated balance sheets until the earlier of the milestones being achieved or such amounts being repaid to Healios at our election, at which time the culmination of the earnings process or the repayment will be complete.
Disaggregation of Revenues
We recognize service revenue when earned over time. The following table presents our contract revenues disaggregated by timing of revenue recognition (in thousands):
 Three months ended
March 31, 2022
Three months ended
March 31, 2021
 Point in
Time
Over TimePoint in
Time
Over Time
Contract Revenue from Healios
Service revenue 2,912 — — 
Total disaggregated revenues$ $2,912 $— $— 
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation
3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Stock-based Compensation Stock-Based Compensation
Our 2019 Equity and Incentive Compensation Plan (the “EICP”) authorized at inception an aggregate of approximately 18,500,000 shares of our common stock for awards to employees, directors and consultants. The EICP authorizes the issuance of stock-based compensation in the form of stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares and units, and other stock-based awards. Under the EICP, in the three months ended March 31, 2022, we granted 33,400 stock options and no RSUs to our employees.
On February 14, 2022, Daniel Camardo was named the Company’s Chief Executive Officer. As an inducement to Mr. Camardo’s acceptance of employment with us, Mr. Camardo was granted an initial equity award (the “Inducement Award”) to purchase 10,000,000 shares of our common stock at a per share exercise price of $0.86. With regard to 4,000,000 shares, vesting of the Inducement Award will occur over a four-year period, with 25% of such portion of the award generally vesting on the first anniversary of the grant date and the remainder generally vesting monthly in substantially equal installments over the remaining 36 months. With regard to 6,000,000 shares, vesting of the Inducement Award will generally occur upon achievement of certain Company milestones. The Inducement Award has up to a 10-year term.
As of March 31, 2022, a total of 3,628,308 shares were available for issuance under the EICP, and stock-based awards representing 23,355,351 shares of our common stock were outstanding under our current and former equity incentive plans, and inducement awards granted outside of our equity incentive plans to purchase 11,000,000 shares of our common stock were outstanding. For the three months ended March 31, 2022 and 2021, stock-based compensation expense was approximately $1.4 million and $3.9 million, respectively. At March 31, 2022, total unrecognized estimated compensation cost related to unvested stock-based awards was approximately $12.7 million, which is expected to be recognized by the end of 2026 using the straight-line method.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Equity and Warrants
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Stockholders’ Equity and Warrants Stockholders’ Equity and Warrants
Equity Purchase Agreement
We have had equity purchase agreements in place since 2011 with Aspire Capital that provide us the ability to sell shares to Aspire Capital from time to time. Currently, we have an agreement with Aspire Capital that was entered into in June 2021 (the “2021 Equity Facility”) and includes Aspire Capital’s commitment to purchase up to an aggregate of $100.0 million of shares of our common stock over a defined timeframe. The terms of the 2021 Equity Facility are similar to the previous equity facilities with Aspire Capital, and we filed a registration statement for the resale of 40,000,000 shares of our common stock in connection with the 2021 Equity Facility. Our prior equity facility that was entered into in November 2019 was fully utilized and terminated during the third quarter of 2021.
We sold 6,800,000 shares to Aspire Capital at an average price of $0.71 per share in the first quarter of 2022, generating proceeds of $4.8 million. We sold 15,200,000 shares to Aspire Capital at an average price of $2.01 per share in the first quarter of 2021, generating proceeds of $30.5 million.
Healios 2021 Warrants
In August 2021, we issued the 2021 Warrants to Healios to purchase up to an aggregate of 10,000,000 shares of our common stock. One of the 2021 Warrants is for the purchase of up to 3,000,000 shares at an exercise price of $1.80 per share, subject to specified increases, and generally is only exercisable within 60 days of receipt of either conditional or full marketing approval from the Pharmaceuticals and Medical Devices Agency in Japan (the “PMDA”) for the intravenous administration of MultiStem to treat patients who are suffering from acute respiratory distress syndrome. The other 2021 Warrant is for the purchase of up to 7,000,000 shares at an exercise price of $2.40 per share, subject to specified increases, and generally is only exercisable within 60 days of receipt of either conditional or full marketing approval from the PMDA for the intravenous administration of MultiStem to treat patients who are suffering from ischemic stroke. The 2021 Warrants may be terminated by us under certain conditions and have an exercise cap triggered at Healios’ ownership of 19.9% of our common stock.
Increase Shares of Authorized Common Stock
In June 2021, the Company’s stockholders approved an Amendment to the Certificate of Incorporation to increase the number of shares of the Company’s authorized common stock from 300,000,000 shares to 600,000,000 shares.
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
3 Months Ended
Mar. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income TaxesWe have United States (“U.S.”) federal net operating loss and research and development tax credit carryforwards, as well as state and city net operating loss carryforwards, which may be used to reduce future taxable income and tax liabilities. We also have foreign net operating loss and tax credit carryforwards, and the foreign net operating loss carryforwards do not expire. Substantially all of our deferred tax assets have been fully offset by a valuation allowance due to our cumulative losses. The carrying value of our deferred tax assets and liabilities is determined by the enacted U.S. corporate income tax rate. Consequently, any changes in the U.S. corporate income tax rate impacts the carrying value of our deferred tax assets and liabilities. Also, there are significant limitations on our ability to utilize our net operating loss and tax credit carryforwards under Section 382 of the Internal Revenue Code of 1986, as amended.
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Accounting Standards Not Yet Adopted (Policies)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and Regulation S-X. Accordingly, since they are interim statements, the accompanying financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments and disclosures that are, in the opinion of management, necessary for a fair presentation of financial position and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Our critical accounting policies, estimates and assumptions are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which is included in this Quarterly Report on Form 10-Q.
Recently Issued Accounting Standards Accounting Standards Not Yet AdoptedIn June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326). This ASU replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Subsequent to issuing ASU 2016-13, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326): Effective Dates, delaying the effective date for smaller reporting companies until January 2023. We are currently evaluating the potential impact of adoption of this standard on our consolidated financial statements and disclosures, and we do not intend to adopt this standard earlier than required.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment, net (Tables)
3 Months Ended
Mar. 31, 2022
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment, net
For the periods ended
Property and equipment consists of (in thousands):March 31,
2022
December 31,
2021
Laboratory equipment$9,535 $9,352 
Office equipment and leasehold improvements4,000 4,000 
Equipment and leasehold improvements not yet in service433 458 
13,968 13,810 
Accumulated depreciation and amortization(10,337)(10,118)
$3,631 $3,692 
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Collaborative Arrangements and Revenue Recognition (Tables)
3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Contract Revenues Disaggregated by Timing of Revenue Recognition The following table presents our contract revenues disaggregated by timing of revenue recognition (in thousands):
 Three months ended
March 31, 2022
Three months ended
March 31, 2021
 Point in
Time
Over TimePoint in
Time
Over Time
Contract Revenue from Healios
Service revenue 2,912 — — 
Total disaggregated revenues$ $2,912 $— $— 
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Background and Basis of Presentation - Additional Information (Details)
$ in Millions
1 Months Ended 3 Months Ended
Feb. 16, 2021
USD ($)
Feb. 15, 2021
USD ($)
Apr. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
segment
Mar. 31, 2021
USD ($)
Apr. 30, 2021
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]            
Number of business segments | segment       1    
Class of Stock [Line Items]            
Unrecognized compensation cost of unvested stock awards       $ 12.7    
Stock-based compensation expense       1.4 $ 3.9  
Former Chief Executive Officer            
Class of Stock [Line Items]            
Severance payments and benefits   $ 1.0        
Severance payments and benefits, period (in months)   18 months        
Lump sum payment   $ 0.2   $ 0.2    
Former Chief Executive Officer | Stock Options            
Class of Stock [Line Items]            
Stock-based compensation expense         1.4  
Former Chief Executive Officer | RSUs            
Class of Stock [Line Items]            
Stock-based compensation expense         0.9  
Deferred Bonus            
Class of Stock [Line Items]            
Unrecognized compensation cost of unvested stock awards         $ 2.7  
Deferred Bonus | Tranche One            
Class of Stock [Line Items]            
Vesting percentage         33.33%  
Deferred Bonus | Tranche Two            
Class of Stock [Line Items]            
Vesting percentage         66.67%  
Deferred Bonus | Additional Employees            
Class of Stock [Line Items]            
Cash retention bonus granted           $ 2.5
Section 220 Litigation | Pending Litigation | Subsequent Event            
Class of Stock [Line Items]            
Insurance reimbursement amount     $ 0.4      
Section 220 Litigation | Maximum | Pending Litigation            
Class of Stock [Line Items]            
Fees and expenses sought by plaintiff $ 0.5          
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Going Concern (Details) - USD ($)
$ in Thousands
1 Months Ended
Aug. 31, 2021
Mar. 31, 2022
Dec. 31, 2021
Accounting Policies And General Information [Line Items]      
Cash and cash equivalents   $ 21,797 $ 37,407
Healios Framework Agreement      
Accounting Policies And General Information [Line Items]      
Potential revenue from milestones $ 3,000    
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Net Loss per Share - Additional Information (Details) - shares
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Aug. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Shares called by warrants (in shares)     10,000,000
Healios Framework Agreement      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Warrants outstanding (in shares)     2
Shares called by warrants (in shares)     10,000,000
Share-based Payment Arrangement      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Stock-based awards (in shares) 28,355,351 21,788,078  
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment, net - Schedule of Property and Equipment, net (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 13,968 $ 13,810
Accumulated depreciation and amortization (10,337) (10,118)
Property and equipment, net 3,631 3,692
Laboratory equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 9,535 9,352
Office equipment and leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 4,000 4,000
Equipment and leasehold improvements not yet in service    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 433 $ 458
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Collaborative Arrangements and Revenue Recognition - Additional Information (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2021
USD ($)
shares
Mar. 31, 2022
USD ($)
performanceObligation
Mar. 31, 2021
USD ($)
Sep. 30, 2020
milestone
Dec. 31, 2021
performanceObligation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Shares called by warrants (in shares) | shares 10,000,000        
Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Accounts receivable, payments due within period of invoicing   45 days      
Minimum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Accounts receivable, payments due within period of invoicing   30 days      
Healios Framework Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential revenue from milestones $ 3,000,000        
Potential revenue from completion of certain manufacturing activities 5,000,000        
Accounts payable to healios $ 1,100,000        
Warrants issued (in shares) | shares 2        
Shares called by warrants (in shares) | shares 10,000,000        
Number of material performance obligations | performanceObligation   1     1
Remaining transaction price for the performance obligations that were not yet delivered   $ 1,400,000      
Revenue recognized   2,800,000      
Revenue recognized from performance obligations satisfied in previous periods   0 $ 0    
Unbilled accounts receivable from Healios   3,000,000      
Healios          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue recognized   $ 1,100,000 $ 0    
Healios | Regulatory and sales milestones          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of future milestones achieved | milestone       2  
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Collaborative Arrangements and Revenue Recognition - Schedule of Contract Revenues Disaggregated by Timing of Revenue Recognition (Details) - Healios - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Point in Time    
Disaggregation of Revenue [Line Items]    
Total disaggregated revenues $ 0 $ 0
Point in Time | Service revenue    
Disaggregation of Revenue [Line Items]    
Total disaggregated revenues 0 0
Over Time    
Disaggregation of Revenue [Line Items]    
Total disaggregated revenues 2,912 0
Over Time | Service revenue    
Disaggregation of Revenue [Line Items]    
Total disaggregated revenues $ 2,912 $ 0
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended
Feb. 14, 2022
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock options and RSUs granted (in shares)   33,400    
Shares available for issuance (in shares)   3,628,308    
Stock-based compensation expense   $ 1.4 $ 3.9  
Unrecognized compensation cost of unvested stock awards   $ 12.7    
Chief Executive Officer | The Inducement Award        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock options granted (in shares) 10,000,000      
Award exercise price (in dollars per share) $ 0.86      
Award expiration period (in years) 10 years      
Chief Executive Officer | The Inducement Award, Four-Year Vesting        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock options granted (in shares) 4,000,000      
Awards vesting period (in years) 4 years      
Chief Executive Officer | The Inducement Award, Four-Year Vesting | Tranche One        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting percentage 25.00%      
Chief Executive Officer | The Inducement Award, Four-Year Vesting | Tranche Two        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Awards vesting period (in years) 36 months      
Chief Executive Officer | The Inducement Award, Performance Based Vesting        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock options granted (in shares) 6,000,000      
2019 Equity And Incentive Compensation Plan        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Common stock authorized for equity incentive plan (in shares)       18,500,000
Shares of common stock outstanding (in shares)   23,355,351    
Inducement Awards Plan        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares of common stock outstanding (in shares)   11,000,000    
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Equity and Warrants - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended
Aug. 31, 2021
Jun. 30, 2021
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
May 31, 2021
Class of Stock [Line Items]            
Shares called by warrants (in shares) 10,000,000          
Common stock, shares authorized (in shares)   600,000,000 600,000,000   600,000,000 300,000,000
Healios            
Class of Stock [Line Items]            
Ownership percentage in common stock for exercise cap to be triggered 19.90%          
Warrant One            
Class of Stock [Line Items]            
Shares called by warrants (in shares) 3,000,000          
Exercise price of warrant (in dollars per share) $ 1.80          
Exercise period (in days) 60 days          
Warrant Two            
Class of Stock [Line Items]            
Shares called by warrants (in shares) 7,000,000          
Exercise price of warrant (in dollars per share) $ 2.40          
Exercise period (in days) 60 days          
Aspire Capital            
Class of Stock [Line Items]            
Equity purchase agreement, value   $ 100.0        
Common stock registered for resale (in shares)   40,000,000        
Net proceeds from sales of common stock     $ 4.8 $ 30.5    
Aspire Capital | Common Stock            
Class of Stock [Line Items]            
Issuance of common stock, new issues (in shares)     6,800,000 15,200,000    
Sale of additional shares at an average price (in dollars per share)     $ 0.71 $ 2.01    
XML 40 athx-20220331_htm.xml IDEA: XBRL DOCUMENT 0001368148 2022-01-01 2022-03-31 0001368148 2022-04-29 0001368148 2022-03-31 0001368148 2021-12-31 0001368148 srt:AffiliatedEntityMember 2022-03-31 0001368148 srt:AffiliatedEntityMember 2021-12-31 0001368148 athx:ConsolidatedEntityExcludingRelatedPartyMember 2022-03-31 0001368148 athx:ConsolidatedEntityExcludingRelatedPartyMember 2021-12-31 0001368148 srt:AffiliatedEntityMember 2022-01-01 2022-03-31 0001368148 srt:AffiliatedEntityMember 2021-01-01 2021-03-31 0001368148 2021-01-01 2021-03-31 0001368148 us-gaap:PreferredStockMember 2021-12-31 0001368148 us-gaap:CommonStockMember 2021-12-31 0001368148 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001368148 us-gaap:RetainedEarningsMember 2021-12-31 0001368148 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001368148 athx:ConsolidatedEntityExcludingRelatedPartyMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001368148 athx:ConsolidatedEntityExcludingRelatedPartyMember us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001368148 athx:ConsolidatedEntityExcludingRelatedPartyMember 2022-01-01 2022-03-31 0001368148 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001368148 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001368148 us-gaap:PreferredStockMember 2022-03-31 0001368148 us-gaap:CommonStockMember 2022-03-31 0001368148 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001368148 us-gaap:RetainedEarningsMember 2022-03-31 0001368148 us-gaap:PreferredStockMember 2020-12-31 0001368148 us-gaap:CommonStockMember 2020-12-31 0001368148 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001368148 us-gaap:RetainedEarningsMember 2020-12-31 0001368148 2020-12-31 0001368148 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001368148 athx:ConsolidatedEntityExcludingRelatedPartyMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001368148 athx:ConsolidatedEntityExcludingRelatedPartyMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001368148 athx:ConsolidatedEntityExcludingRelatedPartyMember 2021-01-01 2021-03-31 0001368148 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001368148 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001368148 us-gaap:PreferredStockMember 2021-03-31 0001368148 us-gaap:CommonStockMember 2021-03-31 0001368148 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001368148 us-gaap:RetainedEarningsMember 2021-03-31 0001368148 2021-03-31 0001368148 athx:Section220LitigationMember srt:MaximumMember us-gaap:PendingLitigationMember 2021-02-16 2021-02-16 0001368148 athx:Section220LitigationMember us-gaap:PendingLitigationMember us-gaap:SubsequentEventMember 2022-04-01 2022-04-30 0001368148 us-gaap:DeferredBonusMember 2021-03-31 0001368148 athx:AdditionalEmployeesMember us-gaap:DeferredBonusMember 2021-04-30 0001368148 athx:FormerChiefExecutiveOfficerMember 2021-02-15 0001368148 athx:FormerChiefExecutiveOfficerMember 2021-02-15 2021-02-15 0001368148 athx:FormerChiefExecutiveOfficerMember 2022-03-31 0001368148 athx:FormerChiefExecutiveOfficerMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001368148 athx:FormerChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001368148 us-gaap:DeferredBonusMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-01 2021-03-31 0001368148 us-gaap:DeferredBonusMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-01-01 2021-03-31 0001368148 athx:HealiosFrameworkAgreementMember 2021-08-01 2021-08-31 0001368148 us-gaap:StockCompensationPlanMember 2022-01-01 2022-03-31 0001368148 us-gaap:StockCompensationPlanMember 2021-01-01 2021-03-31 0001368148 athx:HealiosFrameworkAgreementMember 2021-08-31 0001368148 us-gaap:EquipmentMember 2022-03-31 0001368148 us-gaap:EquipmentMember 2021-12-31 0001368148 athx:OfficeEquipmentAndLeaseholdImprovementsMember 2022-03-31 0001368148 athx:OfficeEquipmentAndLeaseholdImprovementsMember 2021-12-31 0001368148 athx:EquipmentAndLeaseholdImprovementNotYetInServiceMember 2022-03-31 0001368148 athx:EquipmentAndLeaseholdImprovementNotYetInServiceMember 2021-12-31 0001368148 athx:HealiosFrameworkAgreementMember 2022-03-31 0001368148 athx:HealiosFrameworkAgreementMember 2021-12-31 0001368148 athx:HealiosFrameworkAgreementMember 2022-01-01 2022-03-31 0001368148 athx:HealiosFrameworkAgreementMember 2021-01-01 2021-03-31 0001368148 srt:MinimumMember 2022-03-31 0001368148 srt:MaximumMember 2022-03-31 0001368148 athx:HealiosLicenseAgreementMember 2022-01-01 2022-03-31 0001368148 athx:HealiosLicenseAgreementMember 2021-01-01 2021-03-31 0001368148 athx:RegulatoryAndSalesMilestonesMember athx:HealiosLicenseAgreementMember 2020-01-01 2020-09-30 0001368148 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember athx:HealiosLicenseAgreementMember 2022-01-01 2022-03-31 0001368148 us-gaap:ServiceMember us-gaap:TransferredOverTimeMember athx:HealiosLicenseAgreementMember 2022-01-01 2022-03-31 0001368148 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember athx:HealiosLicenseAgreementMember 2021-01-01 2021-03-31 0001368148 us-gaap:ServiceMember us-gaap:TransferredOverTimeMember athx:HealiosLicenseAgreementMember 2021-01-01 2021-03-31 0001368148 us-gaap:TransferredAtPointInTimeMember athx:HealiosLicenseAgreementMember 2022-01-01 2022-03-31 0001368148 us-gaap:TransferredOverTimeMember athx:HealiosLicenseAgreementMember 2022-01-01 2022-03-31 0001368148 us-gaap:TransferredAtPointInTimeMember athx:HealiosLicenseAgreementMember 2021-01-01 2021-03-31 0001368148 us-gaap:TransferredOverTimeMember athx:HealiosLicenseAgreementMember 2021-01-01 2021-03-31 0001368148 athx:A2019EquityAndIncentiveCompensationPlanMember 2019-12-31 0001368148 srt:ChiefExecutiveOfficerMember athx:TheInducementAwardMember 2022-02-14 2022-02-14 0001368148 srt:ChiefExecutiveOfficerMember athx:TheInducementAwardMember 2022-02-14 0001368148 srt:ChiefExecutiveOfficerMember athx:TheInducementAwardFourYearVestingMember 2022-02-14 2022-02-14 0001368148 srt:ChiefExecutiveOfficerMember athx:TheInducementAwardFourYearVestingMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-02-14 2022-02-14 0001368148 srt:ChiefExecutiveOfficerMember athx:TheInducementAwardFourYearVestingMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-02-14 2022-02-14 0001368148 srt:ChiefExecutiveOfficerMember athx:TheInducementAwardPerformanceBasedVestingMember 2022-02-14 2022-02-14 0001368148 athx:A2019EquityAndIncentiveCompensationPlanMember 2022-03-31 0001368148 athx:InducementAwardsPlanMember 2022-03-31 0001368148 athx:AspireMember 2021-06-01 2021-06-30 0001368148 athx:AspireMember 2021-06-30 0001368148 athx:AspireMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001368148 athx:AspireMember 2022-01-01 2022-03-31 0001368148 athx:AspireMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001368148 athx:AspireMember 2021-01-01 2021-03-31 0001368148 2021-08-31 0001368148 athx:WarrantOneMember 2021-08-31 0001368148 athx:WarrantOneMember 2021-08-01 2021-08-31 0001368148 athx:WarrantTwoMember 2021-08-31 0001368148 athx:WarrantTwoMember 2021-08-01 2021-08-31 0001368148 srt:AffiliatedEntityMember 2021-08-01 2021-08-31 0001368148 2021-05-31 0001368148 2021-06-30 shares iso4217:USD iso4217:USD shares athx:segment pure athx:performanceObligation athx:milestone false 2022 Q1 ATHERSYS, INC / NEW 0001368148 --12-31 0.3333 0.6667 P30D 10-Q true 2022-03-31 false 001-33876 DE 20-4864095 3201 Carnegie Avenue, Cleveland, OH 44115-2634 216 431-9900 Common Stock, par value $0.001 per share ATHX NASDAQ Yes Yes Non-accelerated Filer true false false 251967791 21797000 37407000 1643000 1414000 3000000 3000000 4661000 4206000 31101000 46027000 8707000 8960000 3631000 3692000 1520000 1505000 44959000 60184000 16771000 15781000 1119000 1119000 1031000 1011000 3345000 4133000 5770000 3773000 727000 704000 2202000 3340000 30965000 29861000 8488000 8755000 5199000 5199000 10000000 10000000 0 0 0 0 0 0 0.001 0.001 600000000 600000000 249792791 249792791 242844180 242844180 250000 243000 605617000 599470000 -605560000 -583344000 307000 16369000 44959000 60184000 2912000 0 2912000 0 20944000 17508000 4099000 8837000 247000 244000 25290000 26589000 -22378000 -26589000 162000 121000 -22216000 -26468000 -0.09 -0.09 -0.13 -0.13 244197000 244197000 208192000 208192000 0 0 242844180 243000 599470000 -583344000 16369000 1410000 1410000 6800000 7000 4795000 4802000 148611 0 -58000 -58000 -22216000 -22216000 0 0 249792791 250000 605617000 -605560000 307000 0 0 201973582 202000 527549000 -496389000 31362000 3903000 3903000 15200000 15000 30480000 30495000 437925 1000 -612000 -611000 -26468000 -26468000 0 0 217611507 218000 561320000 -522857000 38681000 -22216000 -26468000 247000 244000 1410000 3903000 229000 0 217000 45000 1975000 5273000 -1138000 0 -20168000 -17093000 186000 114000 -186000 -114000 4802000 30506000 58000 622000 4744000 29884000 -15610000 12677000 37407000 51546000 21797000 64223000 Background and Basis of Presentation<div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Athersys, Inc., including its consolidated subsidiaries (collectively, “we,” “us,” “our,” “Athersys,” and the “Company”), is a biotechnology company focused in the field of regenerative medicine and operates in one business segment. Our operations consist of research, clinical development activities, manufacturing and manufacturing process development activities, and our most advanced program is in a pivotal Phase 3 clinical trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the results of the TREASURE study, the clinical trial of our partner in Japan, HEALIOS K.K. (“Healios”), followed by the results of our MASTERS-2 clinical trial, will have a significant impact, favorable or unfavorable, on our ability to access capital from potential third-party commercial partners or the equity capital markets. Depending on the nature of these results, we may accelerate or may delay certain programs. In the long term, we will have to continue to generate additional capital to meet our needs until we become cash flow positive as a result of the sales of our clinical products, if they are approved for marketing. Such capital would come from new and existing collaborations and the related license fees, milestones and potential royalties and the sale of equity securities from time to time including through our equity facility and grant-funding opportunities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healios Framework Agreement</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, we expanded our partnership with Healios by entering into the Comprehensive Framework Agreement for Commercial Manufacturing and Ongoing Support (the “Framework Agreement”). The Framework Agreement provides for planned investment by Healios in certain manufacturing preparation activities. We have agreed to defer certain milestone payments and potentially adjust royalty payments during the initial commercial launch period. Refer to Note 6 for additional information on the Framework Agreement. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2021, the Company, Healios and Dr. Hardy TS Kagimoto, the Chairman and Chief Executive Officer of Healios and a member of the Company’s board of directors (the “Board”), entered into a cooperation agreement (the “Cooperation Agreement”). The Cooperation Agreement provided for the parties’ cooperation on certain commercial matters, including a commitment to work in good faith to finalize negotiations on all aspects of their supply, manufacturing, information provision and regulatory support relationship. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cooperation Agreement also provided for, among related matters, the dismissal with prejudice of the complaint filed by Dr. Kagimoto against the Company seeking the inspection of the Company’s books and records in the Court of Chancery of the State of Delaware on November 21, 2020 (the “Section 220 Litigation”). Pursuant to the Cooperation Agreement, in April 2021, the Company reimbursed Healios and Dr. Kagimoto for reasonable out-of-pocket fees and expenses, including legal expenses, incurred in connection with the Section 220 Litigation, which were not to exceed $0.5 million in the aggregate. In April 2022, the Company received an insurance reimbursement of $0.4 million for legal costs incurred in connection with the Section 220 Litigation.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Framework Agreement, certain issues as contemplated by the Cooperation Agreement were resolved and the Cooperation Agreement was amended to extend certain customary standstill provisions until the conclusion of our 2023 annual meeting of stockholders.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retention Program</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we entered into retention letter agreements (“Retention Agreements”) with our executive officers and certain other employees in leadership positions. Each Retention Agreement provides for, among other things, a cash retention bonus and a stock option award, each with vesting tied to continued employment. The cash retention bonuses generally represent a percentage of the employee’s annual compensation and generally vest in full if employed on May 1, 2022. The stock option awards generally vest one-third on May 1, 2022 with the remainder vesting on May 1, 2023 and include a provision for accelerated vesting upon termination without cause. The total stock compensation expense related to the stock option awards is approximately $2.7 million and is being expensed ratably over the vesting period. In April 2021, we expanded the retention program to all then-current employees of the Company, providing for a cash retention bonus with vesting also tied to continued employment through May 1, 2022. The total cash retention bonus is approximately $2.5 million, which is being expensed ratably over the respective vesting periods.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer Separation Letter Agreement</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 15, 2021, Dr. Gil Van Bokkelen was terminated from his position as the Company’s Chief Executive Officer and Chairman of the Board. In connection with his cessation of service, the Company and Dr. Van Bokkelen entered into a separation letter agreement (the “Separation Letter”) entitling him to severance payments and benefits with an aggregate value of approximately $1.0 million payable in installments over an 18-month period, and providing for a total lump sum payment of approximately $0.2 million. At March 31, 2022, we recorded a liability in the amount of $0.2 million, which represents the remaining installments payable to Dr. Van Bokkelen. The lump sum payment was made to Dr. Van Bokkelen in March 2021. The related expense is recorded in general and administrative expense on the unaudited condensed consolidated statements of operations and comprehensive loss. </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Separation Letter also provide for the accelerated vesting of Dr. Van Bokkelen’s outstanding restricted stock units (“RSUs”) and the modification of his stock option awards by providing for accelerated vesting of his unvested stock options and the extension of time during which certain vested stock options can be exercised. In the first quarter of 2021, following the evaluation of the modification, we recorded stock compensation expense of approximately $1.4 million related to the accelerated vesting of Dr. Van Bokkelen’s stock options and $0.9 million related to the accelerated vesting of his RSUs.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and Regulation S-X. Accordingly, since they are interim statements, the accompanying financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments and disclosures that are, in the opinion of management, necessary for a fair presentation of financial position and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Our critical accounting policies, estimates and assumptions are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which is included in this Quarterly Report on Form 10-Q.</span></div> 1 500000 400000 2700000 2500000 1000000 P18M 200000 200000 1400000 900000 <div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and Regulation S-X. Accordingly, since they are interim statements, the accompanying financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments and disclosures that are, in the opinion of management, necessary for a fair presentation of financial position and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year.</span></div> <div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Our critical accounting policies, estimates and assumptions are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which is included in this Quarterly Report on Form 10-Q.</span></div> Going Concern<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared our unaudited condensed consolidated financial statements on a going concern basis, which assumes that we will realize our assets and satisfy our liabilities in the normal course of business. However, we have incurred net losses since our inception in 1995 and have negative operating cash flows. These factors, among others, raise substantial doubt about our ability to continue as a going concern within one year after the date that these financial statements are issued. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of the uncertainty concerning our ability to continue as a going concern.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022, we had cash and cash equivalents of $21.8 million. We will require significant additional capital to continue our research and development programs, including progressing our clinical product candidates to potential commercialization and preparing for commercial-scale manufacturing and sales. We expect that the results of the TREASURE study, followed by the results of our MASTERS-2 clinical trial, will have a significant impact, favorable or unfavorable, on our ability to access capital from potential third-party commercial partners or the equity capital markets. </span></div>In the long term, we will have to continue to generate additional capital to meet our needs until we become cash flow positive as a result of the sales of our clinical products, if they are approved for marketing. Such capital would come from new and existing collaborations and the related license fees, milestones and potential royalties. Management plans to raise additional capital through the use of our equity purchase agreement with Aspire Capital Fund, LLC (“Aspire Capital”) and, depending on market conditions, through equity offerings. We are entitled to a new milestone payment from Healios in the amount of $3.0 million in June 2022. While management believes this plan to generate additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. For the foreseeable future, our ability to continue our operations is dependent upon the ability to obtain additional capital. 21800000 3000000 Accounting Standards Not Yet Adopted<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Subsequent to issuing ASU 2016-13, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Effective Dates</span>, delaying the effective date for smaller reporting companies until January 2023. We are currently evaluating the potential impact of adoption of this standard on our consolidated financial statements and disclosures, and we do not intend to adopt this standard earlier than required. Accounting Standards Not Yet Adopted<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Subsequent to issuing ASU 2016-13, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Effective Dates</span>, delaying the effective date for smaller reporting companies until January 2023. We are currently evaluating the potential impact of adoption of this standard on our consolidated financial statements and disclosures, and we do not intend to adopt this standard earlier than required. Net Loss per Share<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share have been computed using the weighted-average number of shares of our common stock outstanding during the period. Stock-based awards of approximately 28,355,351 and 21,788,078 for the three months ended March 31, 2022 and 2021, respectively, were excluded from the calculation of diluted net loss per share because their effects would be antidilutive. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two warrants outstanding to purchase an aggregate of 10,000,000 shares of our common stock that were issued to Healios in August 2021 and are excluded from the calculation of diluted net loss per share, as the underlying performance condition associated with each warrant has not been satisfied and is not yet considered probable by the end of the reporting period. Refer to Note 8 for additional information.</span></div> 28355351 21788078 2 10000000 Property and Equipment, net<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the periods ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment consists of (in thousands):</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,535</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,352 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and leasehold improvements not yet in service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,968</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,810 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,337)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,631</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,692 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the periods ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment consists of (in thousands):</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,535</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,352 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and leasehold improvements not yet in service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,968</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,810 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,337)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,631</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,692 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 9535000 9352000 4000000 4000000 433000 458000 13968000 13810000 10337000 10118000 3631000 3692000 Collaborative Arrangements and Revenue Recognition<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healios Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a licensing collaboration with Healios to primarily develop and commercialize our cell therapy technologies for certain disease indications in Japan, pursuant to which we received nonrefundable license fee payments and are entitled to royalties on net sales. We also have the right to receive development and commercial milestone payments from Healios, subject to certain potential credits that have been negotiated from time-to-time and are associated with modifications to the arrangement. Healios is responsible for the development and commercialization of the licensed products in the licensed territories, and we provide certain services to Healios for which we are paid. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company and Healios entered into the Framework Agreement, which provides for clarification under and modifies the existing agreements between the parties and reframes our collaboration to set the stage for productive efforts as Healios and our collaboration move towards commercialization of MultiStem in Japan. It also provides Healios with deferral of certain milestone payments during the expensive initial commercial launch period. We will be entitled to new milestone payments in the amount of $3.0 million in June 2022 and $5.0 million upon the successful completion of certain commercial manufacturing activities. Additionally, accounts payable to Healios have been reduced to $1.1 million and are due on or before December 31, 2022. In August 2021, we also issued two warrants (together, the “2021 Warrants”) to Healios in connection with the Framework Agreement to purchase up to a total of 10,000,000 shares of our common stock. The 2021 Warrants are being accounted for as consideration paid or payable to a customer according to Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under which the recognition of such equity instruments is required at the time that the underlying performance conditions become probable or are satisfied. As of March 31, 2022, the 2021 Warrants have not been recorded as the underlying performance conditions have not been satisfied and are not yet considered probable. Refer to Note 8 for further information. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healios Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Healios arrangement and again each time that the arrangement is modified, all material performance obligations are identified, which currently include one performance obligation for services necessary for regulatory approvals, manufacturing readiness, and commercial launch in Japan. We determined the transaction price includes estimated payments for reimbursable services to be performed by us for Healios and the $3.0 million milestone payment due in June 2022. We allocated the total transaction price to this one performance obligation. We began recognizing this revenue beginning in the third quarter of 2021 as the services were being performed. We expect the services to be completed by the end of 2022. During our evaluation of variable consideration in the first quarter of 2022, we decreased our estimated transaction price due to changes in the estimated cost of the reimbursable services. The remaining transaction price for the performance obligation that was not yet satisfied is approximately $1.4 million at March 31, 2022. During the three months ended March 31, 2022, we recognized approximately $2.8 million of revenue associated with this performance obligation. We recognized no revenue for the three months ended March 31, 2022, and March 31, 2021 from performance obligations satisfied in previous periods. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable from Healios</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable from Healios are related to our contracts and are recorded when the right to consideration is unconditional at the amount that management expects to collect. Accounts receivable from Healios do not bear interest if paid when contractually due, and payments are generally due within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYyZWFkNDUyMTgyMTRjZDJhMzcxODQ3ZGU0MWIxOTkyL3NlYzo2MmVhZDQ1MjE4MjE0Y2QyYTM3MTg0N2RlNDFiMTk5Ml80Ni9mcmFnOmQyNjI4Y2YzOTkxZDRlZWJhYjY1MjhjY2E1ZjY5NjExL3RleHRyZWdpb246ZDI2MjhjZjM5OTFkNGVlYmFiNjUyOGNjYTVmNjk2MTFfNTQ5NzU1ODE1MjM5Nw_afb21ded-939e-43a0-9b06-175bbb44dbf1">thirty</span> to forty-five days of invoicing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unbilled Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unbilled accounts receivable from Healios represent amounts due to us under contractual arrangements and for which we have an unconditional right to consideration, but which we have not yet invoiced Healios. At March 31, 2022, the unbilled accounts receivable from Healios was $3.0 million, which represents a milestone payment owed to us under the Framework Agreement for which we are entitled to receive payment in June 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenue - Healios</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in deferred revenue - Healios on the condensed consolidated balance sheets are considered a contract liability. During the three months ended March 31, 2022, revenue recognized from contract liabilities as of the beginning of the respective period was $1.1 million. No revenue was recognized from contract liabilities during the three months ended March 31, 2021. At March 31, 2022, the contract liability included in deferred revenue - Healios is classified as a current liability because the rights to consideration are expected to be satisfied, in all material respects, within one year. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advance from Healios</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we amended the clinical trial supply agreement for the manufacturing of clinical product for TREASURE to clarify a cost-sharing arrangement. The proceeds from Healios that relate specifically to the cost-sharing arrangement may either (i) result in a reduction in the proceeds we receive from Healios upon the achievement of two potential milestones and an increase to a commercial milestone under the license agreement for stroke or (ii) be repaid to Healios at our election, as defined. The cost-sharing proceeds received are recognized in advance from Healios on the unaudited condensed consolidated balance sheets until the earlier of the milestones being achieved or such amounts being repaid to Healios at our election, at which time the culmination of the earnings process or the repayment will be complete.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize service revenue when earned over time. The following table presents our contract revenues disaggregated by timing of revenue recognition (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:44.861%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three months ended<br/>March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Point in<br/>Time</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over Time</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Point in<br/>Time</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over Time</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Revenue from Healios</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,912</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total disaggregated revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,912</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3000000 5000000 1100000 2 10000000 1 3000000 1 1400000 2800000 0 0 P45D 3000000 1100000 0 2 The following table presents our contract revenues disaggregated by timing of revenue recognition (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:44.861%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three months ended<br/>March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Point in<br/>Time</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over Time</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Point in<br/>Time</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over Time</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Revenue from Healios</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,912</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total disaggregated revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,912</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 2912000 0 0 0 2912000 0 0 Stock-Based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2019 Equity and Incentive Compensation Plan (the “EICP”) authorized at inception an aggregate of approximately 18,500,000 shares of our common stock for awards to employees, directors and consultants. The EICP authorizes the issuance of stock-based compensation in the form of stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares and units, and other stock-based awards. Under the EICP, in the three months ended March 31, 2022, we granted 33,400 stock options and no RSUs to our employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2022, Daniel Camardo was named the Company’s Chief Executive Officer. As an inducement to Mr. Camardo’s acceptance of employment with us, Mr. Camardo was granted an initial equity award (the “Inducement Award”) to purchase 10,000,000 shares of our common stock at a per share exercise price of $0.86. With regard to 4,000,000 shares, vesting of the Inducement Award will occur over a four-year period, with 25% of such portion of the award generally vesting on the first anniversary of the grant date and the remainder generally vesting monthly in substantially equal installments over the remaining 36 months. With regard to 6,000,000 shares, vesting of the Inducement Award will generally occur upon achievement of certain Company milestones. The Inducement Award has up to a 10-year term. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, a total of 3,628,308 shares were available for issuance under the EICP, and stock-based awards representing 23,355,351 shares of our common stock were outstanding under our current and former equity incentive plans, and inducement awards granted outside of our equity incentive plans to purchase 11,000,000 shares of our common stock were outstanding. For the three months ended March 31, 2022 and 2021, stock-based compensation expense was approximately $1.4 million and $3.9 million, respectively. At March 31, 2022, total unrecognized estimated compensation cost related to unvested stock-based awards was approximately $12.7 million, which is expected to be recognized by the end of 2026 using the straight-line method.</span></div> 18500000 33400 10000000 0.86 4000000 P4Y 0.25 P36M 6000000 P10Y 3628308 23355351 11000000 1400000 3900000 12700000 Stockholders’ Equity and Warrants<div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Purchase Agreement</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have had equity purchase agreements in place since 2011 with Aspire Capital that provide us the ability to sell shares to Aspire Capital from time to time. Currently, we have an agreement with Aspire Capital that was entered into in June 2021 (the “2021 Equity Facility”) and includes Aspire Capital’s commitment to purchase up to an aggregate of $100.0 million of shares of our common stock over a defined timeframe. The terms of the 2021 Equity Facility are similar to the previous equity facilities with Aspire Capital, and we filed a registration statement for the resale of 40,000,000 shares of our common stock in connection with the 2021 Equity Facility. Our prior equity facility that was entered into in November 2019 was fully utilized and terminated during the third quarter of 2021.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sold 6,800,000 shares to Aspire Capital at an average price of $0.71 per share in the first quarter of 2022, generating proceeds of $4.8 million. We sold 15,200,000 shares to Aspire Capital at an average price of $2.01 per share in the first quarter of 2021, generating proceeds of $30.5 million.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healios 2021 Warrants</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we issued the 2021 Warrants to Healios to purchase up to an aggregate of 10,000,000 shares of our common stock. One of the 2021 Warrants is for the purchase of up to 3,000,000 shares at an exercise price of $1.80 per share, subject to specified increases, and generally is only exercisable within 60 days of receipt of either conditional or full marketing approval from the Pharmaceuticals and Medical Devices Agency in Japan (the “PMDA”) for the intravenous administration of MultiStem to treat patients who are suffering from acute respiratory distress syndrome. The other 2021 Warrant is for the purchase of up to 7,000,000 shares at an exercise price of $2.40 per share, subject to specified increases, and generally is only exercisable within 60 days of receipt of either conditional or full marketing approval from the PMDA for the intravenous administration of MultiStem to treat patients who are suffering from ischemic stroke. The 2021 Warrants may be terminated by us under certain conditions and have an exercise cap triggered at Healios’ ownership of 19.9% of our common stock.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Increase Shares of Authorized Common Stock</span></div>In June 2021, the Company’s stockholders approved an Amendment to the Certificate of Incorporation to increase the number of shares of the Company’s authorized common stock from 300,000,000 shares to 600,000,000 shares. 100000000 40000000 6800000 0.71 4800000 15200000 2.01 30500000 10000000 3000000 1.80 P60D 7000000 2.40 P60D 0.199 300000000 600000000 Income TaxesWe have United States (“U.S.”) federal net operating loss and research and development tax credit carryforwards, as well as state and city net operating loss carryforwards, which may be used to reduce future taxable income and tax liabilities. We also have foreign net operating loss and tax credit carryforwards, and the foreign net operating loss carryforwards do not expire. Substantially all of our deferred tax assets have been fully offset by a valuation allowance due to our cumulative losses. The carrying value of our deferred tax assets and liabilities is determined by the enacted U.S. corporate income tax rate. Consequently, any changes in the U.S. corporate income tax rate impacts the carrying value of our deferred tax assets and liabilities. Also, there are significant limitations on our ability to utilize our net operating loss and tax credit carryforwards under Section 382 of the Internal Revenue Code of 1986, as amended. EXCEL 41 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 43 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 44 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 102 144 1 false 38 0 false 7 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.athersys.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.athersys.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.athersys.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101101 - Disclosure - Background and Basis of Presentation Sheet http://www.athersys.com/role/BackgroundandBasisofPresentation Background and Basis of Presentation Notes 7 false false R8.htm 2103102 - Disclosure - Going Concern Sheet http://www.athersys.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 2105103 - Disclosure - Accounting Standards Not Yet Adopted Sheet http://www.athersys.com/role/AccountingStandardsNotYetAdopted Accounting Standards Not Yet Adopted Notes 9 false false R10.htm 2107104 - Disclosure - Net Loss per Share Sheet http://www.athersys.com/role/NetLossperShare Net Loss per Share Notes 10 false false R11.htm 2109105 - Disclosure - Property and Equipment, net Sheet http://www.athersys.com/role/PropertyandEquipmentnet Property and Equipment, net Notes 11 false false R12.htm 2112106 - Disclosure - Collaborative Arrangements and Revenue Recognition Sheet http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognition Collaborative Arrangements and Revenue Recognition Notes 12 false false R13.htm 2116107 - Disclosure - Stock-based Compensation Sheet http://www.athersys.com/role/StockbasedCompensation Stock-based Compensation Notes 13 false false R14.htm 2118108 - Disclosure - Stockholders??? Equity and Warrants Sheet http://www.athersys.com/role/StockholdersEquityandWarrants Stockholders??? Equity and Warrants Notes 14 false false R15.htm 2120109 - Disclosure - Income Taxes Sheet http://www.athersys.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 2206201 - Disclosure - Accounting Standards Not Yet Adopted (Policies) Sheet http://www.athersys.com/role/AccountingStandardsNotYetAdoptedPolicies Accounting Standards Not Yet Adopted (Policies) Policies http://www.athersys.com/role/AccountingStandardsNotYetAdopted 16 false false R17.htm 2310301 - Disclosure - Property and Equipment, net (Tables) Sheet http://www.athersys.com/role/PropertyandEquipmentnetTables Property and Equipment, net (Tables) Tables http://www.athersys.com/role/PropertyandEquipmentnet 17 false false R18.htm 2313302 - Disclosure - Collaborative Arrangements and Revenue Recognition (Tables) Sheet http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionTables Collaborative Arrangements and Revenue Recognition (Tables) Tables http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognition 18 false false R19.htm 2402401 - Disclosure - Background and Basis of Presentation - Additional Information (Details) Sheet http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails Background and Basis of Presentation - Additional Information (Details) Details 19 false false R20.htm 2404402 - Disclosure - Going Concern (Details) Sheet http://www.athersys.com/role/GoingConcernDetails Going Concern (Details) Details http://www.athersys.com/role/GoingConcern 20 false false R21.htm 2408403 - Disclosure - Net Loss per Share - Additional Information (Details) Sheet http://www.athersys.com/role/NetLossperShareAdditionalInformationDetails Net Loss per Share - Additional Information (Details) Details 21 false false R22.htm 2411404 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, net (Details) Sheet http://www.athersys.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentnetDetails Property and Equipment, net - Schedule of Property and Equipment, net (Details) Details 22 false false R23.htm 2414405 - Disclosure - Collaborative Arrangements and Revenue Recognition - Additional Information (Details) Sheet http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails Collaborative Arrangements and Revenue Recognition - Additional Information (Details) Details 23 false false R24.htm 2415406 - Disclosure - Collaborative Arrangements and Revenue Recognition - Schedule of Contract Revenues Disaggregated by Timing of Revenue Recognition (Details) Sheet http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionScheduleofContractRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails Collaborative Arrangements and Revenue Recognition - Schedule of Contract Revenues Disaggregated by Timing of Revenue Recognition (Details) Details 24 false false R25.htm 2417407 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 25 false false R26.htm 2419408 - Disclosure - Stockholders??? Equity and Warrants - Additional Information (Details) Sheet http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails Stockholders??? Equity and Warrants - Additional Information (Details) Details 26 false false All Reports Book All Reports athx-20220331.htm athx-20220331.xsd athx-20220331_cal.xml athx-20220331_def.xml athx-20220331_lab.xml athx-20220331_pre.xml ex10120220331.htm ex10220220331.htm ex31120220331.htm ex31220220331.htm ex32120220331.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 47 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "athx-20220331.htm": { "axisCustom": 0, "axisStandard": 20, "contextCount": 102, "dts": { "calculationLink": { "local": [ "athx-20220331_cal.xml" ] }, "definitionLink": { "local": [ "athx-20220331_def.xml" ] }, "inline": { "local": [ "athx-20220331.htm" ] }, "labelLink": { "local": [ "athx-20220331_lab.xml" ] }, "presentationLink": { "local": [ "athx-20220331_pre.xml" ] }, "schema": { "local": [ "athx-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 261, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 3, "http://xbrl.sec.gov/dei/2021q4": 6, "total": 9 }, "keyCustom": 15, "keyStandard": 129, "memberCustom": 17, "memberStandard": 20, "nsprefix": "athx", "nsuri": "http://www.athersys.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.athersys.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107104 - Disclosure - Net Loss per Share", "role": "http://www.athersys.com/role/NetLossperShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109105 - Disclosure - Property and Equipment, net", "role": "http://www.athersys.com/role/PropertyandEquipmentnet", "shortName": "Property and Equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112106 - Disclosure - Collaborative Arrangements and Revenue Recognition", "role": "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognition", "shortName": "Collaborative Arrangements and Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116107 - Disclosure - Stock-based Compensation", "role": "http://www.athersys.com/role/StockbasedCompensation", "shortName": "Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118108 - Disclosure - Stockholders\u2019 Equity and Warrants", "role": "http://www.athersys.com/role/StockholdersEquityandWarrants", "shortName": "Stockholders\u2019 Equity and Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120109 - Disclosure - Income Taxes", "role": "http://www.athersys.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2206201 - Disclosure - Accounting Standards Not Yet Adopted (Policies)", "role": "http://www.athersys.com/role/AccountingStandardsNotYetAdoptedPolicies", "shortName": "Accounting Standards Not Yet Adopted (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - Property and Equipment, net (Tables)", "role": "http://www.athersys.com/role/PropertyandEquipmentnetTables", "shortName": "Property and Equipment, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313302 - Disclosure - Collaborative Arrangements and Revenue Recognition (Tables)", "role": "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionTables", "shortName": "Collaborative Arrangements and Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Background and Basis of Presentation - Additional Information (Details)", "role": "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "shortName": "Background and Basis of Presentation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "ic097975ac9e74e9091350545d23e85aa_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "ic097975ac9e74e9091350545d23e85aa_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "ic097975ac9e74e9091350545d23e85aa_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Going Concern (Details)", "role": "http://www.athersys.com/role/GoingConcernDetails", "shortName": "Going Concern (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i7d2078b4cf654bbc9083292ee086a0c0_I20210831", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Net Loss per Share - Additional Information (Details)", "role": "http://www.athersys.com/role/NetLossperShareAdditionalInformationDetails", "shortName": "Net Loss per Share - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "iffe970d7e82847a5a0e7a5e0a84377ac_D20220101-20220331", "decimals": "0", "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "ic097975ac9e74e9091350545d23e85aa_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, net (Details)", "role": "http://www.athersys.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentnetDetails", "shortName": "Property and Equipment, net - Schedule of Property and Equipment, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "ic097975ac9e74e9091350545d23e85aa_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i7d2078b4cf654bbc9083292ee086a0c0_I20210831", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414405 - Disclosure - Collaborative Arrangements and Revenue Recognition - Additional Information (Details)", "role": "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails", "shortName": "Collaborative Arrangements and Revenue Recognition - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i60555f9099cd464ca09999763cd469de_I20220331", "decimals": null, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetThresholdPeriodPastDue", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "iee7326a7c2444f8fab0b860b4811cc72_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415406 - Disclosure - Collaborative Arrangements and Revenue Recognition - Schedule of Contract Revenues Disaggregated by Timing of Revenue Recognition (Details)", "role": "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionScheduleofContractRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails", "shortName": "Collaborative Arrangements and Revenue Recognition - Schedule of Contract Revenues Disaggregated by Timing of Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "iee7326a7c2444f8fab0b860b4811cc72_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "athx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417407 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "role": "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "athx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i7d2078b4cf654bbc9083292ee086a0c0_I20210831", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419408 - Disclosure - Stockholders\u2019 Equity and Warrants - Additional Information (Details)", "role": "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails", "shortName": "Stockholders\u2019 Equity and Warrants - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i6fa1f4a5e6bb45f9921661e42a733603_I20210630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "ic097975ac9e74e9091350545d23e85aa_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.athersys.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "ic097975ac9e74e9091350545d23e85aa_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "role": "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0c1a3b753e464c23a72d54f895d27735_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0c1a3b753e464c23a72d54f895d27735_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Background and Basis of Presentation", "role": "http://www.athersys.com/role/BackgroundandBasisofPresentation", "shortName": "Background and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Going Concern", "role": "http://www.athersys.com/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105103 - Disclosure - Accounting Standards Not Yet Adopted", "role": "http://www.athersys.com/role/AccountingStandardsNotYetAdopted", "shortName": "Accounting Standards Not Yet Adopted", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "athx-20220331.htm", "contextRef": "i0e169708d4304437b7662bae4c88243c_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 38, "tag": { "athx_A2019EquityAndIncentiveCompensationPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Equity And Incentive Compensation Plan [Member]", "label": "2019 Equity And Incentive Compensation Plan [Member]", "terseLabel": "2019 Equity And Incentive Compensation Plan" } } }, "localname": "A2019EquityAndIncentiveCompensationPlanMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "athx_AccountingPoliciesAndGeneralInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Policies And General Information [Line Items]", "label": "Accounting Policies And General Information [Line Items]", "terseLabel": "Accounting Policies And General Information [Line Items]" } } }, "localname": "AccountingPoliciesAndGeneralInformationLineItems", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/GoingConcernDetails" ], "xbrltype": "stringItemType" }, "athx_AccountingPoliciesAndGeneralInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Policies And General Information [Table]", "label": "Accounting Policies And General Information [Table]", "terseLabel": "Accounting Policies And General Information [Table]" } } }, "localname": "AccountingPoliciesAndGeneralInformationTable", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/GoingConcernDetails" ], "xbrltype": "stringItemType" }, "athx_AccruedClinicalTrialCostsCurrent": { "auth_ref": [], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to clinical trial services received from vendors, such as accrued contract research organization costs, patient costs, clinical site costs and clinical product cost. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Clinical Trial Costs Current", "terseLabel": "Accrued clinical trial related costs" } } }, "localname": "AccruedClinicalTrialCostsCurrent", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "athx_AdditionalEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Employees", "label": "Additional Employees [Member]", "terseLabel": "Additional Employees" } } }, "localname": "AdditionalEmployeesMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "athx_AspireMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aspire.", "label": "Aspire [Member]", "terseLabel": "Aspire Capital" } } }, "localname": "AspireMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "athx_ClassOfWarrantOrRightCommonStockOwnershipPercentageTriggered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Common Stock Ownership Percentage Triggered", "label": "Class Of Warrant Or Right, Common Stock Ownership Percentage Triggered", "terseLabel": "Ownership percentage in common stock for exercise cap to be triggered" } } }, "localname": "ClassOfWarrantOrRightCommonStockOwnershipPercentageTriggered", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "athx_ClassOfWarrantOrRightExercisePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Exercise Period", "label": "Class Of Warrant Or Right, Exercise Period", "terseLabel": "Exercise period (in days)" } } }, "localname": "ClassOfWarrantOrRightExercisePeriod", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "athx_CommonStockSharesRegisteredForResale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock shares registered for resale.", "label": "Common Stock Shares Registered For Resale", "terseLabel": "Common stock registered for resale (in shares)" } } }, "localname": "CommonStockSharesRegisteredForResale", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "athx_ConsolidatedEntityExcludingRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consolidated Entity Excluding Related Party [Member]", "label": "Consolidated Entity Excluding Related Party [Member]", "terseLabel": "Consolidated entity, excluding related party" } } }, "localname": "ConsolidatedEntityExcludingRelatedPartyMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets", "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "athx_DepositsAndOtherAssetsNonCurrent": { "auth_ref": [], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deposits And Other Assets Non Current", "label": "Deposits And Other Assets Non Current", "terseLabel": "Deposits and other" } } }, "localname": "DepositsAndOtherAssetsNonCurrent", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "athx_EquipmentAndLeaseholdImprovementNotYetInServiceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment And Leasehold Improvement Not Yet In Service", "label": "Equipment And Leasehold Improvement Not Yet In Service [Member]", "terseLabel": "Equipment and leasehold improvements not yet in service" } } }, "localname": "EquipmentAndLeaseholdImprovementNotYetInServiceMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "athx_FormerChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Chief Executive Officer", "label": "Former Chief Executive Officer [Member]", "terseLabel": "Former Chief Executive Officer" } } }, "localname": "FormerChiefExecutiveOfficerMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "athx_HealiosFrameworkAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Healios Framework Agreement", "label": "Healios Framework Agreement [Member]", "terseLabel": "Healios Framework Agreement" } } }, "localname": "HealiosFrameworkAgreementMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails", "http://www.athersys.com/role/GoingConcernDetails", "http://www.athersys.com/role/NetLossperShareAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "athx_HealiosLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Healios license agreement.", "label": "Healios License Agreement [Member]", "terseLabel": "Healios" } } }, "localname": "HealiosLicenseAgreementMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails", "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionScheduleofContractRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "athx_InducementAwardsPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inducement Awards Plan [Member]", "label": "Inducement Awards Plan [Member]", "terseLabel": "Inducement Awards Plan" } } }, "localname": "InducementAwardsPlanMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "athx_IssuanceOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of stock price per share.", "label": "Issuance Of Stock Price Per Share", "terseLabel": "Sale of additional shares at an average price (in dollars per share)" } } }, "localname": "IssuanceOfStockPricePerShare", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "athx_NumberOfFutureMilestonesAchieved": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of future milestones achieved.", "label": "Number of Future Milestones Achieved", "terseLabel": "Number of future milestones achieved" } } }, "localname": "NumberOfFutureMilestonesAchieved", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "athx_NumberOfMaterialPerformanceObligations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Material Performance Obligations", "label": "Number Of Material Performance Obligations", "terseLabel": "Number of material performance obligations" } } }, "localname": "NumberOfMaterialPerformanceObligations", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "athx_OfficeEquipmentAndLeaseholdImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office equipment and leasehold improvements.", "label": "Office Equipment And Leasehold Improvements [Member]", "terseLabel": "Office equipment and leasehold improvements" } } }, "localname": "OfficeEquipmentAndLeaseholdImprovementsMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "athx_ProceedsFromLitigationInsuranceReimbursement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from Litigation Insurance Reimbursement", "label": "Proceeds from Litigation Insurance Reimbursement", "terseLabel": "Insurance reimbursement amount" } } }, "localname": "ProceedsFromLitigationInsuranceReimbursement", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "athx_RegulatoryAndSalesMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regulatory and sales milestones.", "label": "Regulatory And Sales Milestones [Member]", "terseLabel": "Regulatory and sales milestones" } } }, "localname": "RegulatoryAndSalesMilestonesMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "athx_RevenueFromContractWithCustomerPotentialRevenueFromCompletionOfCertainManufacturingActivities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue From Contract With Customer, Potential Revenue From Completion Of Certain Manufacturing Activities", "label": "Revenue From Contract With Customer, Potential Revenue From Completion Of Certain Manufacturing Activities", "terseLabel": "Potential revenue from completion of certain manufacturing activities" } } }, "localname": "RevenueFromContractWithCustomerPotentialRevenueFromCompletionOfCertainManufacturingActivities", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "athx_RevenueFromContractWithCustomerPotentialRevenueFromMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue From Contract With Customer, Potential Revenue From Milestones", "label": "Revenue From Contract With Customer, Potential Revenue From Milestones", "terseLabel": "Potential revenue from milestones" } } }, "localname": "RevenueFromContractWithCustomerPotentialRevenueFromMilestones", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails", "http://www.athersys.com/role/GoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "athx_Section220LitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Section 220 Litigation", "label": "Section 220 Litigation [Member]", "terseLabel": "Section 220 Litigation" } } }, "localname": "Section220LitigationMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "athx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Grants In Period, Gross", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Grants In Period, Gross", "terseLabel": "Stock options and RSUs granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "athx_SharebasedCompensationArrangementBySharebasedPaymentAwardCommonStockOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Common Stock, Outstanding, Number", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Common Stock, Outstanding, Number", "terseLabel": "Shares of common stock outstanding (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCommonStockOutstandingNumber", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "athx_StockIssuableDuringPeriodValueEquityPurchaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issuable during period value equity purchase agreement.", "label": "Stock Issuable During Period Value Equity Purchase Agreement", "terseLabel": "Equity purchase agreement, value" } } }, "localname": "StockIssuableDuringPeriodValueEquityPurchaseAgreement", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "athx_SupplementalUnemploymentBenefitsPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental Unemployment Benefits, Period", "label": "Supplemental Unemployment Benefits, Period", "terseLabel": "Severance payments and benefits, period (in months)" } } }, "localname": "SupplementalUnemploymentBenefitsPeriod", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "athx_TheInducementAwardFourYearVestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Inducement Award, Four-Year Vesting", "label": "The Inducement Award, Four-Year Vesting [Member]", "terseLabel": "The Inducement Award, Four-Year Vesting" } } }, "localname": "TheInducementAwardFourYearVestingMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "athx_TheInducementAwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Inducement Award", "label": "The Inducement Award [Member]", "terseLabel": "The Inducement Award" } } }, "localname": "TheInducementAwardMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "athx_TheInducementAwardPerformanceBasedVestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Inducement Award, Performance Based Vesting", "label": "The Inducement Award, Performance Based Vesting [Member]", "terseLabel": "The Inducement Award, Performance Based Vesting" } } }, "localname": "TheInducementAwardPerformanceBasedVestingMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "athx_WarrantOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant One", "label": "Warrant One [Member]", "terseLabel": "Warrant One" } } }, "localname": "WarrantOneMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "athx_WarrantTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Two", "label": "Warrant Two [Member]", "terseLabel": "Warrant Two" } } }, "localname": "WarrantTwoMember", "nsuri": "http://www.athersys.com/20220331", "presentation": [ "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.athersys.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r208", "r276", "r277", "r280", "r340" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Healios", "verboseLabel": "Healios" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets", "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r65", "r145", "r149", "r154", "r252", "r253", "r254", "r255", "r281", "r340" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets", "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r65", "r145", "r149", "r154", "r252", "r253", "r254", "r255", "r281", "r340" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets", "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r30", "r32", "r63", "r64", "r157", "r164" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r156", "r163", "r209", "r210", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r326", "r328", "r341", "r342" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r156", "r163", "r209", "r210", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r326", "r328", "r341", "r342" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r123", "r191", "r194", "r295", "r325", "r327" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionScheduleofContractRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r123", "r191", "r194", "r295", "r325", "r327" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionScheduleofContractRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r156", "r163", "r207", "r209", "r210", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r326", "r328", "r341", "r342" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r156", "r163", "r207", "r209", "r210", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r326", "r328", "r341", "r342" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r31", "r32", "r63", "r64", "r157", "r164" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r126", "r279" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r24", "r284" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r24", "r62", "r278", "r280" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Related Parties, Current", "terseLabel": "Accounts payable to Healios" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.", "label": "Accounts Payable, Related Parties, Noncurrent", "terseLabel": "Accounts payable to healios" } } }, "localname": "AccountsPayableRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r6", "r13", "r127", "r128" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable from Healios" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r23", "r139" ], "calculation": { "http://www.athersys.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentnetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r14" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r66", "r67", "r68", "r225", "r226", "r227", "r258" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r211", "r213", "r231", "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r213", "r222", "r230" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Stock-based awards (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/NetLossperShareAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/NetLossperShareAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/NetLossperShareAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/NetLossperShareAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails", "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionScheduleofContractRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails", "http://www.athersys.com/role/GoingConcernDetails", "http://www.athersys.com/role/NetLossperShareAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r60", "r113", "r116", "r121", "r132", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r252", "r254", "r261", "r282", "r284", "r311", "r318" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r8", "r29", "r60", "r132", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r252", "r254", "r261", "r282", "r284" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r215", "r224" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/AccountingStandardsNotYetAdoptedPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r21", "r56" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets", "http://www.athersys.com/role/GoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r51", "r56", "r57" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of the period", "periodStartLabel": "Cash and cash equivalents at beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r51", "r265" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "(Decrease) Increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInAccountingEstimateByTypeAxis": { "auth_ref": [ "r78", "r99" ], "lang": { "en-us": { "role": { "documentation": "Information by type of change in accounting estimate.", "label": "Change in Accounting Estimate by Type [Axis]", "terseLabel": "Change in Accounting Estimate by Type [Axis]" } } }, "localname": "ChangeInAccountingEstimateByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingEstimateTypeDomain": { "auth_ref": [ "r78", "r99" ], "lang": { "en-us": { "role": { "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.", "label": "Change in Accounting Estimate, Type [Domain]", "terseLabel": "Change in Accounting Estimate, Type [Domain]" } } }, "localname": "ChangeInAccountingEstimateTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r185", "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrant (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Shares called by warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails", "http://www.athersys.com/role/NetLossperShareAdditionalInformationDetails", "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding (in shares)", "verboseLabel": "Warrants issued (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails", "http://www.athersys.com/role/NetLossperShareAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r248", "r249", "r251" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative Arrangements and Revenue Recognition" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r66", "r67", "r258" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r12", "r177" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common stock, ending balance (in shares)", "periodStartLabel": "Common stock, beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r12", "r284" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 600,000,000 shares authorized with 249,792,791 and 242,844,180 shares issued and outstanding at March\u00a031, 2022 and December\u00a031, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r34", "r36", "r37", "r43", "r314", "r323" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Net comprehensive loss", "totalLabel": "Net loss and comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetThresholdPeriodPastDue": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Threshold period for when right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, is considered past due, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes threshold period past due to write off as uncollectible.", "label": "Contract with Customer, Asset, Threshold Period Past Due", "terseLabel": "Accounts receivable, payments due within period of invoicing" } } }, "localname": "ContractWithCustomerAssetThresholdPeriodPastDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r187", "r188", "r192" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue - Healios", "verboseLabel": "Remaining transaction price for the performance obligations that were not yet delivered" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails", "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r187", "r188", "r192" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Advance from Healios" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r193" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "verboseLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": { "auth_ref": [ "r189" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.", "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period", "terseLabel": "Revenue recognized from performance obligations satisfied in previous periods" } } }, "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r45" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain": { "auth_ref": [ "r205", "r206" ], "lang": { "en-us": { "role": { "documentation": "Deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]", "terseLabel": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]" } } }, "localname": "DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredBonusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An contractual arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a bonus, as defined in the agreement, of the entity or portion thereof. Employer contributions may be discretionary or may be based on a fixed formula related to individual, group and entity-wide performance goals, compensation, or other factors. It is a form of incentive compensation to employees in addition to their regular salary and profit sharing.", "label": "Deferred Bonus [Member]", "terseLabel": "Deferred Bonus" } } }, "localname": "DeferredBonusMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of commitment made to pay deferred cash remuneration.", "label": "Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount", "terseLabel": "Cash retention bonus granted" } } }, "localname": "DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis": { "auth_ref": [ "r205", "r206" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]", "terseLabel": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r54", "r137" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionScheduleofContractRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r191", "r194", "r195", "r196", "r197", "r198", "r199", "r200" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionScheduleofContractRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Contract Revenues Disaggregated by Timing of Revenue Recognition" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockbasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r44", "r75", "r76", "r77", "r78", "r79", "r86", "r88", "r90", "r91", "r92", "r96", "r97", "r259", "r260", "r315", "r324" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r44", "r75", "r76", "r77", "r78", "r79", "r88", "r90", "r91", "r92", "r96", "r97", "r259", "r260", "r315", "r324" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r93", "r94", "r95", "r98" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/NetLossperShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and related benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r223" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost of unvested stock awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Laboratory equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r38", "r39", "r40", "r66", "r67", "r68", "r72", "r80", "r82", "r100", "r133", "r177", "r184", "r225", "r226", "r227", "r238", "r239", "r258", "r266", "r267", "r268", "r269", "r270", "r271", "r329", "r330", "r331", "r350" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r46" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r61", "r235", "r236", "r237", "r243", "r244", "r245", "r246", "r247" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r53" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued expenses and other" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": { "auth_ref": [ "r53" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Accounts Receivable, Related Parties", "negatedLabel": "Accounts receivable from Healios - billed and unbilled" } } }, "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r53", "r293" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue - Healios" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r53" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses, deposits and other" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r60", "r132", "r261", "r284", "r312", "r320" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r26", "r60", "r132", "r145", "r146", "r147", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r253", "r254", "r255", "r261", "r282", "r283", "r284" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r142", "r143", "r144" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Fees and expenses sought by plaintiff" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r51" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r51" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r51", "r52", "r55" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r33", "r35", "r40", "r42", "r55", "r60", "r71", "r75", "r76", "r77", "r78", "r81", "r82", "r89", "r113", "r115", "r117", "r120", "r122", "r132", "r145", "r146", "r147", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r260", "r261", "r313", "r322" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r1", "r69", "r70", "r73", "r74", "r83", "r84", "r85", "r130", "r131", "r134", "r135", "r201", "r202", "r203", "r204", "r228", "r240", "r241", "r242", "r257", "r262", "r263", "r264", "r275", "r296", "r297", "r298", "r332", "r333", "r334", "r335", "r336", "r351" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "Accounting Standards Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/AccountingStandardsNotYetAdopted" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/AccountingStandardsNotYetAdoptedPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of business segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r113", "r115", "r117", "r120", "r122" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r274" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r274" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r273" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating right-of-use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r4", "r256" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Background and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r47" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r50" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Shares retained for withholding tax payments on stock-based awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMachineryAndEquipment": { "auth_ref": [ "r48" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for acquisition of machinery and equipment.", "label": "Payments to Acquire Machinery and Equipment", "negatedLabel": "Purchases of equipment" } } }, "localname": "PaymentsToAcquireMachineryAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r215", "r224" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r11", "r161" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred stock shares, ending balance (in shares)", "periodStartLabel": "Preferred stock shares, beginning balance (in shares)", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r11", "r284" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, at stated value; 10,000,000 shares authorized, and no shares issued and outstanding at March\u00a031, 2022 and December\u00a031, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r7", "r19", "r20" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r49" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds from sales of common stock", "verboseLabel": "Proceeds from issuance of common stock, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r23", "r140" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r141", "r337", "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/PropertyandEquipmentnet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r22", "r138" ], "calculation": { "http://www.athersys.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentnetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r10", "r140", "r284", "r317", "r321" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.athersys.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentnetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets", "http://www.athersys.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r9", "r140" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/PropertyandEquipmentnetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r9", "r138" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r208", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r208", "r276", "r280", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r234", "r294", "r343" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r15", "r184", "r229", "r284", "r319", "r332", "r336" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r66", "r67", "r68", "r72", "r80", "r82", "r133", "r225", "r226", "r227", "r238", "r239", "r258", "r329", "r331" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r111", "r112", "r114", "r118", "r119", "r123", "r124", "r125", "r190", "r191", "r295" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Contract revenue from Healios", "verboseLabel": "Total disaggregated revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionScheduleofContractRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails", "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r41", "r60", "r111", "r112", "r114", "r118", "r119", "r123", "r124", "r125", "r132", "r145", "r146", "r147", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r261", "r316" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "Revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/NetLossperShareAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r23", "r140" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r215", "r224" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r27", "r58", "r101", "r102", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r166", "r170", "r175", "r178", "r179", "r180", "r181", "r182", "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service revenue" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionScheduleofContractRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r53" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Awards vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price", "terseLabel": "Award exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Common stock authorized for equity incentive plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Stock options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r212", "r219" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche One [Member]", "terseLabel": "Tranche One" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Tranche Two" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Award expiration period (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r28", "r38", "r39", "r40", "r66", "r67", "r68", "r72", "r80", "r82", "r100", "r133", "r177", "r184", "r225", "r226", "r227", "r238", "r239", "r258", "r266", "r267", "r268", "r269", "r270", "r271", "r329", "r330", "r331", "r350" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets", "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r66", "r67", "r68", "r100", "r295" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets", "http://www.athersys.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-based Payment Arrangement [Member]", "terseLabel": "Share-based Payment Arrangement" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/NetLossperShareAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r11", "r12", "r177", "r184" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, new issues (in shares)", "verboseLabel": "Issuance of common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.athersys.com/role/StockholdersEquityandWarrantsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r11", "r12", "r177", "r184" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "verboseLabel": "Issuance of common stock under equity compensation plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r11", "r12", "r177", "r184" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r11", "r12", "r184", "r214", "r220" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock under equity compensation plan" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r12", "r16", "r17", "r60", "r129", "r132", "r261", "r284" ], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets", "http://www.athersys.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets", "http://www.athersys.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r59", "r162", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r176", "r184", "r186" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders\u2019 Equity and Warrants" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/StockholdersEquityandWarrants" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r272", "r285" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r272", "r285" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r272", "r285" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalUnemploymentBenefits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability for benefits due terminated employees.", "label": "Supplemental Unemployment Benefits", "terseLabel": "Severance payments and benefits" } } }, "localname": "SupplementalUnemploymentBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment.", "label": "Supplemental Unemployment Benefits, Severance Benefits", "terseLabel": "Lump sum payment" } } }, "localname": "SupplementalUnemploymentBenefitsSeveranceBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "auth_ref": [ "r191", "r199" ], "lang": { "en-us": { "role": { "documentation": "Information by timing of transfer of good or service to customer.", "label": "Timing of Transfer of Good or Service [Axis]", "terseLabel": "Timing of Transfer of Good or Service [Axis]" } } }, "localname": "TimingOfTransferOfGoodOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionScheduleofContractRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "auth_ref": [ "r191", "r199" ], "lang": { "en-us": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.", "label": "Timing of Transfer of Good or Service [Domain]", "terseLabel": "Timing of Transfer of Good or Service [Domain]" } } }, "localname": "TimingOfTransferOfGoodOrServiceDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionScheduleofContractRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredAtPointInTimeMember": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred at point in time.", "label": "Transferred at Point in Time [Member]", "terseLabel": "Point\u00a0in Time" } } }, "localname": "TransferredAtPointInTimeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionScheduleofContractRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredOverTimeMember": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred over time.", "label": "Transferred over Time [Member]", "terseLabel": "Over\u00a0Time" } } }, "localname": "TransferredOverTimeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionScheduleofContractRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails", "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionScheduleofContractRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails", "http://www.athersys.com/role/GoingConcernDetails", "http://www.athersys.com/role/NetLossperShareAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnbilledReceivablesCurrent": { "auth_ref": [], "calculation": { "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.", "label": "Unbilled Receivables, Current", "verboseLabel": "Unbilled accounts receivable from Healios" } } }, "localname": "UnbilledReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CollaborativeArrangementsandRevenueRecognitionAdditionalInformationDetails", "http://www.athersys.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r103", "r104", "r105", "r106", "r107", "r108", "r109" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/AccountingStandardsNotYetAdoptedPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/BackgroundandBasisofPresentationAdditionalInformationDetails", "http://www.athersys.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r87", "r92" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r86", "r92" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.athersys.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r247": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r344": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r345": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r346": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r347": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r348": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r349": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e777-108305" } }, "version": "2.1" } ZIP 48 0001368148-22-000053-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001368148-22-000053-xbrl.zip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�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